Mathew Thakur, PhD

Curriculum Vitae

Last updated: March 11, 2021

Table of Contents


A

Activities in Local Committees 12

Activities in other Professional Societies (As of 2000): 10

Awards 4

B

Biographical References 83

C

Consultations 3

E

Editor 13

Education 2

G

Granting Agencies Review Services 16

J

Journal Services 14

L

Labeled Compounds Prepared and Developed 5

O

Other Honors 4

P

Patents 5

Positions Held 2

Presentations 59

Commercial and Radiopharmaceutical Institutions 80

National and International 65

Training Courses 63

Universities 59

Professional Societies Memberships 7

Publications 17

Abstracts 34

Book Chapters 53

Books 53

Editorials 58

Original Articles 17

R

Research Experience 3

Research Grants 3

S

Society of Nuclear Medicine Activities 8

Symposiums and Meetings 58

T

Teaching Experience 3

V

Visiting Professorships 3



Name: Thakur ML

Place of Birth: Bombay, India

Marital Status: Married – Lalita BA, BEd.

Two Children –Netra, MD – 1993 TJU

Neil, PhD – 1996 Yale

Education:

1961 BS Chemistry, Bombay University

Government Merit Scholarship

1969 MS Analytical Chemistry, University of London, UK

1973 PhD Radiochemistry, University of London, UK

Thesis: “Investigations into Problems Related to Preparation and Chemical

Control of Some Radiopharmaceuticals made with a Medical Cyclotron”

Positions Held:

July 1982 – Present Director of Laboratories of Radiopharmaceutical

Research, Molecular Imaging and Bio-Fluid Diagnostics

Professor of Radiology, Radiation Oncology and Urology

Thomas Jefferson University, SK Cancer Center

Philadelphia, PA 19107.

July 1982 – June 1994 Professor and Director of Radiopharmaceutical

Research, Division of Nuclear Medicine, Department of

Radiation Oncology and Urology

Thomas Jefferson University Hospital

Philadelphia, PA 19107

July 1991 – Present Professor, Radiology, Radiation Oncology and Urology

Thomas Jefferson University Hospital

Philadelphia, PA 19107

July 1995 Present Member Sidney Kimmel Cancer Center, Thomas Jefferson University

Philadelphia, PA 19107

July 1982 – Present Professor, Radiation Oncology

Thomas Jefferson University Hospital

Philadelphia, PA 19107

July 2015-Present Professor, Urology, Thomas Jefferson University Hospital

Philadelphia, PA 19107

February 1977 – June 1982 Associate Professor of Diagnostic Radiology,

Yale University School of Medicine, New Haven

CT 06510

February 1977 – June 1983 Research Associate, Chemistry Department,

Brookhaven National Laboratory, Washington

University School of Medicine, St. Louis, MO

06310.

June 1975 – June 1976 Visiting Professor, Mallinckrodt Institute

of Radiology, Washington University School

of Medicine, St. Louis, MO 06310.

April 1967 – February 1977 Medical Research Council, Cyclotron Unit,

Hammersmith Hospital, London W12 O(HS

England. Last position held – Scientific Staff,

Grade I (Permanent Appointment).

March 1961 – 1967 Bhabha Atomic Research Center, Isotope Div.

Trombay, Bombay, India. Last Position Held:

Scientific Assistant, Grade "B".

Research Experience:

    • Production and isolation of many medically useful reactor produced radionuclides.

    • Production and isolation of many medically useful cyclotron produced radionuclides.

    • Development of analytical and radiochemical techniques.

    • Development and evaluation of a variety of radioactive labeled compounds of medical potential.

    • Extensive experience in the use of a variety of experimental animal models.

    • Extensive experience in the use of Hematological techniques.

    • Extensive experiences in the use of biomedical techniques.

    • Extensive experience in radiolabeling blood proteins, antibodies, peptides, and peptide nucleic acids.

Teaching Experience:

Mainly Radiopharmaceutical Chemistry to Nuclear Medicine and Radiology Residents and Technologists.

Research: Post Doctorate Research Associates and Research Assistants.

Thesis: MD, MS, and PhD Students.

Consultations:

Universities at home and abroad and private institutions in the USA.

Visiting Professorships:

To many institutions in the USA and abroad.

Research Grants:

Principal and co – principal investigator of major and minor, federal, state, Foundational and Institutional research grants.

  • Awards:

      • Michael and Melina Pellini Award for “ Innovations in Biomedical Sciences and Significant contributions to Research” Thomas Jefferson University/ Kimmel Cancer Research Center, 2022

      • Albert Nelson Marquis achievement Award for having achieved Career Longevity and demonstrated unwavering excellence in his chosen field 2021.

      • Ajit Padhy Award, 2019 World Association of Radiopharmaceutical and Molecular Therapy (WARMTH)

      • John McAfee medal for “outstanding achievements in the field of radiolabeled blood cells and his meritorious contributions to ISORBE.” International Soc. of radiolabeled Blood elements, Vienna, Austria, 2009.

      • Benedict Cassen Award for “Outstanding Contributions to the Pharmaceutical Science and Devotion as the Practice and Promotion of Nuclear Medicine.” Society of Nuclear Medicine and ERF 2008.

      • Berson – Yalow Award for "Outstanding Scientist and Superb Educator". Awarded by the Greater New York and New England Chapter of the Society of Nuclear Medicine, 2001.

      • George de Hevesy Award for “Outstanding Contribution to the Field of Nuclear Medicine”. Awarded by the Society of Nuclear Medicine, 2000.

      • Lifetime Achievement Award, Indo – American Society of Nuclear Medicine, 1998.

      • Vikram Sarabhai Oration Award for “brilliant accomplishments in the field of radiopharmaceuticals” awarded by the Society of Nuclear Medicine – India, 1995.

      • Paul Aebersold award for “outstanding achievement in basic science applied to Nuclear Medicine.” Awarded by the Society of Nuclear Medicine, 1992.

      • Maurice Chamberland Award for the "Contribution to the Improvement of the Quality of Life Through Chemistry". Awarded by the American Chemical Society, New Haven Chapter, 1980.

Other Honors:

  • Meet our Advisors: Mathew Thakur, J. Labelled compounds and radiopharmaceuticals, 1-4, 2021

  • Invited Keynote Speaker, The Black Graduate Student Organization 2nd Annual Diversity Graduate Research Symposium, 2018

  • “Fellow” National Academy of Inventors, 2017

  • “Fellow” Society of Nuclear Medicine and Molecular Imaging, 2016

  • Distinguished Investigators” Academy of Radiology Research, 2015

  • “Image of the Year” Award, Siemens Medical Incorporation, 2009

  • “Fellow” Indian College of Nuclear Medicine Physicians 1989

  • President Society of Nuclear medicine and Molecular imaging, 2004-2005

  • Chair board of directors, the Society of nuclear medicine and Molecular Imaging, 2003-2005

  • President, Society of radiolabeled blood elements, 1989-1992

  • President Indo American society of nuclear medicine, 1993-1994

Labeled Compounds Prepared and Developed

Available Commercially:

  • In – 111 Oxine, GE Health

  • In – 111 Oxine, Radiochemical Center, Amersham.

  • In – 111 Bleomycin, Metaphysics, USA, Phillip Duphar, Europe.

  • In – 111 Oxine, Mediphysics, Inc.

  • In – 111 – Oxine, Diagnostic Isotopes, USA.

  • Tc – 99m anti – CD15 antibody for imaging infection

  • Kr – 81m generator

Patents:

  • Method of using PACAP and VIP peptides for detecting shed or circulating tumor cells in biological fluids. EU Patent No. EP 2956773. Thakur ML

  • Method of using PACAP and VIP peptides for detecting shed or circulating tumor cells in biological fluids. Singapore, patent pending 17/089,103. Thakur ML

  • Kit for tumor imaging. Canada Patent and Trademark Office. Publication No. 2,901,231. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids Hong Kong Patent No. HK1222450. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. China Patent No. ZL201480008845.3. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Canada Patent No. 2,901,246. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Japan Patent No. JP,2015/558076 6346202. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. South Korea Patent No. 1020187005123 10-1890885. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Singapore Patent No. 11201506406X. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Germany Patent No.60 2014 071 459.5. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. France Patent No. 2956773. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. United Kingdom Patent No. 2956773. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Spain Patent No. 502021000016511. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. Italy Patent No. 2956773. Thakur ML

  • Method for detecting shed or circulating tumor cells in biological fluids. IP Australia. July 2017; 2014216517. Thakur, ML.

  • Method for detecting shed or circulating tumor cells in biological fluids. India, patent pending, 8325/DELNP/2015. Thakur ML

  • Method for detecting circulating tumor cells in biological fluids, United States Patent and Trademark Office. February 2013. Publication No. WO2014126904. Thakur, ML.

  • Kit for tumor imaging. United States Patent and Trademark Office. Publication No. WO2014126902. February 2013. Thakur, ML.

  • Compounds and methods for diagnostic imaging and therapy. US Patent & Trademark Office. April 21, 2005. US. Publication No. 20050085417. Thakur ML.

  • Imaging with Tc – 99m labeled fibrin – a – chain peptide. United States Patent. April 2004; THA01.NP003. Thakur ML.

  • Lipid soluble radioactive active chelates for tumor therapy. United States Patent Feb. 3 2004 US 6,685,913 B1. Thakur ML.

  • Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy. United States patent Nov. 30 2004; US 6,824,759. Thakur ML.

  • Intratumoral Delivery Device. US Patent. Pub No US 0184989 A1. 23 Sep 2004. Thakur ML.

  • Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy. U.S. Patent No. 6,824,759. Thakur ML.

  • Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy. United States Patent and trademark Office March 1, 2002; US. Patent. No. 6,359,255. Thakur ML,

  • PACAP Compositions and methods for tumor imaging and therapy. U.S. Patent No. 6,855,308 B2. Thakur ML.

  • PACAP Compositions and methods for tumor imaging and therapy. Canada patent 2,464,002. Thakur ML

  • PACAP Compositions and methods for tumor imaging and therapy. US Patent No. 6,855,308. Thakur ML

  • Imaging with Tc – 99m labeled fibrin α – chain peptide. Publication No. WO2000009076 A8. Thakur ML.

  • Lipid soluble radioactive chelates for tumor therapy. U.S. Patent No. US 6,685,913, B1. Thakur ML.

  • Radiolabeled Vasoactive Intestinal Peptide analogs for imaging and therapy. U.S. Patent No 6,395,255. Thakur ML.

  • Indium – 8 – hydroxyquinoline in blood stream. US Patent No. 4,360,509. Thakur ML.

  • Radiolabeled thrombus imaging agents. U.S. Patent No. 5,886,142. Thakur ML.

  • Improved Method to directly Radiolabeled Antibodies for diagnostic Imaging and Therapy. U.S Patent No. 5,011,676. Thakur ML.

  • Improved Method to directly Radiolabeled Antibodies for diagnostic Imaging and Therapy. U.S. Patent No. 5,308,603. Thakur ML.

  • Novel use of a radiolabeled antibody, against stage specific embryonic antigen for the detection of occult abscesses in mammals. U.S. Patent No. 4, 917, 878. Thakur ML.

  • Blood Agent. US Patent No. 4, 443, 426. Thakur ML.

Professional Societies Memberships:

  • Honorary member International Society of Radiolabeled Blood Elements (ISORBE) 2002 –

  • Indian College of Nuclear Medicine 1998 –

  • Radiological Society of North America (RSNA) 1994 –

  • European Association of Nuclear Medicine 1993 –

  • Association of Latin American Society of Biology and Nuclear Medicine 1985 –

  • American College of Nuclear Physicians 1985 –

  • Cancer Research Club Philadelphia 1982 –

  • Radiation Research Society 1982 –

  • American Institution of Chemists 1981 –

  • Indo – American Society of Nuclear Medicine 1980 –

  • Society of Nuclear Medicine India 1980 –

  • New York Academy of Sciences 1980 –

  • Sigma Xi 1977 –

  • American Association for the Advancement of Science 1977 –

  • American Chemical Society – New Haven Chapter 1977 –

  • American Chemical Society 1977 –

  • American Heart Association 1977 –

  • Society of Nuclear Medicine – New York Chapter 1977 –

  • Society of Nuclear Medicine 1977 –

  • Society of Radiopharmaceutical Sciences 1977 –

Society of Nuclear Medicine Activities:

  • Board of Directors, Therapy Center of Excellence 2016 – 2017

  • Chair, Award Committee, SNMMI Therapy Center of Excellence 2016

  • Fellow, SNMMI 2016

  • Board of Directors National Oncology Council, SNMMI 2013 – 2015

  • Member Publication Committee, SNMMI 2008 –

  • Member, Society of Nuclear Medicine Publication Committee 2008 –

  • Member, Society of Nuclear Medicine Wagner – Terruzuka Fellowship Committee 2006 –

  • Organizer, Soc. Nucl. Med/Industry summit on Molecular Imaging, 2006 –

  • Member, Past President, Committee Society of Nuclear Medicine 2005 –

  • Chair, Society of Nuclear Medicine, Award Committee, 2005 – 2009

  • President, Society of Nuclear Medicine, Molecular Imaging Center of Excellence, 2005 – 2007

  • Member, Society of Nuclear Medicine, Public Relations Committee, 2005 –

  • Member, Board of Governors, Greater New York Chapter of the Society of Nuclear Medicine 2004 –

  • President Elect Society Of Nuclear Medicine, 2003 – 2004

  • President, Society of Nuclear Medicine 2004 – 2005

  • Chair, Society of Nuclear Medicine Board of Directors, 2004 – 2005

  • Co – Organizer, Society of Nuclear Medicine Molecular Imaging Summit, 2005

  • Chair, Society of Nuclear Medicine International Task Force, 2004 – 2006

  • Lead member, Society of Nuclear Medicine National Radionuclide Availability Task Force, 2004 – 2005

  • Member, Society of Nuclear Medicine, Public Relations Committee 2004 - 2007

  • Chair, Society of Nuclear Medicine Molecular Imaging Task Force, 2004 – 2005

  • Member, Society of Nuclear Medicine, Physicians Self – Referral Task Force, 2004 – 2006

  • Member, Society of Nuclear Medicine, Education Research Committee, 2004 – 2006

  • Second Term as Delegate – at – Large, Society of Nuclear Medicine, 2004 – 2008

  • Liaison, Society of Nuclear Medicine Radiopharm Science Council to SNM Board of Directors, 2004 – 2009

  • Member, Society of Nuclear Medicine, Financial Committee, 2003 – 2008

  • Chair, Society Nuclear Medicine 50th Anniversary Committee 2002 – 2004

  • Member Society Nuclear Medicine Board of Directors, 2002 – 2009

  • Chair, Scientific Session, 49th Annual Meeting, Los Angeles, 2002

  • Reviewer, Abstract Committee, 49th Annual Meeting, Los Angeles, 2002

  • Member Society Nuclear Medicine House of Delegates, 2001 – 2008

  • Chair, Scientific Session, 48th Annual Meeting, Toronto, 2001

  • Chair, Scientific Session, 47th Annual Meeting, Los Angeles, 1999

  • Chair, Scientific Session, 46th Annual Meeting, Toronto, 1998

  • Sub-chairman, Society of Nuclear Medicine, Scientific Program Committee, 1997 – 1998

  • Society of Nuclear Medicine, Delegate – at – Large, 1997 – 2006

  • Society of Nuclear Medicine, Greater New York Chapter, Scientific Program Committee, 1995 – 1997

  • Sub-chairman Scientific Program Committee, 1995 – 1996

  • Member Scientific Exhibit Committee 1989 – 2006

  • Member SNM Central Chapter Annual Meeting, Scientific Program, 1988 – 1989

  • Member Scientific Exhibit Committee 1988 – 1990

  • Chairman panel discussion, Greater New York Chapter 1987

  • Sub – chairman Scientific Program Committee Annual Meeting 1987

  • Society of Nuclear Medicine, Radiopharm. Science Council, Board of Directors, 1986 – 1987

  • Member, SNM Annual Meeting Scientific Program Committee 1986

  • Member, Scientific Exhibit Review Committee 1985 – 1991

  • Member, Ad – hoc, Committee on the recruitment of basic scientists 1985 – 1987

  • Member Annual Meeting Scientific Program Committee 1984 – 2002, 2007 –

  • Member, Scientific Exhibit Award Committee 1984

  • Secretary – treasurer Radiopharmaceutical Science Council 1984 – 1985

  • Member, Radiopharmaceutical Council Communications Committee since 1981 – 1988

  • Sub – chairman Scientific Program Committee 1981

  • Member, New York Chapter Education Committee 1980 – 2007

  • Chaired Annual Meeting Scientific Sessions, 1978 – 1982, 1984, 1986 – 1990

  • Reviewer Scientific Program 1978 – 1982, 1984 – 1986, 1988 – 1991, 1992 – 1994, 1995 – 2002, 2006 –

  • Member, Radiopharmaceutical Council since 1977-

  • Member, New York Chapter and New England Chapter since 1977-

  • Member of Panel Discussion 1977 – 1981

  • Member since 1977-

Activities in other Professional Societies (As of 2000):

  • Member, Advisory Committee SNM India, Annual Meeting, Orissa, India 2012

  • Member, Imaging Initiative Committee, Association of American Cancer Institute

  • Chair, IAEA Review Committee 2009

  • Organizer, Molecular Imaging, symposium, WFNMB, Seoul, Korea, 2006

  • Japanese Soc. Nucl. Med, Kagoshima, 2006

  • WRNMB, Seoul, Korea, 2006

  • British Society of Nucl. Med. Manchester, 2006

  • Organizer, Molecular Imaging, symposium, WFNMB, Seoul, Korea, 2006

  • Member, Scientific Program Committee, World Federation of Nuclear Medicine and Biology, 2006

  • Member, Eagle Alliance, Board of Directors, 2005 –

  • Senate Caucus, 2005

  • American Association of Pharmacists, Annual Meeting, 2005

  • American College of Nuclear Physicians, 2005

  • American College of Nuclear Medicine, Physicians Annual Meeting, 2005

  • Member, Board of Directors, Eagle Alliance 2004 – 2015

  • Japanese Society of Nuclear Medicine, Annual Meeting, 2004

  • Asia Oceania Federation in Nuclear Medicine and Biology, Beijing, China 2004

  • International Congress on Radiopharmacy and Radiochemistry, 2004

  • Chair, Young Investigators Award Committee, International Society of Radiolabeled Blood Elements, 2003 –

  • Annual meeting of the Brazilian Society of Nuclear Medicine and AIASBNM, 2003

  • Annual meeting of European Association of Nuclear Medicine, 2003

  • Annual Congress of International Society of Radiopharmaceutical Chemistry and Biology, 2003

  • Round Table Coordinator, International Society of Radiolabeled Blood Elements

  • Session Chair, Annual Meeting of the International Society of Radiolabeled Blood Elements, 2003

  • Member, International Science Committee, International Society of Radiolabeled Blood Elements, 2002

  • Session Chair, Continuing Medical Education, World Federation of Nuclear Medicine and Biology, 2002

  • Organizer, Continuing Medical Education, World Federation of Nuclear Medicine and Biology, 2002

  • Member, Scientific Program Committee, 8th World Federation of Nuclear Medicine and Biology, 2002

  • Session Chair, Annual Post – Congress of the European Association of Nuclear Medicine, 2002

  • Member, Best Abstract Award Committee, Indo – American Society of Nuclear Medicine, 2002

  • Chair, Lifetime Achievement Award Committee, Indo – American Society of Nuclear Medicine, 2002

  • Chair, Plenary Session, 7th Asia and Oceania Congress in Nuclear Medicine and Biology, 2001

  • Member, Scientific Program Committee, Annual Post – Congress of the European Association of Nuclear Medicine, 2001

  • Chair, Scientific Session, Annual Meeting of the European Association of Nuclear Medicine, 2001

  • Session Chair, 8th Annual Meeting of the International Society of Radiolabeled Blood Elements, 2001

  • Chair, Scientific Program Committee, Post – Congress Symposium to World Federation of Nuclear Medicine and Biology, 2001

  • Reviewer, Abstract Committee, 7th World Federation of Nuclear Medicine and Biology, 2001

  • Member, Best Abstract Award Committee, Indo – American Society of Nuclear Medicine, Toronto, 2001

  • Chair, Lifetime Achievement Award Committee, Indo – American Society of Nuclear Medicine, 2001

  • Chair, Young Investigators Award Committee, International Society of Radiolabeled Blood Elements, 2001

  • Member, Scientific Program Committee, Annual Post – Congress of the European Association of Nuclear Medicine, 2001

  • Member, Scientific Program Committee, World Federation of Nuclear Medicine and Biology and European Assoc. of Nuclear Medicine, Berlin, Germany 1998

  • Member, Advisory Committee, International Atomic Energy Agency 1995 – 2000

  • President Indo – American Society of Nuclear Medicine: 1993 – 1994

  • President Elect Indo – American Society of Nuclear Medicine: 1992 – 1993

  • Member of United States Pharmacopeia Committee of Revision 1990 – 2000

  • NATO Scientific Exchange Program Committee 1990 – 1994

  • President, International Society of Radiolabeled Blood Elements (ISORBE) 1989 – 1993.

  • Secretary, Indo – American Society of Nuclear Medicine 1988 – 1991.

  • Fellow, Indian College of Nuclear Medicine 1982

  • Chairman TAG Parents Committees, Hamden, CT 1980 – 1982

  • Member TAG Parents Committees, Hamden, CT 1979 – 1980

  • Member Radioisotope Committee, Yale University Medical Center 1977 – 1982

  • Member, Scientific Program Committee, European Association of Nuclear Medicine

Activities in Local Committees:

  • Member DTSA Grant Review Committee at Thomas Jefferson University 2014 –

  • Member Jefferson Accelerator Zone (JAZ) at Thomas Jefferson University 2014 –

  • Member Innovation Committee at Thomas Jefferson University 2014 –

  • Vice President, National Academy of Inventors at Thomas Jefferson University 2013 –

  • Member, Thomas Jefferson faculty, Committee on Committees 2012 – 2013

  • Member Jefferson Professional Faculty Advisory Committee 2008 – 2011, 2015 – 2018

  • Member, Thomas Jefferson University, Tenure Committee 2006 – 2010

  • Chairman, Subcommittee to the Research Committee, 1997 – 2000

  • Member Thomas Jefferson University Committee on Research 1995 – 2001

  • Member of the Thomas Jefferson University, Department Radiation Therapy & Nuclear Medicine Publication Committee since 1985 – 2013

  • Member of the Thomas Jefferson University Radioactive Drug Research Committee since 1984 –

  • Member of the Thomas Jefferson Internal Review Board 1983 – 2015

  • Member of the Thomas Jefferson University "Non – human Radioactive Isotope Users Committee" since 1983 –

Editorial Board Memberships:

  • Member, Editorial Board, Journal of The Association of Latin American Societies of Nuclear Medicine & Biology 1989-

  • Member, Editorial Board, Journal of The Asia pacific Academy of Science 2022-Member, Editorial Board, Turkish, Journal of Molecular Imaging and Radionuclide Therapy

  • Member, Editorial Board, Molecular Imaging and Radionuclide Therapy. 2015 –

  • Member, Editorial Board, “Current Molecular Imaging” 2012 –

  • Member, Editorial Board, Molecular Imaging and Therapy 2011 –

  • Member of the Editorial Board of the Journal Biological Chemistry 2001 –

  • Member, The editorial board of The Turkish Journal of Nuclear Medicine. 1999 –

  • Member of Editorial Board Journal Labelled Compounds and Radiopharmaceuticals 1999 –

  • Member: Editorial Board, The Journal of Labelled Compounds and Radiopharmaceuticals 1999

  • Assoc. Editor: Cancer Research 1998 – 2000

  • Member of Editorial Board Cancer Research 1998 – 2000

  • Member, Editorial Board, Journal of Labeled Compounds and Radiopharmaceuticals 1998 –

  • Member, Editorial Board The Journal of Ind -Associated Clinical Medicine 1994 –

  • Member, Editorial Board The Journal of Nuclear Medicine 1993 –

  • Member of Editorial Board European Journal of Nuclear Medicine 1992 –

  • Member, Editorial Board ALASBIMN, 1991 –

  • Member of the Editorial Board, The World Journal of Nuclear Medicine and Biology, 1990 –

  • Member, Editorial Board The International Journal of Nuclear Medicine and Biology 1989 –

  • Member, Editorial Board The Journal of Nuclear Medicine Communications 1982 – 2012

  • Member, Editorial Board, European Journal of Nuclear Medicine and Molecular Imaging 1980 –

  • Advisory Editor to the Nuclear Medicine Communications 1979 –

  • Member, Editorial Board, Journal of Nuclear Medicine 1978 –

  • Member, Editorial Board, Nuclear Medicine Communications 1977 – 2010

  • Member, Editorial Board, Journal of the Indian Association of Clinical Medicine 1976 –

Scientific Journal Review Services:

  • Reviewer Am J. Pathology

  • Reviewer Applied Organometallic Chemistry

  • Reviewer Bioconjugate Chemistry

  • Reviewer Bioorganic & Medicinal Chemistry Letters

  • Reviewer Bioorganic and Medicinal Chemistry

  • Reviewer Biotechniques

  • Reviewer Blood

  • Reviewer Breast Cancer Research

  • Reviewer Cancer

  • Reviewer Cancer Biotherapy & Radiopharmaceuticals

  • Reviewer Circulation

  • Reviewer Current Molecular Imaging

  • Reviewer Digestive Diseases and Sciences

  • Member Editorial Board, European Journal of Nuclear Medicine, 1992 –

  • Member Editorial Board, Spanish Journal of Nuclear Medicine 2001 –

  • Member Editorial Board, World Journal of Nuclear Medicine 2002 – 2005

  • Reviewer European Journal of Nuclear Medicine

  • Reviewer European Journal of Nuclear Medicine and Molecular Imaging

  • Reviewer Future Pharmaceuticals

  • Reviewer Investigative Radiology

  • Reviewer JACC: Cardiovascular Imaging

  • Reviewer Journal Molecular Imaging and Therapeutics

  • Reviewer Journal of Chromatography

  • Reviewer Journal of Labeled Compounds and Radiopharmaceuticals

  • Reviewer Journal of Nuclear Medicine

  • Reviewer Journal of Nuclear Medicine and Biology

  • Reviewer Life Sciences

  • Reviewer Metabolites

  • Reviewer Molecular Imaging & Biology

  • Reviewer Molecular Pharmaceutics

  • Reviewer Netherland Government Grant

  • Reviewer Nuclear Medicine and Biology

  • Reviewer Nuclear Medicine Communications

  • Reviewer Oncology

  • Reviewer Postgraduate Medical Journal, London, England

  • Reviewer Radiology

  • Reviewer Science

  • Guest Editor Seminars in Nuclear Medicine (October 2001)

  • Reviewer Separation Science

  • Reviewer The American Review of Respiratory Disease

  • Reviewer The International Journal of Applied Radiation and Isotopes

  • Reviewer The International Journal of Bio – chromatography

  • Reviewer The International Journal of Nuclear Medicine and Biology

  • Reviewer The Journal of Laboratory and Clinical Medicine

  • Reviewer The Journal of Radiopharmaceutical Analytical Chemistry

  • Reviewer The Open Medical Imaging Journal

  • Reviewer Thrombosis Research

  • Reviewer Vet. J. Pharmacology

  • Reviewer Veterinarian Journal of Pharmaceuticals and Therapy

Granting Agencies Review Services:

  • The Netherland Center for Translational Molecular Medicine

  • The Austrian Association Of Medical research

  • Member, Grant Review Service, Canadian Medical Research Council, 2002

  • Member, site visit, National Institutes of Health, 2002, 2010, 2015

  • Member, Grant Review Service, Foundation for Medical Research , Vienna, Austria 2002 - 2007

  • Member, NIH, NExT Study Section 2001-2005, 2017-2018

  • Ad hoc member, Grant Review Service, National Institutes of Health, 2001

  • Chairman, DOE, Special Review Committee, 2000

  • Chairman, Special NIH Review Committee, 2000

  • Kuwait Medical Research Council 1998 –

  • Ad hoc member, Grant Review Service, National Institutes of Health 1996 –

  • Member Grant Review Panel, National Cancer Institute, Canada 1995 – 2002

  • The Welcome Trust, London, England, 1995 –

  • NIH Ad Hoc Study Sections, 1995,1996, 1997, 1998,1999, 2000- Present,

  • NIH Diagnostic Radiology Study Section 1991 – 1994.

  • Member NIH Diagnostic Radiology Study Section 1990 – 1994, 2001 – 2005

  • Foundation for Medical Research, Vienna, Austria, 1990 –

  • Canadian Science Research Council 1990 – 2019

  • Kuwait National Research Council, 1989 – Present

  • NIH Special Study Section 1985, 1987, 1990 –Present

  • Veterans Administration 1977 –

  • Department of Energy 1977 –

  • North Atlantic Treaty Organization (NATO) 1982 – 1988

Publications:

Original Articles:

1. Chhabra A. Thakur ML Theragnostic Radionuclide pairs for prostate cancer Management: Cu-64/Cu67, Can Be a Budding Hot Duo; Biomedicines 2022, 10, 2787, Https/doi.org/10.3390/ biomedicines1011787

2. Nerli, RB, Ghagane SC, Thakur ML, Chandra S, L. Gomella L. Voided Urine Sample in the Diagnosis of Prostate Cancer in Patients with Serum PSA Ranging Between 2.6 to 10 ng/mL. J. Cancer & Therapeutics In Press.

3. Thakur ML, Tripathi SK, Gomella LG, Salmanoglu E, Kim S, Kelly WK, Keith SW, Intenzo C, McCue P, Hoffman-Censits J, Trabulsi EJ. Imaging urothelial bladder cancer: A VPAC PET targeted approach. Can J Urol. 2021 Apr;28(2):10596-10602. PMID: 33872557.

4. Nerli RB, Ghagane SC, Bidi SR, Thakur ML, Gomella L. Voided urine test to diagnose prostate cancer: Preliminary report. CytoJournal 37,(4), 345-349, 2021 May 28. DOI 10.25259/Cytojournal_76_2020.

5. Nerli RB, Ghagane SC, Rangrez S, Chandra S, Thakur ML, Gomella L. Detection of bladder cancer using voided urine sample and by targeting genomic VPAC receptors. Indian J. Urology, Indian J. Urology, DOI, 10.4103/iju.iju_132-21. 37, 345349, 2021.

6. Thakur ML, Tripathi SK, Gomella LG, Salmanoglu E, Kim S, Kelly WK, Keith SW, Intenzo C, McCue P, Hoffman-Censits J, Trabulsi EJ. Imaging Imaging urothelial bladder cancer: A VPAC PET targeted approach. Can J Urol 2021;28(2): 10596-10602.

7. Eisler G, Kastner JR, Torjman MC, Khalf A, Diaz D, Dinesen AR, Loeum C, Thakur ML, Strasma P, Joseph JI. In vivo investigation of the tissue response to commercial Teflon insulin infusion sets in large swine for 14 days: the effect of angle of insertion on tissue histology and insulin spread within the subcutaneous tissue. BMJ Open Diabetes Research & Care. 2019;7(1):e000881. doi: 10.1136/bmjdrc-2019-000881.

8. Salmanoglu E, Klinger K, Bhimani C, Sevrukov A, and Thakur ML. Advanced approaches to imaging primary breast cancer: An Update. Clin Transl Imaging. 2019 Sep 10. doi: doi.org/10.1007/s40336-019-00346-z.

9. Tripathi SK, Kean R, Bongiomo E, Hooper DC, Jin YY, Wickstrom EJ, McCue PA, and Thakur ML. Targeting VPAC1 Receptors for Imaging Glioblastoma. Mol Imaging and Biol 2019 Jun 18. doi: 10.1007/s11307-019-01388-5. [Epub ahead of print].

10. Kumar P, Tripathi SK, Chen CP, Wickstrom E, Thakur ML. Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics. Molecular Imaging and Biology. 2019:21(1): 130-139. doi: 10.1007/s11307-018-1207-x. PMID: 29802552

11. Krishn SR, Singh A, Bowler N, Duffy AN, Friedman A, Fedele C, Kurtoglu S, Tripathi SK, Wang K, Hawkins A, Sayeed A, Goswami CP, Thakur ML, Iozzo RV, Peiper SC, Kelly WK, Languino LR. Prostate cancer sheds the αvβ3 integrin in vivo through exosomes. Matrix Biology. 2019;77:41-57. doi: https://doi.org/10.1016/j.matbio.2018.08.004.

12. Yang J, Simonneau C, Kilker R, Oakley L, Byrne MD, Nichtova Z, et al. Murine MPDZ-linked hydrocephalus is caused by hyperpermeability of the choroid plexus. EMBO Molecular Medicine. 2019;11(1):e9540.

13. Salmanoglu E, Halpern E, Trabulsi EJ, Kim S, Thakur ML. A glance at imaging bladder cancer. Clin Transl Imaging. 2018:6(35): 1-13. https://doi.org/10.1007/s40336-018-0284-9.

14. Truong H, Gomella LG, Thakur ML, Trabulsi EJ. VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. World J Urol. 2018;36(5):719-26. doi: 10.1007/s00345-018-2263-1. PubMed PMID: 29541892.

15. Salmanoglu E, Kim S, Thakur ML. Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail. Semin Nucl Med. 2018;48(2):86-99. doi: 10.1053/j.semnuclmed.2017.10.003. PubMed PMID: 29452623.

16. Thakur ML. Prostate Cancer: Beyond PSA. Urol Res Ther J. 2017; 1(1):114.

17. Tripathi SK., Kumar P, Trabulsi EJ., Kim S, McCue P, Intenzo C, Berger A, Gomella L, Thakur ML, VPAC-1 Targeted 64Cu-TP3805 kit preparation and its evaluation, Nuclear Medicine and Biology, 2017;51, 55-61. DOI: 10.1016/j.nucmedbio.2017.04.007.

18. Trabulsi EJ, Tripathi S, Gomella L, Solomides C, Wickstrom E, Thakur, M. Development of a voided urine assay for detecting prostate cancer noninvasively: A pilot study. BJUI. 2017;119:6 885-895. DOI:10.1111/bju.13775. PubMed PMID: 28075510 PMCID: PMC5444967.

19. Tripathi S, Trabulsi EJ, Gomella L, Kim S, McCue P, Intenzo C, Birbe R, Gandhe A, Kumar P, Thakur M. VPAC1 targeted 64Cu – TP3805 Positron emission tomography imaging of prostate cancer: Preliminary evaluation in man. Urology. 2016;88:111–18. PubMed PMCID: PMC4788593.

20. Kumar P, Tripathi SK, Chen C, Mehta N, Paudyal B, Wickstrom E, Thakur ML. Evaluation of a PACAP peptide analogue labeled with 68 Ga using two different chelating agents. Cancer Biotherapy and Radiopharmaceuticals. 2016;31:29–36. PMCID: PMC4753581.

21. Lisanti S, Tavecchio M, Chae YC, Liu Q, Brice AK, Thakur ML, Languino LR, Altieri DC. Deletion of the mitochondrial chaperone TRAP – 1 uncovers global reprogramming of metabolic networks. Cell Reports. 2014;8:671–7. PMCID: PMC4127146.

22. Sonar M, Wampole M, Jin Y, Chen C, Thakur Ml, Wickstrom E. Fluorescence detection of KRAS2 mRNA Hybridization in lung cancer cells with PNA-Peptides containing an internal Thiazole orange. Bioconjugate Chemistry. 2014;25:1697–708. PMCID: PMC4166030.

23. Sicoli D, Jiao X, Ju X, Velasco-Velazquez M, Ertel A, Addya S, Li Z, Ando S, Fatatis A, Paudyal B, Cristofanilli M, Thakur ML, Lisanti MP, Pestell RG. CCR5 receptor antagonists block metastasis to bone of v – src oncogene – transformed metastatic prostate cancer cell lines. Cancer Research. 2014;74:7103–14. PMCID: PMC4294544.

24. Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncology. 2014;10:457–74.

25. Thakur ML. Radiolabeled biomolecules for specific imaging of cancers of the breast, prostate and lungs. J Radioanal Nucl Chem (2014) 302:857 https://doi.org/10.1007/s10967-014-3268-x.

26. Sanders J, Wampole M, Chen C, Sethi D, Singh A, Dupradeau F, Wang F, Gray B, Thakur M, Wickstrom E. Effects of Hypoxanthine substitution in peptide nucleic acids targeting KRAS2 Oncogenic mRNA molecules: Theory and experiment. The Journal of Physical Chemistry B. 2013;117:11584–95.

27. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular Determinants of Epidermal Growth Factor Binding: A Molecular Dynamics Study. PLoS One. 2013; 8:1 e54136.

28. Wampole ME, Kairys JC, Mitchell EP, Ankeny ML, Thakur ML, Wickstrom E. Consistent surgeon evaluations of three – dimensional rendering of PET/CT scans of the abdomen of a patient with a ductal pancreatic mass. PLoS One. 2013;8:e75237.

29. Paudyal B, Zhang K, Chen C, Wampole M, Mehta N, Mitchell E, Gray B, Mattis J, Pak K, Thakur M, Wickstrom E. Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nuclear Medicine and Biology. 2013;40:994–9. PubMed PMCID: PMC5842439.

30. Thakur ML, Zhang K, Berger A, Cavanaugh B, Kim S, Channappa C, Frangos AJ, Wickstrom E, Intenzo CM. VPAC1 receptors for imaging breast cancer: A feasibility study. Journal of Nuclear Medicine. 2013;54:1019–25. PubMed PMCID: PMC5506835.

31. Sethi D, Thakur M, Wickstrom E. Receptor – specific peptides for targeting of Liposomal, polymeric, and Dendrimeric Nanoparticles in cancer diagnosis and therapy. Current Molecular Imaging. 2012;1:3–11.

32. Sethi D, Chen C, Jing R, Thakur M, Wickstrom E. Fluorescent Peptide–PNA Chimeras for imaging Monoamine Oxidase A mRNA in neuronal cells. Bioconjugate Chemistry. 2012;23:158–63.

33. Thakur ML, Zhang K, Paudyal B, Devakumar D, Covarrubias MY, Cheng C, Gray BD, Wickstrom E, Pak KY. Targeting apoptosis for optical imaging of infection. Molecular Imaging and Biology. 2011;14:163–71. PubMed PMCID: PMC5842677.

34. Wickstrom E, Chen C, Devadhas D, Wampole M, Jin Y, Sanders JM, Kairys JC, Ankeny ML, Hu R, Barner KE, Steiner KV, Thakur ML. Three dimensional projection environment for molecular design and surgical simulation. Studies in Health Technologies and Informatics 2011;163:691–5.

35. Sadri K, Ren Q, Zhang K, Paudyal B, Devadhas D, Rodeck U, Thakur M. PET imaging of EGFR expression in nude mice bearing MDA - MB - 468, a human breast adenocarcinoma. Nuclear Medicine Communications. 2011;32:563–9.

36. Goldberg BB, Merton DA, Liu J, Forsberg F, Zhang K, Thakur ML, Schulz S, Schanche R, Murphy GF and Waldman SA. Contrast – Enhanced Ultrasound Imaging of Sentinel Lymph Nodes after Peritumoral Administration of Sonazoid in a Melanoma Tumor Animal Model. J Ultrasound Med 2011;30:441–53.

37. Opitz AW, Wickstrom E, Thakur ML, Wagner NJ. Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determined in tumor – bearing mice. Oligonucleotides Electronic Publications. 2010;20:117–25.

38. Amirkhanov NV, Zhang K, Aruva MR, Thakur ML, Wickstrom E. Imaging human Pancreatic cancer Xenografts by targeting mutant KRAS2 mRNA with [ 111 In] DOTA n - Poly(diamidopropanoyl) m - KRAS2 PNA - d (Cys - Ser - Lys - Cys) Nanoparticles. Bioconjugate Chemistry. 2010;21:731–40. PMCID: PMC5912162.

39. Penn DL, Kim C, Zhang K, Mukherjee A, Devakumar D, Jungkind D, Thakur ML. Apoptotic abscess imaging with 99mTc - hYNIC - rh - annexin - v. Nuclear Medicine and Biology. 2010;37:29–34.

40. Thakur ML, Devadhas D, Zhang K, Pestell RG, Wang C, McCue P, Wickstrom E. Imaging spontaneous MMTVneu transgenic murine mammary tumors: Targeting metabolic activity versus genetic products. Journal of Nuclear Medicine. 2009;51:106–11.

41. Mukherjee A, Wickstrom E, Thakur ML. Imaging oncogenic expression. Euro J. Radiology. 2009;70:265–73. PubMed PMCID: PMC2680925.

42. Thakur ML. Genomic biomarkers for molecular imaging: Predicting the future. Seminars in Nuclear Medicine. 2009;39:236–46. PubMed PMCID: PMC2731478.

43. Petruzzi N, Shanthly N, Thakur M. Recent trends in soft – tissue infection imaging. Seminars in Nuclear Medicine. 2009;39:115–23. PubMed PMCID: PMC2657227.

44. Snook AE, Stafford BJ, Li P, Huang L, Birbe R, Schulz S, Schnell M, Thakur M, Rothstein JL, Eisenlohr LC, and Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunityCancer mucosal antigen evokes lineage – specific T cell responses opposing tumor metastasis and autoimmunity. J. National Cancer Inst. 2008;100:950–61.

45. Amirkhani NV, Dimitrov I, Opitz AW, Zhang K, Lackey JP, Cardi CA, Lai S, Wagner NJ, Thakur ML, Wickstrom E. Design of (Gd – DO3A)n - polydiamidopropanoyl - peptide nucleic acid - d(Cys - Ser - Lys - Cys) magnetic resonance contrast agents. Biopolymers. 2008;89:1061–76. PMCID: PMC2668199.

46. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RT, McQuillan DJ, Iozzo RV. An Antimetastatic role for decorin in breast cancer. The American Journal of Pathology. 2008;173:844–55. PubMed PMID: 18688028 PMCID: PMC2527080.

47. Zhang K, Mohan R. Aruva, Nylla Shanthly, Christopher A. Cardi, Satish Rattan, Chirag Patel, Christopher Kim, Peter A. McCue, Wickstrom E and Thakur ML. PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. J Nucl Med. 2008;49:112–21. PubMed PMCID: PMC5850935.

48. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, Yancopoulos GD, Dicker AP. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67(5):1526-37. doi: 10.1016/j.ijrobp.2006.11.011. PubMed PMID: 17234361.

49. Tian X, Aruva MR, Zhang K, Shanthly N, Cardi CA, Thakur ML, Wickstrom E. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor positive breast cancer xenografts with oncogene - specific [64Cu]Chelator - Peptide nucleic Acid - IGF1 analog radiohybridization probes. Journal of Nuclear Medicine. 2007;48:1699–707. PubMed PMID: 17909257.

50. Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, Cesarone G, Wickstrom E, Thakur ML. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regulatory Peptides. 2007;144:91–100. PubMed PMCID: PMC2587158.

51. Chakrabarti A, Zhang K, Aruva MR, Opitz AW, Wagner NJ, Thakur ML, Wickstrom E. Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [64Cu]DO3A - peptide nucleic acid - peptide nanoparticles. Cancer Biology & Therapy. 2007;6:948–56. PubMed PMID: 17611392.

52. Tian X, Chakrabarti A, Amirkhanov N, Aruva MR, Zhang K, Cardi CA, Lai S, Thakur ML, Wickstrom E. Receptor - mediated internalization of chelator-PNA-peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochemical Society Transactions. 2007;35:72–6. PubMed PMID: 17233604.

53. Seidler D, Goldoni S, Agnew C, Cardi C, Thakur M, Owens R, McQuillan D, Iozzo R. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase – 3 activation. Journal of Biological Chemistry. 2006;281:26408–18.

54. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, Iozzo RA, Cardi C, Thakur ML, Barker CA, Camphausen K. Endorepellin in vivo: Targeting the tumor vasculature and retarding cancer growth and metabolism. Journal of the National Cancer Institute. 2006;98:1634–46.

55. Welch MJ, Thakur ML. Session 3: Basic Research Issues. Journal of Nuclear Medicine. 2006;47(12):38N-40N.

56. Thakur ML, Sandler M. Shaping the future: The 2006 SNM Molecular Imaging Summit. J Nuc. Med. 2006;47:15–59.

57. Shanthly N. Aruva MR, Zhang K, Mathew B, Thakur ML. Stem cells: - a regenerative pharmaceutical. J Nucl Med Mol Imaging.2006;50:205–16.

58. Shanthly N, Aruva M, Zhang K, Thakur ML. 99mTc - Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. Q J Nucl Med Mol Imaging. 2006;50:104–12.

59. Wickstrom E & Thakur ML. Imaging Cancer Gene Activity Patients From Outside the Body. Biotechnology Healthcare. 2006;3:45–8.

60. Aruva MR, J Daviau, SS Sharma and Thakur ML. Imaging Thromboembolism with Fibrin – Avid 99m Tc Peptide: Evaluation in Swine. J Nucl Med. 2006;47:1–8. PubMed PMCID: PMC1525044.

61. Aruva MR, Tian X, Zhang K, Mathew B, Shanthly N, Cardi CA, Wickstrom E, Thakur ML. Imaging oncogene expression in breast cancer with receptor specific peptides and peptide nucleic acids. Symposium on trends in Radiopharmaceuticals (ISTR – 2005), Vienna, Austria, Book of extended synopses. 2005:19–20.

62. Tian X, Chakrabarti A, Amirkhanov N, Aruva M, Zhang K, Mathew B, Cardiq C, Qin W, Sauter E, Thakur M, Wickstrom E. External imaging of CCND1 , MYC , and KRAS oncogene mRNAs with tumor - targeted Radionuclide - PNA - Peptide Chimeras. Annals of the New York Academy of Sciences. 2005;1059:106–44.

63. Weiner RE, Thakur ML. Radiolabeled peptides in oncology role in diagnosis and treatment. BioDrugs. 2005;19:145–63.

64. C Cardi, Z Cao, Thakur ML, J Karp, P Acton. Pinhole PET (pPET): A Multi – Pinhole Collimator Insert for Small Animal SPECT Imaging on PET Cameras. IEEE Nucl. Sci. Symp. Conf. Rec. 2005:1973–75.

65. Chakrabarti A, Aruva MR, Sajankila SP, Thakur ML, Wickstrom E. Synthesis of novel peptide nucleic acid – peptide chimera for non - invasive imaging of cancer. Nucleosides, Nucleotides and Nucleic Acids. 2005;24:409–14.

66. Tian X, Aruva MR, Wolfe HR, Qin W, Sauter ER, Thakur ML, Waldman SA, Wickstrom E. Tumor - targeting peptide - PNA - peptide chimeras for imaging overexpressed oncogene mRNAS. Nucleosides, Nucleotides and Nucleic Acids. 2005;24:1085–91.

67. Thakur M, Lentle BC. Joint SNM/RSNA Moleculr Imaging Summit Statement. 2005;236:753–5.

68. Thakur ML. An interview with Society of Nuclear Medicine President Thakur ML, PhD Radiology Today. 2005;10.

69. Thakur ML. Meeting our patients’ current, future needs for radionuclides. J Nucl Med. 2005;46:22–4.

70. Thakur ML. SNM to Establish Center of Molecular Imaging as New Field Emerges, Grows Rapidly. J Nucl Med. 2005;45:23N - 4N.

71. Thakur ML. It’s time to voice why this nation needs to invest in molecular imaging/nuclear medicine. J Nucl Med. 2005;46:25N - 6N.

72. Thakur ML. SNM: Today and Tomorrow. J Nucl Med. 2005;46.

73. Tian X, Aruva MR, Qin W, Zhu W, Sauter ER, Thakur ML, Wickstrom E. Noninvasive molecular imaging of MYC mRNA expression in human breast cancer Xenografts with a [ 99m Tc]Peptide-Peptide nucleic Acid-Peptide Chimera. Bioconjugate Chemistry. 2005;16:70–9.

74. Thakur ML. Leadership update from the new SNM president. J Nucl Med. 2004;45.

75. Thakur ML. Strategic goals generate SNM success in 2004. J Nucl Med. 2004;46.

76. Tian X, Aruva MR, Qin W, Zhu W, K Duffy, Sauter ER, Thakur ML. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with Tc - 99m – peptide – peptide nucleic acid – peptide chimeras. J Nucl Med. 2004;45:2070–82.

77. Thakur ML, Tian X, Amirkhanov NV, Chakrabarti A, Aruva MR, Rao PS, Qin W, Zhu W, Sauter ER, Wickstrom E. The role of radiolabeled peptide – nucleic acid chimeras and peptides in imaging oncogene expression. Ind J Nucl Med. 2004;19:98–114.

78. Thakur ML, Aruva MR, J Gariepy, P Acton, S, Rattan, S Prasad, Wickstrom E, A Alavi. PET imaging of oncogene overexpression using Cu - 64 - VIP analog. Comparison with Tc - 99m - VIP analog. J Nucl Med. 2004;45:1381–9.

79. BB Goldberg, Merton DA, Liu JB, Thakur ML, Murphy GF, Needleman L, Tornes A, Forsberg F. Sentinel Lymph Nodes in a Swine Model with Melanoma: Contrast - enhanced Lymphatic US. Radiology. 2004;230:727–34.

80. Tian X, Aruva MR, Rao PS, Qin W, P Read, Sauter ER, Thakur ML, Wickstrom E. Ann NY. Imaging oncogene expression. Acad Sci. 2003;1002:165–88.

81. Rao PS, Tian X, Qin W, Aruva MR, Sauter ER, Thakur ML, Wickstrom E. 99mTc - peptide - peptide nucleic acid probes for imaging oncogene mRNAs in tumors. Nucl Med Comm. 2003;24:857 – 63.

82. Thakur ML, R Coss, R Howell, DL Leeper, J Liu, SP Rao, G Spana, P Wachsberger. Role of lipid soluble complexes in targeted tumor therapy. J Nucl Med. 2003;44:1293–300.

83. Wickstrom E, Tian X, Rao PS, Thakur ML, Qin W, and Sauter ER. Oncogene mRNA imaging with 99mTc- chelator - PNA - peptides. Russian Chemical Bulletin, International Edition. 2002;51:1083–99.

84. Weiner RE and Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Int J Radiat and Isotopes. 2002;57:749–63.

85. Wickstrom E, E Sauter, W Tian, Rao PS, W Quin, Thakur ML. Radiolabeled PNAs for imaging gene expression. Brazilian Archives of Biol and Tech. 2002; 45:57–69.

86. F Forsberg, AP Dicker, Thakur ML, NM Rawool, JB Liu, WT Shi, and LN Nazarian. Comparing contrast - enhanced ultrasound to immunohistochemical markers of angiogenesis in a human melanoma xenografts model. Preliminary results. Ultrasound in Med and Biol. 2002;28:445–51.

87. Rao PS, H Li, KC Reddy, Thakur ML. Solid Phase Preparation of 99mTc labeled radiopharmaceuticals. J Labelled Compounds and Radiopharm. 2001;45:231–39.

88. Thakur ML and JG McAfee. In Memoriam to Gopal Subramanian. Semin Nucl Med. 2001;21:259.

89. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med. 2001; 21:296–311.

90. Rao PS, Thakur ML, VR Pallela, R Patti, K Reddy, H Li, S Sharma, HL Pham, L Diggles, C Minami, CS Marcus. Tc - 99m labeled VIP analog. Evaluation for imaging colorectal cancer. Nucl Med and Biol. 2001;28:445–50.

91. Thakur ML, CS Marcus, SL Kipper, R Ahdoot, L Diggles, HL Pham, C Minami, BA Rhodes, MC Patel, T Smith. Imaging infection with LeuTech®. Nucl Med Comm. 2001;22:513–19.

92. Krishnamurthy GT, Krishnamurthy S, Thakur ML, McAfee JG. Gopal Subramanian and the Tc - 99m bone scan: a continuing benefactor. Semin Nucl Med. 2001:31:258–9.

93. Thakur ML, CS Marcus, S Saeed, VR Pallela, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski, and T Moody. Imaging tumors in humans with Tc - 99m - VIP. Annals of NY Academy of Science. 2000;921:37–44.

94. Rao PS, VR Pallela, D. Vassileva - Belnikolovska, D Jungkind, and Thakur ML. A receptor specific peptide for imaging infection and inflammation. Nucl Med Comm. 2000;21:1063–70.

95. VR Pallela, SP Rao, Thakur ML. Interferon - alpha - 2b immunoconjugate for improving immunoscintigraphy and immunotherapy. J Nucl Med. 2000;41:1108–13.

96. SL Kipper, EB Rypins, DG Evans, Thakur ML, TD, Smith, B Rhodes. Neutrophil - specific 99mTc - labeled anti - CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. J Nucl Med. 2000;41:449–55.

97. Thakur ML, VR Pallela, PM Consigny, S Rao, D Vassileva – Belnikolovksa, and R Shi. Imaging vascular thrombosis with Tc - 99m fibrin alpha - chain peptide. J Nucl Med. 2000;41:161–8.

98. Thakur ML, CS Marcus, S Saeed, V Pallela, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski. Tc - 99m - labeled Vasoactive Intestinal Peptide for rapid localization of tumors in humans. J Nucl Med. 2000;41:107–10.

99. PD Mozley, Thakur ML, A Alavi, T Smith, ED Barraclough, P Wilding, BA Rhodes, M Patel, A Mathur, and P Li. Effects of a 99mTc - labeled murine immunoglobulin M antibody to CD15 antigens on human granulocyte membranes in healthy volunteers. J Nucl Med. 1999;40:2107–14.

100. M Rodrigues, H Sinzinger, Thakur ML, W Becker, M Dewanjee, M Ezekowitz, Y Isaka, J Martin – Comin, M Peters, M Roca, J Stratton. Labelling of platelets with indium – 111 oxine and technetium – 99m hexamethylpropylene amine oxime: suggested methods. International Society of Radiolabelled Blood Elements (ISORBE). Eur J Nucl Med. 1999;26:1614–16.

101. W Becker, A Signore, Thakur ML. Imaging Infection: Introduction. Q J Nucl Med. 1999;43.

102. Weiner RE and Thakur ML. Imaging infection/inflammations. Pathophysiologic basis and radiopharmaceuticals. Q J Nucl Med. 1999;43.

103. VR Pallela, Thakur ML, PM Consigny, Rao PS, D Vasileva – Belnikolovska, and R Shi. Imaging thromboembolism with Tc - 99m labeled thrombospondin receptor analogs TP - 1201 and TP - 1300. Thrombosis Research. 1999; 3:191–201.

104. PD Mozley, JB Stubbs, SH Dresel, ED Barraclough, T Smith, M Patel, RB Sparks, and Thakur ML. Radiation dosimetry of a Tc – 99m – labeled IgM murine antibody to CD15 antigens on human granulocytes. J Nucl Med. 1999;40:625–30.

105. Thakur ML, J Li, S Kim, et al. Targeting tumors with Iodine – 123 labeled deoxyuridine. Cancer Detection and Prevention. Cancer Detection and Prevention. 1999;23:72–7.

106. VR Pallela, Thakur ML, S Chakder, and S Rattan. Tc – 99m labeled VIP receptor agonist. Functional studies. J Nucl Med. 1999; 40: 3552–360.

107. M Roca, J Martin – Comin, W Becker, M Bernardo – Filho, B Gutfilen, A Moisan, M Peters, E Prats, M Rodrigues, C Sampson, A Signore, H Sinzinger, Thakur ML. A consensus protocol for white blood cell labeling with Technetium - 99m hexamethylpropylene amine oxine. Eur J Nucl Med. 1998;25:797–9.

108. John CS, Gulden ME, Li J, Bowen WD, McAfee JG, Thakur ML. Synthesis, in vitro binding, and tissue distribution of radioiodinated 2 – [125I]N - (N - benzylpiperidin - 4 - yl) - 2 - iodo benzamide, 2 - [125I]BP: a potential sigma receptor marker for human prostate tumors. Nucl Med Biol. 1998;25:189–94.

109. Kolan HR, Pallela V, Thakur ML. Technetium - 99m labeled Vasoactive Intestinal Peptide (VIP). Preparation and preliminary evaluation. J Labelled Compounds and Radiopharmaceuticals. 1997;40:457–9.

110. Pallela V, Consigny M, Patti R, Thakur ML. Thrombospondin analog Tc - 99m - TP - 1201 for imaging thrombosis. J Labelled Compounds and Radiopharmaceuticals. 1997;40:452–4.

111. Thakur ML. Thromboembolism. Challenges for non - invasive diagnosis assessment. Nucl Med Comm. 1997;18:386–87.

112. Thakur ML, Li J, Donegan M, Pallela VR, Kolan HR, Duggaraju R, Maish D, Srivastava SC. Improved antibody targeting with interferon - alpha - 2b conjugate. J Immunotherapy. 1997;20:194–201.

113. Sands H, Li J, Duggaraju R, Kolan H, Donegan M, Elove GA and Thakur ML. Biodistribution and Pharmacokinetics of I - 131 - labeled LEX 032, a recombinant hybrid of Antichimotrypsin with inhibitory activity against human neutrophil elastase which affects neutrophil adhesion interactions. Int J Pharmacol Drug Metabolism and Disposition. 1997;25:631–36.

114. Thakur ML, Kolan HR, Li J, Duggaraju R, and Schally AV. Radiolabeled Somatostatin analogs in prostate cancer. Nucl Med Biology. 1997;24:105–13.

115. J Li, DA Merton, R Duggaraju and Thakur ML. Augmentation of tumor uptake of anti – melanoma antibody MEM – 136: Influence of enhanced tumor blood flow. Int J Nucl Med Biol. 1996;28:873–9.

116. Thakur ML, CS Marcus, P Henneman, J Butler, R. Sinow, L Diggles, C Minami, G Mason, S Klein and B Rhodes. Technetium – 99m labeled anti – SSEA – 1 antibody specific for human neutrophils: In vivo evaluation and assessment as an agent for imaging infectious diseases. J Nucl Med. 1996;37:1789–95.

117. Kolan H, Li J, Thakur ML. Sandostatin® labeled with Tc – 99m. In vitro stability, in vivo validity and comparison with In- 111 - DTPA - octreotide. Peptide Research. 1996;9:144–50.

118. Thakur ML, Kolan HR, Rifat S, Li J, Rux A, John E, Halmos G and Schally AV. Vapreotide labeled with Tc - 99m for imaging tumors: Preparation and preliminary evaluation. Int J Oncology. 1996;9:445–51.

119. Thakur ML. Molecular Probes in Nuclear Medicine: A new era. The V. Sarabhai Oration. Int J Nucl Med, 1996.

120. Li J, Duggaraju R, Maish DR, Thakur ML. Effect of Interferon - alpha - 2b on the enhancement of tumor uptake of Tc - 99m labeled monoclonal antibody. J Nucl Med Comm. 1996;17:346–52.

121. Weiner R, Thakur ML. Metallic Radionuclides: Application in Diagnostic and Therapeutic Nuclear Medicine. Radiochemical Acta. 1996;70/71:273–87.

122. Thakur ML, Li J, Chandy B, John EK. Transient Neutropenia: Neutrophil Distribution and Replacement. J Nucl Med. 1996;37:489–94.

123. Thakur ML. Radiolabeled Peptides: Now and the Future. Nucl Med Comm. 1995;16:724–32.

124. Thakur ML. Acerbate plays a major role in labeling proteins with Technetium – 99. J Nucl Med. 1994;35:1566.

125. Varnum J, Thakur ML, Schally A, et al. Rhenium labeled Somatostatin analog RC–160 1H NMR and computer modeling conformational analysis. J Biol Chem. 1994;269:12583 –88.

126. Li J, Merton DA, Thakur ML, et al. Influence of Biological Response Modifiers: Measurement of Tumor Blood Flow and Temperature. J of Immunotherapy. 1994;16:175–80.

127. Marcus C, Thakur ML, Huynh TV, et al. Imaging Rheumatic Joint Diseases with Anti – T Lymphocyte Antibody OKT3. Nucl Med Comm. 1994;15:824–30.

128. John E, Wilder S, Thakur ML. Tc - 99m labeled Monoclonal Antibodies: Significance of Specific and Non - specific Binding. J Nucl Med. 1994;35:876–81.

129. John E, Thakur ML. Structural Perturbations of Antibodies (MAbs) following radiolabeling. In vitro evaluating of different techniques. J Nucl Med Comm. 1994;15:24–28.

130. Vinitski S, Thakur ML, Consigny PM, et al. Use of Ferrum in MRI of lung parenchyma and pulmonary embolism. Magnetic Resonance Imaging. 1993;11:499–508.

131. John E, Thakur ML, DeFulvio J, et al. Rhenium – 186 labeled Monoclonal Antibodies for Radioimmunotherapy. Preparation and Evaluation. J Nucl Med. 1993;34:260–67.

132. Thakur ML. Scintigraphic Imaging of Venous Thrombosis: A State of the Art. Thrombotic and Hematologic Disorders. 1992;5:29–36.

133. Thakur ML, DeFulvio J, Tong J, et al. Evaluation of Biological Response Modifiers in the Enhancement of Tumor Uptake of Tc - 99m labeled macromolecules. A preliminary report. J Immun Methods. 1992;152:209–216.

134. Thakur ML, DeFulvio J. Technetium-99m labeled Monoclonal Antibodies for Immunoscintigraphy. Simplified Preparation and Evaluation. J Immun Methods. 1991;137: 217–24.

135. Thakur ML, DeFulvio J, Richard MD, et al. Technetium - 99m Labeled Monoclonal Antibodies: Evaluation of Reducing Agents. Int J Nucl Med Biol. 1991;18:227–33.

136. Thakur ML, DeFulvio J, Park CH, Damjanov A, Yaghsezian H, Jungkind D, Epstein A, McAfee JG. Technetium - 99m - labeled proteins for imaging inflammatory foci. Int J Rad Appl Instrum B. 1991;18:605–12.

137. Thakur ML, Vinitski S, Mitchell DG, Consigny PM, Lin S, Rifkin M. MR Imaging of Pulmonary Parenchyma and Emboli by Paramagnetic and Superparamagnetic Contrast Agents. Magnetic Resonance Imaging. 1990;8:625–30.

138. Thakur ML, DeFulvio J. Determination of Reduced Disulfide Groups in Monoclonal Antibodies. Biotechniques. 1990;8:512–16.

139. Thakur ML, DeFulvio J, Richard MD. Human Neutrophils: Evaluation of Adherence, Chemotaxis Phagocytosis, following interaction with radiolabeled antibodies. J Nucl Med Comm. 1990;11:37–43.

140. Richard MD, Thakur ML, Stedman J, et al. Preparation and Evaluation of New Bifunctional Chelating Agents: A preliminary report. Nucl Med Biol. 1990;17:181–91.

141. Thakur ML. Immunoscintigraphic Imaging of Inflammatory Lesions. Preliminary findings and future possibilities. Sem in Nucl Med. 1990;20:92–8.

142. Thakur ML. Radiolabeled Blood Cells: Perspectives and Directions. Nucl Med Biol. 1990;17:41 – 7.

143. Thakur ML. In vitro and in vivo evaluation of Tc – 99m labeled leukocytes. Indian J Nucl Med. 1989;44:119 – 25.

144. Thakur ML, Richard MD, and FW White III. Monoclonal Antibodies as agents for selective Radiolabeling of human neutrophils. J Nucl Med. 1989;29:1817 – 25.

145. Thakur ML, DB Leeper, Rowley R and Park CH. Radioiodinated Rhodamine – 123: Preparation and Preliminary Evaluation as an agent for Tumor Scintigraphy. Nucl Med Biol. 1988;15:517 – 24.

146. Madsen MT, Park CH and Thakur ML. Dosimetry of Iodine – 131 Ethiodol in the treatment of Hepatoma. J Nucl Med. 1988;29:1038 – 44.

147. Zoghbi SS, Thakur ML, HD Sostman. Indium – 111 – oxine labeled Swine platelets and their survival in vivo. Laboratory Animal Sciences. 1988;38:444 – 47.

148. Thakur ML. Live bacteria with In – 111. Eur J Nucl Med. 1987;13:266.

149. Park CH, Thakur ML, Madsen MT. Distribution of Iodized Oil within the liver after Hepatic Arterial Injection. Radiology. 1987;164:585 – 96.

150. C Intenzo, Desai A, Thakur ML and Park CH. Comparison of Leukocytes labeled with Indium – 111 – 2 – Mercapto – N – oxide and Indium – 111 – oxine for Abscess Detection. J Nucl Med. 1987;28:438 –41.

151. SM Kim, Park CH and Thakur ML. Platelet Sequestration in Widespread Pulmonary Hemangiolymphangiectasia. Demonstration by Indium – 111 labeled platelets. Clin Nucl Med. 1987;12:215 – 16.

152. Thakur ML, Thiagarajan P, F White, Park CH and PH Maurer. Monoclonal Antibodies for Specific Cell Labeling: Considerations, Preparations, and Preliminary Evaluation. Nucl Med Biol. 1987;14:51 – 58.

153. Thakur ML, Sedar AW. Ultrastructure of human platelets following Indium – 111 labeling in plasma. Nucl Med Comm. 1987;8:69 – 78.

154. L Simerman, Park CH, Thakur ML. Articfactual Focal Lung Activity with Indium – 111 labeled leukocytes. A technical pitfall. Clin Nucl Med. 1986;12:840 – 41.

155. Desai AG, Thakur ML. Radiolabeled Blood Cells: Techniques and Applications. Critical Reviews in Clin Laboratory Sci. 1986;24:95 – 122.

156. Thakur ML. A look at Radiolabeled Blood Cells. J Nucl Med Biol. 1986;13:147 – 58.

157. Thakur ML and McKenney SM. Indium – 111 – 2 – Mercaptopyridine – N – oxide (Merc) labeled human platelets. Mechanism of labeling and intracellular location of In – 111 and Merc. J Lab Clin Med. 1986;107:141 – 47.

158. Thakur ML, McKenney SM, and Park CH. Evaluation of Indium – 111 – 2 – Mercaptopyridine – N – oxide for labeling leukocytes in plasma: A kit preparation. J Nucl Med. 1985;26:518 – 23.

159. Thakur ML, Intenzo CM, Desai AG, et al. The use of 111In – Merc in localization of abscesses in humans. Int J Nucl Med Biol. 1985;12:404 – 07.

160. Desai AG and Thakur ML. Radiopharmaceuticals for spleen and bone marrow studies. Sem in Nucl Med. 1985;15:229 – 38.

161. Thakur ML, Zoghbi SS, HD Sostman, RD Neuman, P Carbo, P Lord, RH Greenspan, and Gottschalk A. The Influence of Heparin on the in vivo distribution of In – 111 labeled platelets. Investigative Radiology. 1985;20:198 – 202.

162. Thakur ML, SL McKenney, Park CH. Simplified and efficient labeling of human platelets in plasma using Indium – 111 – 2 – mercaptopyridine – N – oxide: Preparation and evaluation. J Nucl Med. 1985;26:510 – 17.

163. C Intenzo, Thakur ML, Park CH. Discordant Gallium – 67 and Indium – 111 leukocyte images in a suspected pelvic abscess. Clin Nucl Med. 1984;9:654.

164. Thakur ML, et al. The significance of chromosomal aberrations in Indium – 111 labeled lymphocytes. J Nucl Med. 1984;25:922 – 27.

165. Thakur ML, et al. Preparation and Evaluation of 99mTc DEPE as a Cardiac Perfusion Agent. Int J Appl Radiat Isotopes. 1984;6:35:507 – 15.

166. Thakur ML, et al. Radioisotopenmarkiering Menschlicher Blutzellen – Ein Historischer Uberlick. Jahrgang, Heft 3, 1984.

167. Thakur ML, CL Seifert, Madsen MT, McKenney SM, AD Desai, Park CH. Neutrophil Labeling: Problems and Pitfalls. Sem in Nuclear Medicine. 1984;14:107 – 17.

168. Thakur ML. Radioisotopic labeling of platelets: A historical perspective. Sem in Thrombosis and Hemostasis. 1983;9:79 – 85.

169. Thakur ML. Preparation, characterization and evaluation of Tc – 99m DMPE as a myocardial imaging agent. In J Appl Radiat Isotopes. 1983;34: 617 – 24.

170. Thakur ML. Approaches to radiolabeling blood cells: Past, present and future. Nuclear Geneeskundig Bull. 1982;4:4 – 8.

171. HD Sostman, RD Neuman, J Loke, Zoghbi SS, Thakur ML, et al. Detection of pulmonary embolism in man with 111 Indium labeled autologous platelets. Am J Radiology. 1982;138:945 – 47.

172. HD Sostman, RD Neuman, Zoghbi SS, PF Lord, Thakur ML, P Carbo, et al. Experimental studies with 111 Indium labeled platelets in pulmonary embolism. Inv Radiology. 1982;17:367 – 74.

173. Thakur ML, LJ Walsh, Zaret BL and Gottschalk A. Effect of antiarrhythmic drugs on the chemotactic ability and nylon wool adherence of Indium – 111 labeled human polymorphonuclear leukocytes. J Nucl Med. 1982;23:131 – 35.

174. Thakur ML. Cell labeling achievements. Challenges and prospects. J Nucl Med. 1981;22:1011 – 14.

175. Thakur ML. New radionuclides in the diagnosis of obscure infection. J Conn Md. 1981;45:302 – 05.

176. Thakur ML, Walsh L, HL Malech, and Gottschalk A. Indium – 111 platelets: Improved method, efficacy and evaluation. J Nucl Med. 1981;22:381 – 85.

177. Davies RA, Thakur ML, Berger HJ, et al. Imaging the inflammatory response to acute myocardial infarctions in man Indium – 111 labeled autologous leukocytes. Circulation. 1981;63:826 – 32.

178. Weiner R, Hoffer PB, Thakur ML. Lactoferrin: Its role as a Ga – 67 binding to protein in polymorphonuclear leukocytes. J Nucl Med. 1981;22:32 – 7.

179. Thakur ML, Riba AL, Gottschalk A, Zaret BL. Canine and rabbit platelets labeled with In-111 oxine. J Nucl Med. 1980;21:597.

180. RR Armas, Thakur ML, Gottschalk A. A simplified method of selective spleen scintigraphy with Tc – 99m labeled erythrocytes. Clinical Applications: Concise Communications. J Nucl Med. 1980;21:413.

181. Ruth TJ, Lambrecht RM, Wolf AP, Thakur ML. Cyclotron isotopes and radiopharmaceuticals. Aspects of production, elution, and automation of 81Kr generators. International J Appl Radiat and Isotopes. 1980;31:51 – 9.

182. Dwyer JM, Wade N and Thakur ML. Development of an isotope dilation assay to determine the T – cell mass in guinea pigs. Adv Exp Med Biol. 1979;114:113 – 17.

183. Riba AL, Thakur ML, Gottschalk A, Zaret BL. Imaging experimental coronary artery thrombosis with Indium – 111 platelets. Circulation. 1979;60:767 – 75.

184. Ferluga J, Allison AC, Thakur ML. The use of Indium – 111 for studies of cytotoxicity mediated by lymphocytes or by antibodies and complement. Clin Lab Immunol. 1979;1:339 – 42.

185. Hoffer PB, Samuel A, Bushberg JT, Thakur ML. Desferrioxamine mesylate (desferal): A contrast enhancing agent for 67Ga imaging. Radiology. 1979; 31:775 –79.

186. Zakhireh B, Thakur ML, Malech HL, Cohen MS, Gottschalk A, Root RK. Indium-111-labeled human polymorphonuclear leukocytes: Viability, random migration, chemotaxis, bactericidal capacity, and ultrastructure. J Nucl Med. 1979;20:741 –47.

187. Armas R, Thakur ML, Gottschalk A. A simple method of spleen imaging with 99m Tc-Labeled Erythrocytes 1. Radiology. 1979;132:215 – 16.

188. Thakur ML, Gottschalk A, Zaret BL. Imaging experimental myocardial infarction with In – 111 labeled autologous leukocytes: Effect of infarct age and residual regional myocardial blood flow. Circulation. 1979;60:297.

189. Hoffer PB, Samuel A, Bushberg J, Thakur ML. Effect of desufferioxamine on tissue and tumor retention of 67Ga: Concise communication. J Nucl Med. 1979;20:248 – 51.

190. Riba AL, Thakur ML, Gottschalk A, et al. Imaging experimental infective endocarditis with In – 111 labeled blood cellular components. Circulation. 1979;59:336 – 43.

191. Zakhireh B, Thakur ML, Maleeh HL, Gottschalk A, Root RK. Chemotaxis and random migration of In – 111 labeled neutrophils. Clin Research. 1978;26:459.

192. Joist JH, Baker RK, Thakur ML and Welch MJ. Indium – 111 labeled platelets: Uptake and loss of label and in vitro function of labelled platelets. J Lab Clin Med. 1978;92:829 – 36.

193. Riba AL, Downs J, Thakur ML, et al. Technetium – 99m stannous pyrophosphate. Imaging of experimental endocarditis. Circulation. 1978;58:111 – 19.

194. Lavender JP, Goldman JM, Arnot RN and Thakur ML. Kinetics of In – 111 labeled lymphocytes in normal subjects and patients with Hodgkin's Disease. Br Med J. 1977;2:797 – 99.

195. Rannine GH, Thakur ML, and Ford WL. Indium – 111 labeled lymphocytes: Preparation, evaluation and comparison with 51 – Cr lymphocytes in rats. Clinical and Experimental Immunology. 1977;29:509 – 14.

196. Thakur ML, Segal AW et al. Indium – 111 labeled cellular blood components: Mechanisms of labeling and intracellular localization in human neutrophils. J Nucl Med. 1977;18:1022 – 17.

197. Thakur ML, JP Lavender, RNArnot, DJ Silvester and Segal AW. Indium – 111 labeled leukocytes in man. J Nucl Med. 1977;18:1014 – 21.

198. Welch MJ, Thakur ML, Coleman RE, Patel MC, Seigal BA, Ter – Pogassian MM. Gallium – 68 Red Cells and platelets. New agents for positron tomography. J Nucl Med. 1977;18:558 – 62.

199. Thakur ML. Indium – 111. A New Radioactive tracer for leukocytes. Exper Hematol. 1977;5:145 – 50.

200. Thakur ML. A review of Radiopharmaceutical prepared with Gallium – 67 and Indium – 111 (an invited review article). Int J Radiat and Appl Isotopes. 1977;28:183 – 201.

201. Weiss ES, Ahmed SA, Thakur ML, Welch MJ, Coleman RE, Sobel BE. Imaging of the inflammatory response in ischemic canine myocardium with 111indium-labeled leukocytes. The American Journal of Cardiology. 1977;40:195 – 99.

202. Thakur ML, Coleman RE and Welch MJ. Indium – 111 labeled leukocytes for the localization of abscesses: Preparation, analysis, tissue distribution and comparison with Ga – 67 citrate in dogs. J Lab Clin Med. 1977;89:217 – 28.

203. Thakur ML, Coleman RE, Hoist JH and Welch MJ. Indium – 111 labeled platelets: Studies on preparation and evaluation of in vivo and in vitro functions. Thrombosis Research. 1976;9:345.

204. Segal AW, Thakur ML, Arnot RN, and Lavender JP. Indium – 111 labeled leukocytes for localization of abscesses. Lancet. 1976;1057.

205. Thakur ML, Coleman RE, Mayhall CG, Welch MJ. Preparation and evaluation of 111 in-labeled Leukocytes as an abscess imaging agent in dogs. Radiology. 1976;119:731 – 2.

206. Thakur ML and Waters SL. Evaluation of a method for the preparation of high specific activity radioionated oestradiol. Int J Appl Radiat Isotopes. 1976;27:585 – 88.

207. McAfee JG and Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. Part II Particles. J Nucl Med. 1976;17:488 – 92.

208. McAfee JG and Thakur ML. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. Part I Soluble Agents. J Nucl Med. 1976;17:480 – 87.

209. Horlock PL, Thakur ML, Watson IA. Cyclotron produced lead-203. Postgraduate Medical Journal. 1975;51:751 – 4.

210. Thakur ML, Chauser BM, Hudson RF. The preparation of iodine-123 labelled sodium ortho-iodo hippurate and its clearance by the rat kidneys. The International Journal of Applied Radiation and Isotopes. 1975;26:319 – 20.

211. Ghanadian R, Waters SL, Thakur ML, Chisholm GD. Studies with radioactive iodine labelled oestrogens as prostate scanning agents. The International Journal of Applied Radiation and Isotopes. 1975;26:343 – 6.

212. Merrick MV, Lavender JP, Poole GW, Stradling P, Thakur ML, Walter LH. 111 in-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen. The British Journal of Radiology. 1975;48:279 – 85.

213. Merrick MV, Nunn AD, Thakur ML, Gunasekera SW. The influence of ligand on the tissue distribution of carrier free 111In in the rat. International Journal of Nuclear Medicine and Biology. 1975;2:45 – 8.

214. Thakur ML. Analytical control of a radiopharmaceutical using a cathode ray polarograph. Journal of Radioanalytical Chemistry. 1975;24:89 – 97.

215. Thakur ML. The preparation of Iodine – 123 labeled contrast agents. Int J Appl Radiat Isotopes. 1974;25:576.

216. Thakur ML. Determination of microgram quantities of gadolinium by cathode-ray polarography Cathode ray polarography of rare earths: Determination of microgram quantities of gadolinium. Talanta. 1974;21:771.

217. Waters SL, Nunn AD and Thakur ML. Cross section measurements for the 75As (a, 2n) 77Br reaction. J Inorg Nucl Chem. 1973;35 3414 – 16.

218. Thakur ML. The preparation of indium-111 labelled bleomycin for tumour localisation The preparation of Indium – 111 Bleomycin for tumor localization. Int J Appl Radiat Isotopes. 1973;24:357 – 59.

219. Thakur ML, Merrick MV, Gunasekera SW. Some pharmacological aspects of a new radiopharmaceutical Indium – 111 bleomycin. IAEA/SM – 171, Radiopharmaceuticals and Labeled Compounds, Vol. 11, 183 – 193, I.A.E.A., Vienna. 1973.

220. Merrick MV, Gunasekers SW, Lavender PL, Nunn AD, Thakur ML and Williams ED. The use of Indium – 111 for tumor localization. A comparison of several chelates with gallium – 67 in inflammatory and neoplastic lesions, with a note on Indium – labeled Bleomycin. In Medical Radioisotope Scintigraphy, Vol. 11, 221 – 229, I.A.E.A. Vienna. 1973.

221. Thakur ML and Waters SL. Production and separation of cyclotron produced Dysprosium – 157. J Inorg Nucl Chemistry. 1973;35:1787 – 91.

222. Thakur ML, Merrick MV. Indium – 111 labeled Bleomycin as a tumor localizing agent. Proceedings of the International Symposium on Bleomycin, London, Lundbeck Ltd. Welwyn, Herts. 1972.

223. Thakur ML and Nunn AD. Cyclotron produced Indium – 111 for medical use. Int J Appl Radiat Isotopes. 1972;23:139.

224. Clark JC, Thakur ML and Watson IA. The production of Potassium – 43 for medical use. Int J App Radiat Isotopes. 1972;23:329.

225. Thakur ML, Nunn AD and Waters SL. Iron – 52: Improving its recovery from cyclotron targets. Int J App Radiat Isotopes. 1971;22:481.

226. Thakur ML. The separation of the oxidation states of some elements with the use of Tri – n – butyl orthophosphate. Separation Sciences. 1970;5:645 – 51.

227. Goulding RW, Palmer AJ and Thakur ML. The preparation of Aryl derivatives labeled with Fluorine – 18. Sixth Radiochemical Conference, Czeckloslovakia, 1970.

228. Silvester DJ and Thakur ML. Cyclotron production of carrier free gallium – 67. Int J Appl Radiat Isotopes. 1970;21:630.

229. Thakur ML, Clark JC and Silvester DJ. The production of 117Sb – labeled Potassium antimony tartrate for medical use. Int J Appl Radiat Isotopes. 1970;21:33.

230. Thakur ML and Nunn AD. Preparation of carrier free zinc – 62 for medical use. Radiochem. Radioanal Letter. 1969;2:301.

Abstracts:

  1. S.K. Tripathi, M. Kumari, B. Thapa, O. Dahlgren, K. Wang, A. Lnu, E. Dale, C. Clark, E. Trabulsi, L. Gomella, M. Thakur. Targeting VPAC in voided urine for detecting prostate cancer. 23rd Annual Meeting of Society of Urologic Oncology, San Diego, CA, November 29-December 2, 2022.

  2. S.K. Tripathi, M. Kumari, B. Thapa, O. Dahlgren, C. Clark, E. Trabulsi, L. Gomella, M. Thakur. Prostate Cancer: Novel approaches to Diagnosis and therapy. 23rd Annual Meeting of Society of Uroligic Oncology, San Diego, CA, November 11-December 2, 2022.

  3. S.K. Tripathi, M. Kumari, B. Thapa, O. Dahlgren, C. Clark, E. Trabulsi, L. Gomella, M. Thakur. Prostate Cancer: Novel approaches to Diagnosis and therapy. European Society of Medicine General Assembly, Virtual, August 4-6, 2022.

  4. S.K. Tripathi, B. Thapa, M. Thakur. Targeted Cu-67-TP3805: An effective theranostic for prostate cancer. SNMMI Annual Meeting, Vancouver, Canada, June 11-14, 2022.

  5. M. L. Thakur, S. K. Tripathi, L. G. Gomella, E. Salmanoglu, S. W. Keith, W. K. Kelly, J. H. Censits, C. Intenzo, S. Kim, P. McCue, and E. J. Trabulsi. Imaging urothelial bladder Cancer using Cu-64: A novel approach. International Discussion Meeting on Future of Accelerator Applications and Radiotracers Research (FAAARR-2021). University of Calcutta, Kolkata, India, July 26, 2021.

  6. M. L. Thakur, S. K. Tripathi. VPAC targeted Cu-67-TP3805 for prostate cancer therapy. ACS Radiotherapeutics: From Isotope Production to Targeted Radiotherapy. Online presentation, April 5, 2021.

  7. M. L. Thakur, S. K. Tripathi, E. J. Trabulsi, and L. G. Gomella. Targeting VPAC receptors on cells shed in voided urine to image prostate cancer: A novel approach. Annual Congress Liquid Biopsy, Barcelona, Spain, October 30-31, 2021.

  8. SNMMI Annual Meeting, Anaheim, CA. Mathew Thakur, Leonard Gomella, Sushil Tripathi, Ebru Salmanoglu, Scott Keith, William Kelly, Jean Hoffman-Censits, Charles Intenzo, Sung Kim, Peter McCue, and Edouard Trabulsi. “PET imaging of urothelial bladder cancer: addressing an unmet need”. J Nucl Med 2019 60:502.

  9. SNMMI Annual Meeting, Anaheim, CA. Molecular Targeting Probes - Radioactive & Nonradioactive - Radiochemistry & Chelation Posters: Sushil Tripathi, Paul Jicman, and Mathew Thakur. “Comparison of N2S2 and NODAGA as chelators for 64Cu-labeled PET imaging in mice bearing prostate tumor”. J Nucl Med 2019 60:1624b.

  10. ISORBE & Israel Society of Nuclear Medicine, Neve Ilan Hotel, Tel Aviv, Israel. “Stem cells; A regenerative pharmaceutical”, March 8, 2019.

  11. SNMMI Annual Meeting, Philadelphia, PA. “Currently Available Radiopharmaceuticals”, “Diagnostic Approaches to Urological Oncology”, “VPAC1 biomarker for imaging triple negative breast cancer”, “A comparison of in vivo stability of Ga-68 labeled peptide conjugate for targeting VPAC receptors”. Philadelphia, PA, June 2018.

  12. Kumar P, Tripathi S, Mehta N, Wickstrom E and Thakur ML. A preclinical evaluation of Ga-68 labeled NODAGA and DOTA peptide conjugates to image breast cancer. J Nucl Med May 2017; 58:1 675.

  13. Tripathi S, Kumar P, Manoff D, Barta J, Hehn B and Thakur ML. An emerging biomarker for detection of lung cancer. J Nucl Med 2017; 58:1 1044.

  14. Thakur ML, Tripathi S, Manoff D and Kavuru M. Targeting VPAC1 genomic receptors for optical imaging of lung cancer. European Journal Nuclear Medicine and Molecular Imaging 2016; 41: 2 S151 – S705.

  15. Tripathi S, Trabulsi EJ, McCue P, Kumar P, Gomella L, Thakur, ML: VPAC-1 targeted 64Cu-TP3805 kit preparation and evaluation for translational research in humans. J Nucl Med. 2016;57:suppl. 2, 6.

  16. Pardeep K, Tripathi S, Chen C, Mehta N, Paudyal B, Wickstrom E, Thakur ML: A preclinical evaluation of Ga-68 labeled VPAC receptor specific peptide using different chelating agents, Nodaga and N2S2. J Nucl Med 2016;57:suppl. 2, 1171.

  17. Thakur ML, Trabulsi EJ, Tripathi S, Kim S, McCue P, Birbe R, Randhe A, Kumar P, Intenzo C, Gomella L: Targeting VPAC1 for imaging prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:S1-S924.

  18. Thakur ML. Investigation into novel but simple, non – invasive approach for detection of genitourinary cancers (Invited) World Congress on Cancer and Prevention Methods. Dubai, August 2015.

  19. Thakur, ML. Optical Imaging of Genitourinary Cancer: A Biofluid Assay (Invited) Biofluid Biopsies and High – Value Diagnostics. Boston, 2015.

  20. Thakur ML. Cancer Biomarkers: Challenges and Opportunities: (invited) 47th Annual Conference of SNM India. Punducherry, India, 2015.

  21. Tripathi S, Trabulsi E, Thakur ML, et al.: VPAC1 targeted Cu – 64 – TP3805 imaging of prostate cancer. Journal of Nuclear Medicine 2015; 56:454.

  22. Tripathi S, Trabulsi EJ, Thakur ML, et al.: VPAC1 targeted detection of genitourinary cancer: a urinary assay. Journal of Nuclear Medicine 2015; 56:388.

  23. Kumar P, Tripathi S, Cheng C, Wickstrom E, Thakur ML. Evaluation of a peptide labeled with Ga – 68 using two chelating agents. 3rd Theranostics World Congress on Galliun – 68 and PRRT. Journal of Nuclear Medicine. 56 (s2): 13. May 2015.

  24. Thakur ML. Stem cells. Molecular Imaging and Radionuclide Therapy; 24(1):37. 17th ISORBE Congress. Izmir, Turkey, 4 – 8 March 2015.

  25. Wickstrom E, Chen C – P, Paudyal B, Wampole ME, Zhang K, Paudyal B, Wang A, Tripathi SK, Kumar P, Lu B, Thakur ML: Hypoxanthine wobble base multimutant KRAS2 mRNA PET imaging agent in G12D mice. American Association for Cancer Research Conference on RAS Oncogenes: From Biology to Therapy, Lake Buena Vista, Florida, February 24 – 27 2014.

  26. Gomella LG, Solomides C, Trabulsi EJ, Chen C – P, Tripathi SK, Wickstrom E, Zhang K, Thakur ML: Vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide receptor 1 (VPAC1 targeted detection of genitourinary cancer: a urinary assay. American Association of Genitourinary Surgeons 123rd Meeting, Amelia Island, Florida, April 23 – 26 2014.

  27. Thakur M, Tripathi S, Solomides C, et al.: Non – invasive urine assay for detection of genitourinary cancer. European Journal Nuclear Medicine and Molecular Imaging 2014; 41 (Supplement 2):S151 – S705.

  28. Tripathi SK, Trabulsi E, Kim S, Intenzo C, McCue P, Mashayekh A, Gandhe A, Wickstrom E, Gomella L, Thakur ML. VPAC1 targeted PET imaging of prostate cancer. J Nucl Med; (Supplement 1):1393. 2014.

  29. Kumar P, Tripathi SK, Cheng C, Paudyal B, Mehta N, Wickstrom E, Thakur ML. Preparation and preliminary evaluation of Ga – 68 NODAGA – peptide for targeting VPAC1 receptor. J Nucl Med; (Supplement 1):1175. 2014.

  30. Tripathi SK, Trabulsi E, Kumar P, Birbe R, Cotzia P, McCue P, Solomides C, Gomella L, Thakur ML. Imaging bladder cancer: correlation with histopathologic findings. J Nucl Med; 55 (Supplement 1):67. 2014.

  31. Sonar MV, Wampole ME, Jin Y – Y, Thakur ML, Wickstrom E: Thiazole orange PNA – peptides as intercalative fluorescence imaging agents to detect hybridization with KRAS2 mRNA. Gordon Research Conference on Chemistry & Biology of Peptides, Ventura Beach, California, February 23 – 28 2013.

  32. Tripathi SK, Zhang K, Birbe R, Cotzia P, McCue PA, Solomides C, Gomella LG, Trabulsi EJ, Thakur ML. Detecting genitourinary cancer ex vivo: correlation with histopathologic findings. Eur J Nucl Med Mol Imaging; 40 (Suppl 2):S179. 2013.

  33. Wickstrom E, Chen CP, Paudyal B, Wampole ME, Zhang K, Wang A, Lu B, Thakur ML. Mutant KRAS2 mRNA, PET imaging in spontaneous transgenic lung cancers. American Association for Cancer Research 104th Annual Meeting 2013.

  34. Tripathi SK, Zhang K, Paudyal B, Mehta NA, Wang Y Wampole ME, Wickstrom E, Lu B. Imaging of KRAS2 – activated early onset lung cancer in transgenic mice. J Nucl Med 54: Supplement; 2 p 100P. 2013.

  35. Thakur ML, Zhang K, Tripathi SK, Solomides C, Channappa C, Chen CP, Wickstrom E, Trabulsi EJ, Gomella LG. Gene based detection of genitourinary cancer cells. J Nucl Med 54: Supplement; 2 p 19P. 2013.

  36. Sonar MV, Wampole ME, Sanders JM, Thakur ML, Wickstrom E. Design and synthesis of thiazole orange PNA, – peptides as fluorescence imaging agents for KRAS2 mRNA. International Meeting on Chemical Biology Indian Institute of Science Education and Research 2013.

  37. Thakur ML, Zhang K, Tripathi SK, Channappa C, McCue PA, Trabulsi EJ. Ex vivo evaluation of Cu – 64 – TP3805 for imaging prostate cancer. J Nucl Med Abstract Book Supplement; 54: 248P. 2013.

  38. Chen CP, Sethi D, Thakur ML, Wickstrom E. Hypoxanthine – containing peptide nucleic acid hybridization agents to detect multiple KRAS2 mutations. XX International Roundtable on Nucleosides Nucleotides and Nucleic Acids 2012.

  39. Sanders JM, Wampole ME, Thakur ML, Wickstrom E. Molecular dynamics analysis of the binding affinities of seven ligands of human epidermal growth factor receptor. Division of Computers in Chemistry American Chemical Society 244th Annual Meeting 2012.

  40. Wampole ME, Sanders JM, Thakur ML, Wickstrom E. Computational design of peptide nucleic acid conjugates for imaging oncogenic KRAS2 mRNA, in vivo. Division of Computers in Chemistry American Chemical Society 244th Annual Meeting 2012.

  41. Chen CP, Sethi D, Thakur ML, Wickstrom E. Hypoxanthine – containing peptide nucleic acid hybridization agents to detect multiple KRAS2 mutations. Division of Biological Chemistry American Chemical Society 244th Annual Meeting 2012.

  42. Jin YY, Chen CP, Thakur ML, Wickstrom E. Directing miRNA, – regulatory PNAs to breast cancer cells with synthetic targeting peptides. Division of Biological Chemistry American Chemical Society 244th Annual Meeting 2012.

  43. Chen CP, Zhang K, Paudyal B, Gray BD, Pak KY, Wickstrom E, Thakur ML. Synthesis and critical evaluation of a peptide – NIR fluorophore conjugate for molecular imaging of a breast cancer biomarker. World Molecular Imaging Congress 2012.

  44. Jin YY, Chen CP, Thakur ML, Wickstrom E. Directing miRNA, – regulatory PNAs to breast cancer cells with synthetic targeting peptides. American Society of Human Genetics Annual Meeting 2012.

  45. Thakur ML, Zhang K, Paudyal B, Mehta N, Gray B, Pak K, and Wickstrom E. Optical imaging for determination of apoptosis medicated therapeutic efficacy. J. Nucl. Med. Meeting, May; 53: 342P. 2012.

  46. Thakur ML, Paudyal B, Zhang K, Chen C, Mehta M, Wickstrom E, Gray B, Mattis J, and Pak K. Determining efficacy of breast cancer (BC) therapy by PET imaging of HER2 mRNA. J. Nucl. Med. Meeting, May; 53: 210P. 2012.

  47. Thakur ML, Zhang K, Chen C, Gray B, Pak K, Wickstrom E. Optical imaging of breast cancer using a peptide – NIR fluorophore TP4303. J. Nucl. Med. Meeting, May; 53: 23P. 2012.

  48. Thakur ML, Zhang K, Berger A, Cavanaugh BC, Kim S, Frangos AJ, Dascenzo C, Wickstrom E, Intenzo CM. Positron Emission Mammography (PEM): Beyond F – 18 – FDG. J. Nucl. Med. Meeting, May; 53: 3P. 2012.

  49. Wickstrom E, Chen CP, Devadhas D, Wampole M, Jin YY, Sanders JM, Thakur ML, Kairys JC, Ankeny ML, Hu R, Barner KE, Steiner KV. Three dimensional projection environment for molecular design and surgical simulation. Medicine Meets Virtual Reality 18th Annual Meeting/NeXT MEd, Newport Beach, CA. ;9 – 12. Sept. 18th–23rd 2011.

  50. Goldberg BB, Merton DA, Liu JB, Forsberg F, Aruva M, Zhang K, Thakur ML, Shulz S, Schanche R, Murphy G, Waldman S. Contrast – enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of Sonazoid in a melanoma swine model. American Institute of Ultrasound in Medicine Annual Convention. J Ultrasound Med. ; 30: S71. 2011.

  51. Thakur ML, Zhang K, Paudyal B, Devakumar D, Covarrubias M, Cheng C, Gray BD, Wickstrom E, Pak KY. Targeting apoptosis for optical imaging of infection. J Nucl Med.; 52 Supplement 1: 328P. 2011.

  52. Thakur ML, Zhang K, Berger A, Intenzo CM, Sim S, Cavanaugh BC, Frangos AJ, Dascenzo C, Wickstrom E. Profiling VPAC1 receptors for imaging breast cancer. J Nucl Med.; 52 Supplement 1: 59P. 2011.

  53. Goldberg BB, Merton DA, Liu JB, Zhang K, Murphy GF, Thakur ML, Waldman SA, Forsberg F. Contrast – enhanced ultrasound detection and characterization of sentinel lymph nodes in melanoma swine model. The 96th Scientific Assembly and Annual Meeting Program of the Radiological Society of North America, Chicago, IL, PP: 562. Nov. 28 – Dec. 3, 2010.

  54. Sadri K, Zhang K, Devadhas D, Ren Q, Rodeck U, Thakur ML. Targeting epidermal growth factor receptors (EGFR) for PET imaging of breast cancer (BC). World Journal of Nuclear Medicine; 9, Supplement 1: S150 – S151. 2010.

  55. Thakur ML, Wickstrom E. Imaging gene expression. World J of Nucl Med; 9, Supplement 1: S76. 2010.

  56. Thakur ML. Radiolabeled stem cells. World J of Nucl Med; 9, Supplement 1: S68. 2010.

  57. Thakur ML, Zhang K, Chen CP, Tian X, Wickstrom E. Targeting genomic biomarkers in molecular imaging. World J of Nucl Med; 9, Supplement 1: S67 – S68. 2010.

  58. Penn DL, Zhang K, Mukherjee A, Kumar D, Thakur ML. Apoptotic abscess imaging with 99mTc – HYNIC – annexin – V. Abstract Book Supplement to the J Nucl Med; 50(2S): 261. 2009.

  59. Zhang K, Kumar D, Wang C, Penn DL, Mukherjee A, McCue PA, Wickstrom E, Thakur ML. PET imaging of spontaneous mouse mammary tumor virus (MMTV) infected breast cancer (BC) using Cu – 64 – TP3805: Abstract Book Supplement to the J Nucl Med; 50(2S): 86 – 87. 2009.

  60. Goldberg BB, Merton DA, Liu JB, Zhang K, Forsberg F, Ahmed R, Aruva M, Fox TB, Thakur ML. Sentinel lymph node identification in swine with melanomas. Comparing contrast – enhanced us and nuclear medicine. Proceedings of the 95th Scientific Assembly and Annual Meeting Program of the Radiological Society of North America, Chicago, IL; Prog.: RSNA, 409. 2009.

  61. Thakur ML, Zhang K, Devadhas D, Penn, Frangos A, Wickstrom E, Cavanaugh B, Brill K, Berger A, Rosenberg A, Kim S, Intenzo C. VPAC1 gene product targeted PET imaging of breast cancer. From rodents to humans. Labelled Compounds and Radiopharmaceuticals; S34(P): 52. 2009.

  62. Goldberg BB, Merton DA, Liu JB, Aruva M, Fox TB, Zhang K, Thakur ML, Forsberg F. Sentinel lymph node detection in swine with melanoma. Comparison of lymphosonography to lymphoscintigraphy. American Institute of Ultrasound in Medicine Annual Convention. J Ultrasound Med March; 27(S): S36. 2008.

  63. N Shanthly, K Zhang, Aruva MR, C Cardi, CA Patel, S Rattan, C Gregory, Wickstrom E, Thakur ML. Targeting VPAC1 Receptors in Human Breast Tumor Xenografts. Indian Journal of Nuclear Medicine; 22(4): 77. 2007.

  64. Zhang K, Shanthly N, Aruva MR, Cardi C, Wickstrom E, Thakur ML. Role of IGF1R in PET hybridization imaging of ER positive human breast cancer xenografts using 64Cu – PNA. J Nucl Med; 48: 22: (P)73. 2007.

  65. Aruva MR, Zhang K, Shanthly N, Cardi CA, Patel C, Ratan S, Thakur ML. PET/CT imaging of VPAC1 receptors in human breast cancer xenografts using 64Cu Labeled cyclized peptide. J Nucl Med; 1354: (P)307. 2007.

  66. Thakur ML. In vivo microPET imaging of CCND1 mRNA in breast cancer xenograft model using 64Cu – labeled antisense peptide nucleic acid peptide probes. Euro J Nucl and Mol Img; 33: (P)S219. 2006.

  67. Cao Z, Cardi C, Thakur ML, Acton PD: Small animal SPECT imaging on PET cameras using a multi – pinhole collimator insert. World Journal of Nucl Med Biol; 5: (P)S32. 2006.

  68. Thakur ML, Zhang K, Aruva M, Shanthly N, Ratan S, Patel C, Cardi C, Wickstrom E: Targeting VPAC1 oncogene receptors for PET imaging of breast cancer. World of J. Nucl Med; 5(P)S29. 2006.

  69. Thakur ML. Peptides and peptide nucleic acids for PET imaging synthesis, evaluation and applications. World Journal of Nucl Med; 5(P)S18. 2006.

  70. Thakur ML. Genomic and proteomic approaches to MI of cancer. World Journal of Nucl Med; 5: (P)S1. 2006.

  71. Thakur ML, Zhang K, Aruva MR, Shanthly N, Ratan S, Patel C, Cardi C, Wickstrom E: Targeting VPAC1 oncogene receptors for PET imaging of breast cancer. World federation of nuclear medicine and biology. World Journal of Nuclear Medicine; 5: 529 (i.e. S – 29). 2006.

  72. Thakur ML. Cu – 64 – Peptide PET imaging of VPAC1 oncogene product in breast tumors. European Journal of Nuclear Medicine and Molecular Imaging, Volume 33, 2006.

  73. Thakur ML, Thomas Jefferson University, Philadelphia. In vivo micro PET imaging of ccnd1 mRNA a in breast cancer xenograft model using Cu – 64 – labeled antisense peptide nucleic acid peptide probes. TX, United States. European Journal of Nuclear Medicine and Molecular Imaging, Volume 33, 2006.

  74. A Chakrabarti, K Zhang, MR Aruva, CA Cardi, Thakur ML, Wickstrom E. Activated KRAS mRNA detected in pancreas cancer xenografts by PET imaging of 64Cu – DOTA –PNA – peptide chimers. Biochemistry1, Department of Radiology2, Thomas Jefferson University, Philadelphia, PA, Abstract Book Supplement, Volume 47, number 5, 2006.

  75. Thakur ML. Genomic and Proteomic Approaches to MI of Cancer. Thomas Jefferson Univ. Hospital. World J of Nucl Med, Volume 5, 2006.

  76. Thakur ML. Peptides and Peptide Nucleic Acids for PET Imaging; Synthesis, Evaluation and Applications. Thomas Jefferson Univ. Hospital, U.S.A. World J of Nucl Med, Volume 5, 2006.

  77. Zixiong Cao., Chris A. Cardi, Thakur ML, Paul D. Acton. Small Animal SPECT Imaging on PET Cameras using a Multi – Pinhole collimator insert. Thomas Jefferson University. USA World J of Nucl Med, Volume 5, 2006.

  78. Thakur ML, Zhang K, Mohan Aruva, Nylla Shanthly, Satish Ratan, Chirag Patel, Christopher Cardi. Wickstrom E. Targeting VPAC1 Oncogene Receptors for PET imaging of breast cancer. World J of Nucl Med, Volume 5, 2006.

  79. Amirkhanov N, Dimitrov I, Zhang K, Aruva M, Lai S, Thakur ML, Wickstrom E. (Gd – DOTA)2 – KRAS PNA – Peptide MRI Contrast Enhancement in AsPC1 Pancreatic Xenografts: 97th Annual Meeting, Washington, D.C., Proc. American Association of Cancer Research (AACR), vol. 47, April 1 – 5, 2006.

  80. Xiaobing T, Aruva M, Zhang K, Cardi C, Wickstrom E, and Thakur ML. In vivo micro PET Imaging of CCND1 mRNA in Breast Cancer Xenografts model using Cu – 64 labeled antisense peptide nucleic acid peptide probes. First JPA Research Symposium, TJU, Philadelphia, PA. May 2006.

  81. Zhang K. Aruva M, Shanthly N, Rattan S, Patel C, Cesarone G, Wickstrom E and Thakur ML. Cu – 64 peptide PET Imaging of CCNDI mRNA in breast tumors. First JPA Research Symposium, TJU, Philadelphia, PA. May 2006.

  82. Zhang, K, Rattan S, Patel C, Shanthly N, Aruya M, Cardi C, Wickstrom E, Thakur ML. A new vasoactive intestinal peptide (VIP) analogue for the detection of VIP receptor – Positive breast cancer. First JPA Research Symposium, TJU, Philadelphia, PA. May 2006.

  83. Chakrabarti A, Zhang K, Thakur ML, Wickstrom E. KRAS mRNA expression in human pancreatic cancer xenografts imaged externally with Tc – 99m – labeled and Cu – 64 labeled peptide – peptide nucleic acid – peptide chimeras. First JPA Research Symposium, TJU, Philadelphia, PA. May 2006.

  84. Goldberg BB, Merton DA, Liu JB, Aruva M, Zhang K, Forsberg F, Fox TB, Thakur ML. Lymphosonography of sentinel lymph nodes in a melanoma tumor model; A comparison to lymphoscintigraphy. 18th Congress of Ultrasound Euroson SIUMB Conference (BoLogna, Italy). 2006.

  85. Chakrabarti A, Zhang K, Aruva MR, Cardi CA, Thakur ML, Wickstrom E. Activated KRAS mRNA detected in pancreas cancer xenografts by PET imaging of 64Cu DOTA – PNA – peptide chimeras. J. Nucl. Med. Vol: 47, Number 5, May 2006.

  86. Xiaobing T, Winter R, Aruva M, Zhang K, Cardi C, Thakur ML, and Wickstrom E. CCND1 mRNA Visualized in Human Estrogen Receptor Negative Breast Cancer Xenografts by PET Imaging of Antisense Cu – 64 – DOTA – PNA – peptide. Molecular Targets and Cancer therapeutics, AACR, Philadelphia, PA November 14 – 18, 2005.

  87. Amirkhanov N, Aruva M, Zhang K, Mathew B, Thakur ML, and Wickstrom E. In – 111 and Gd – 157 – DOTA – Polydiamidopropanoate (PDAP) dendrimer – PNA – Peptide Chimera for non – invasive imaging of intracellular Oncogene mRNA Expression. International Conference on Chemical Biology (ICCA) Novosibirsk, Russia, July 2 – 7, pp: 19, 2005.

  88. Zhang K, Aruva M, Mathew B, Chakrabarthi A, Cardi C, Wickstrom E and Thakur ML. PET Imaging of Pancreatic cancer using Cu – 64 Labeled DOTA – PNA – Peptide Chimera. 16th International Symposium on Radiopharmaceutical Chemistry, Iowa City, Iowa J. of labeled Compounds June 24 – 28, Abstract No: S53, 48, S1 – S341, 2005.

  89. Chakrabarti A, Aruva M, Zhang K, Thakur ML, Wickstrom E. PET AND SCIENTIGRAPHIC IMAGING OF KRAS mRNA in pancreas cancer. 1st meeting of the oligonucleotides therapeutics society. New York Academy of Sciences (OTS), Sep. 15 – 18, pp: 5, 2005.

  90. Xiaobing T, Aruva M, Zhang K, Thakur ML and Wickstrom E. IN VIVO PET Imaging of CCND1 mRNA in human ER and Breast Cancer Xenografts with Cu – 64 DOTA – PNA – PEPTIDE CHIMERAS. 1st meeting of the oligonucleotides therapeutics society. New York of Sciences (OTS), Sep. 15 – 18, pp: 36, 2005.

  91. Amirkhanov N, Aruva M, Zhang K, Mathew B, Thakur ML, Wickstrom E. {In – 111}DOTA 16 – DENDRIMER – PNA – PEPTIDE – IMAGING OF KRAS mRNA IN TUMORS. 1st meeting of the oligonucleotides therapeutics Society. New York Academy of Sciences (OTS), Sep. 15 – 18, pp: 2, 2005.

  92. Xiaobing T, Aruva M, Zhang K, Mathew B, Cardi C, Thakur M, and Wickstrom E. Micro PET/CT Imaging of Human Breast Cancer Xenografts in Immunocompromised mice with Tumor – Specific PNA – peptide Chimeras for Targeting CCND1 Oncogene mRNA. The Society of Molecular Imaging. The 4th Annual Meeting of Molecular Imaging, Cologne, Germany. Sep 7 – 10, 2005.

  93. Tian X, Winter R, Aruva M, Zhang K, Cardi C, Thakur ML, Wickstrom E. CCND1 mRNA Visualized in Human Estrogen Receptor Negative Breast Cancer Xenografts by PET Imaging of Antisense Cu – 64 – DOTA – PNA – peptide. Molecular Targets and Cancer Therapeutics, AACR, Philadelphia, November. 14 – 18, 2005.

  94. Chakrabarti A, Aruva M, Sanjankila SP, Thakur ML, Wickstrom E. Synthesis of novel peptide nucleic acid – peptide chimera for non – invasive imaging of cancer. Nucleotides and Nucleic Acids International Journal for Rapid Communication, Vol: 24, Numbers: 5 – 7,409 – 414, 2005.

  95. Chakrabarti A, Aruva MR, Zhang K, Mathew B, Fong DT, Thakur ML, Wickstrom E. External Imaging of Oncogene KRAS mRNA Overexpression In Pancreatic Cancer Xenografts with Tc – 99m and Cu – 64 Chelator PNA – Peptide Chimeras. 52nd Annual meeting of the Society of Nucl. Med, Toronto, Canada. J Nucl Med 2005; 46(5), Suppl.2,P191. June 18 – 22, 2005.

  96. Nariman V, Amirkhanov N, Aruva MR, Zhang K, Mathew B, Thakur ML, Wickstrom E. Design, synthesis and evaluation of chelator – dendrimer – peptide nucleic acid – peptide chimeras for non – invasive magnetic resonance imaging(MRI) of intracellular messenger RNA and oncogene expression. Salve Regina University, New Port, RI J of Nucleosides, Nucleotides & ligonucleotide 2005.

  97. Nariman V, Amirkhanov N, Aruva MR, Zhang K, Mathew B, Thakur ML, Wickstrom E. Synthesis and evaluation of In – 111 DOTA – Polydiamidopropanoate(PDAP) dendrimer – PNA – Peptide Chimeras for non – invasive imaging of Cancer. 16th International Symposium on Radiopharmaceutical Chemistry, Iowa City, Iowa. J of Labeled Compounds; Abstract No: S53. 2005.

  98. Zhang K, Aruva MR, Mathew B, Chakrabarti A, Cardi C, Wickstrom E, Thakur ML. PET imaging of pancreatic cancer using Cu – 64 labeled DOTA – PNA – Peptide chimera. 16th International Symposium on Radiopharmaceutical Chemistry, Iowa City, Iowa. J of Labeled Compounds, Abstract No: S229. 2005.

  99. Cardi CA, Acton PD, Thakur ML, Karp JS: Evaluation of PET – CT mutual information registration in mice. 52nd Annual meeting of the Society of Nuclear Medicine, June 18 – 22, 2005, Toronto, Canada. J Nucl Med; 46(5), Suppl. 2, P246. 2005.

  100. Chakrabarti A, Aruva MR, Zhang K, Mathew B, Fong DT, Thakur ML, Wickstrom E. External Imaging of Oncogene KRAS mRNA Overexpression in Pancreatic Cancer Xenografts with Tc – 99m and Cu – 64 Chelator PNA – Peptide Chimeras. 52nd Annual meeting of the Society of Nucl. Med., June 18 – 22,2005, Toronto, Canada. J Nucl Med; 46(5), Suppl.2,P191. 2005.

  101. Nariman V, Amirkhanov N, Aruva MR, Zhang K, Mathew B, Thakur ML, Wickstrom E. In – 111 and Gd – 157 DOTA – Polydiamidopropanoate(PDAP) dendrimer – PNA – Peptide chimeras for non – invasive imaging of cancer. 9th Annual meeting AACR, Anaheim, CA J of American Association of Cancer Research; Proce.Suppl.LB – 182. 2005.

  102. Chakrabarti A, Aruva MR, Zhang K, Thakur ML, Wickstrom E. Tc – 99m and Cu – 64 PNA – Peptide hybridization probes for imaging of oncogene activation in pancreatic cancer. 96th Annual meeting AACR, Anaheim, CA.J of American Association of Cancer Research. 2005.

  103. Aruva MR, Daviau J, Sharma A, Thakur ML. Imaging experimental pulmonary embolism(PE) in swine using fibrin specific peptide Tc – 99m – TP850. J Nucl Med; 311(P): 45. 2004.

  104. Tian X, Aruva MR, Qin W, Duffy KT, Sauter ER, Thakur ML, Wickstrom. Preparation and evaluation of Tc – 99m – peptide chimeras for imaging of CCND1 mRNA expression in human breast cancer xenografts. J of Nucl Med; 173(P): 45. 2004.

  105. Thakur ML, Aruva MR, Gariepy J, Acton P, Rattan S, Wickstrom E, Alvai A. PET imaging of VPAC1 oncogene overexpression with Cu – 64 Vasoactive intestinal peptide(VIP). J Nucl. Med; 173(P): 45. 2004.

  106. Amirkhanov N, Aruva MR, Sanjankila SP, Lai S, Thakur ML, Wickstrom E. Synthesis of novel polydiamidopropanoate (PDAP) dendrimer – PNA – peptide chimeras for non – invasive magnetic resonance imaging(MRI) of cancer. IS3NA(international Society for Nucleosides, Nucleotides and Nucleic Acids XVI International Roundtable) Programs & Abstracts, Minneapolis, MN. J of Nucleoside, Nucleotides and Nucleic Acids;24(6). 2004.

  107. Chakrabarti A, Aruva MR, Sanjankila SP, Thakur ML, Wickstrom E. Synthesis of novel PNA – peptide chimaera for noninvasive imaging of cancer. IS3NA (International Society for Nucleosides, Nucleotides and Nucleic Acids XVI International Roundtable) Programs& Abstracts, Minneapolis, MNJ of Nucleosides, Nucleotides and Nucleic Acids; 24(47). 2004.

  108. Tian X, Aruva MR, Qin W, Sajankila SP, Sauter ER, Thakur ML, Wickstrom E. Tumor – targeting peptide – pna – peptide chimeras for imaging overexpressed oncogene mRNAs. ISNA (International Society for Nucleosides, Nucleotides and Nucleic Acids XVI International Roundtable) Programs & Abstracts, Minneapolis, MN J of Nucleosides, Nucleotides and Nucleic Acid; 24(238). 2004.

  109. Thakur ML, Tian X, Aruva MR, Qin W, Duffy K, Rao P, Sauter E, Wickstrom E. J. Labelled Comp. & Radiopharm; 510(P): 45. 2003.

  110. Thakur ML, Aruva MR, E Bolewska – Pedyczak, J Gariepy. Preparation of Cu – 64 and Tc99m – N2S2 – Vasoactive Intestinal Peptide (VIP) for imaging gene expression. J Label Compd Radiopharm; 46: S128. 2003.

  111. Thakur ML, Tian X, M Aruva, Qin W, K Duffy, P Rao, E Sauter, Wickstrom E. Imaging oncogene mRNA with Tc – 99m – PNA – peptide chimeras. J Label Compd Radiopharm; 46: S10. 2003.

  112. Thakur ML, Aruva MR, J Gariepy. Tc – 99m – Vasoactive Intestinal Peptide (VIP). Influence of N4 vs. N2S2 chelation. Eur J Nucl Med and Molecular Imaging; 30: S323. 2003.

  113. Thakur ML, Aruva MR, J Daviau, SP Rao, S Sharma. Targeting α – chain fibrin to image fresh and aged venous thrombosis (VT) and pulmonary embolism (PE) in swine. Eur J Nucl Med and Molecular Imaging; 30: S182. 2003.

  114. Thakur ML, M Aruva, E Bolewska – Pedyczak, J Gariepy. Preparation of Cu – 64 and Tc – 99m – N2S2 – Vasoactive Intestinal Peptide (VIP) for imaging gene expression. J Labelled Comp and Radiopharm; 46: S128. 2003.

  115. Thakur ML, Tian X, M Aruva, Qin W, K Duffy, P Rao, E Sauter, Wickstrom E. Imaging oncogene mRNA with Tc – 99m – PNA – peptide chimeras. J Labelled Comp and Radiopharm; 46: S10. 2003.

  116. GS Spana, J Liu, Rao PS, ML Thakur. Mapping lymphatic nodes. Role of thrombospondin. World J Nucl Med Biol; 2: P5126. 2002.

  117. Thakur ML, Rao PS, J Daviau, S Kim, Aruva MR, SS Sharma. Targeting experimental venous thrombosis and pulmonary embolism. Eur J Nucl Med; 29: S169. 2002.

  118. Thakur ML. Imaging inflammatory bowel disease. Nucl Med Comm; 22: 1152. 2002.

  119. Rao PS, S Sharma, Thakur ML. 99mTc – leukokinin residue for N – F – Met – Leu – Phe analogs for imaging inflammation/infection. Quantitative comparison in a canine model. J Nucl Med; 43: 335P. 2002.

  120. J Liu, G Spana, Rao PS, D Leeper, R Howell, R Coss, P Wachsberger, Thakur ML. Targeted lipid soluble radiopharmaceuticals in cancer therapy. J Nucl Med; 43: 279P. 2002.

  121. Thakur ML, E Sauter, Rao PS, Zhu W, Tian X, Qin W, Wickstrom E. 99mTc – PNA – peptide. Imaging oncogene expression in breast lesions. J Nucl Med; 43: 124P. 2002.

  122. Thakur ML. Imaging inflammatory bowel disease. J Nucl Med Comm; 22: 1152. 2002.

  123. G Forsberg, AP Dicker, Thakur ML, NM Rawool, JB Liu, WT Shi, LN Nazarian. Contrast enhanced ultrasound correlates with COX – 2, a predictor of angiogenesis in a human melanoma xenograft model. J Ultrasound Med; 21: S89. 2002.

  124. F Forsberg, AP Dicker, Thakur ML, NM Rawool, JB Liu, WT Sahi, LN Nazarian. Comparison of contrast enhanced ultrasound to immunohistochemical predictors of angiogenesis in a human xenograft model. J Ultrasound Med; 20: S84. 2001.

  125. Rao PS, MP Consigny, S Sharma, Thakur ML. Fibrin avid Tc – 99m – peptide for imaging thrombosis. J Labelled Compounds and Radiopharm; 44: S48. 2001.

  126. Thakur ML, Rao PS, S Sharma. Evaluation of Tc – 99m leukokinin residue analogs for imaging inflammatory foci. J Nucl Med; 42(5): 259P. 2001.

  127. Thakur ML, Rao PS, Li H, Reddy K. Particle based preparations of Tc – 99m peptides. J Nucl Med; 442: 21P. 2001.

  128. Rao PS, Reddy KC, Li H, Sharma S, and Thakur ML. Imaging colorectal cancer. Comparison of receptor specific biomolecules. Turkish J Nucl Med; 9: 68. 2000.

  129. Rao PS, CK Reddy, H Li, Thakur ML. Reducing renal uptake of radiolabeled peptides. Nucl Med Comm: 580, 2000.

  130. SD Sharma, HZ Cai, W Yang, YQ Shi, A Shadiack, C Blood, Rao PS, K Reddy, H Li, and ML Thakur. Melanocortin receptor – 1 specific Tc – 99ME – Tallopeptides for targeting melanoma. J Nucl Med : 230P, 2000.

  131. Thakur ML, CS Marcus, S Saeed, VR Pallela, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski, S Rattan. Imaging tumors with 99m – Tc labeled Vasoactive Intestinal Peptide. Indian J Nucl Med 2. 14, 1999.

  132. H Sinzinger, A Arakil – Aghajanian, Thakur ML. Fibrinogen modification. Causative for insufficient radioimaging results. Eur J Nucl Med 26. 1108P, 1999.

  133. VR Pallela, Rao PS, D Vassileva – Belnikolovska,Thakur ML. Improving radioimmunodetection of tumors. Influence of the quantity of IFN: Mab conjugate. Eur J Nucl Med 26: 1026P, 1999.

  134. VR Pallela, Thakur ML, Rao PS, S Chakder, S Rattan. Tc – 99m labeled adenylate cyclase activating peptide (PACAP). Preparation and preliminary evaluation. Eur J Nucl Med 26. 998P, 1999.

  135. Thakur ML. Tc – 99m labeled chemotactic peptide for imaging infection. Nucl Med Comm 20. 940P, 1999.

  136. Thakur ML. Imaging vascular thrombosis. Role of radiolabeled peptides. Nucl Med Comm 20. 937P, 1999.

  137. Thakur ML, CS Marcus, S Saeed, V Pallela, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski, T Moody. Imaging tumors in humans with Tc – 99m – VIP. Regulatory Peptides 83. 59, 1999.

  138. Rao PS, VR Pallela, Thakur ML, D Vassileva – Belnikolovska.Tc – 99m labeled peptide for imaging infection. J Nucl Med 40. 319P, 1999.

  139. VR Pallela, Rao PS, T Moody, ML Thakur. Vasoactive Intestinal Peptide (VIP) receptor imaging of breast tumors. Comparison with I – 125 – VIP, In – 111 – Octreotide, and Tc – 99m – SestaMIBI. J Labelled Cpd Radiopharm 42: 717 – 719, 1999.

  140. CS Marcus, ML Thakur, S Saeed, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski. Human dosimetry of Tc – 99m – Vasoactive Intestinal Peptide (VIP). J Nucl Med 40. 310P, 1999.

  141. Thakur ML, CS Marcus, S Saeed, V Pallela, C Minami, L Diggles, HL Pham, R Ahdoot, EA Kalinowski. Tc – 99m labeled vasoactive intestinal peptide (VIP) analog for imaging tumors in humans. J Nucl Med 40. 243P, 1999.

  142. 141. SL Kipper, EL Kramer, DG Evans, EB Rypins, Thakur ML, JJ Sanger, D. Landsman. Tc – 99m anti – CD15 neutrophil monoclonal antibody (LeuTech) scan for diagnosis of equivocal appendicitis. Clinical evaluation of safety, efficacy, and patient management. J Nucl Med 40. 16P, 1999.

  143. 142. SD Sharma, Y – Q Shi, H – Z Cai, WH Yang, CH Blood, V Pallela, Rao PS, ML Thakur. Novel melanocortin receptor – 1 specific Tc – 99m – metallopeptide for melanoma tumor imaging. J Nucl Med 40. 120P, 1999.

  144. VR Pallela, ML Thakur, PM Consigny, Rao PS, D Vassileva – Belnikolovska, R Shi. Imaging vascular thrombosis with Tc – 99m labeled fibrin binding peptide. J Nucl Med 40. 121P, 1999.

  145. VR Pallela, PM Consigny, R Shi, Thakur ML. Tc – 99m labeled fibrin – chain analog for imaging vascular thrombosis. Eur J Nucl Med 25. 1170P, 1998.

  146. VR Pallela, R Patti, J Li, Thakur ML. Interferon – – 2b immunoconjugate enhances tumor targeting of 99m – Tc labeled monoclonal antibodies (MAbs). Eur J Nucl Med 25: 878P, 1998.

  147. VR Pallela, MVR Reddy, VK Senadhi, Thakur ML. Synthesis and evaluation of Tc – 99m – labeled VIP – analogs as prostate tumor imaging agents. J Nucl Med 39: 226P, 1998.

  148. PD Mozley, Thakur ML, A Alavi, M Patel, T Smith, ED Barraclough, A Mathur. Transient changes in white blood cell (WBC) counts after administration of a technetium – 99m labeled murine antibody (MAb) to human granulocytes. J Nucl Med 39. 265 P, 1998.

  149. PD Mozley, ED Barraclough, S Dresel, JB Stubbs, C Finkelman, A Mathur, RB Sparks, M Patel, T Smith, Thakur ML, et al. Dosimetry of anti – SSEA – 1. A technetium – 99m labeled IGM murine antibody to human granulocytes. J Nucl Med 39: 268P, 1998.

  150. V Pallela, S Chakdar, S Rattan, and Thakur ML. Tc – 99 labeled VIP receptor agonist. Functional and pharmacokinetic studies. J Nucl Med 39: 64P, 1998.

  151. V Pallela, PM Consigny, R Shi, and Thakur ML. Imaging vascular thrombosis with Tc – 99m – TP – 1300 peptide derived from active domain of thrombospondin (TSP). J Nucl Med 39: 64P, 1998.

  152. Thakur ML. Development of peptide radiopharmaceuticals. Indian J Nucl Med 12. 253 – 254, 1998.

  153. Thakur ML, PM Consigny, V Pallela, P Ratnakar. Tc – 99m – TP 1201 for imaging thromboembolism. Radiology 205 (P). 267, 1997.

  154. Thakur ML. New radiopharmaceuticals for imaging inflammation. Nucl Med Comm 18: 460, 1997.

  155. Thakur ML, W Becker, CS Marcus, R Ahdoot, B Sinow and B Rhodes. Imaging Infection/Inflammation with Tc – 99m labeled anti – human PMN antibody LeuTech. Comparison with Tc – 99m – HMPAO – WBC. Radiology 205 (P): 266, 1997.

  156. H Sands, J Li and Thakur ML. I – 131 – LEX – 032, a recombinant hybrid of antichymotrypsin. Pharmacokinetics and distribution. Quarterly J Nucl Med 31: 3P, 1997.

  157. JJ Zhang, SM Kim, DW Andrews, Thakur ML and Intenzo CM. Dosimetry of I – 123 Iododeoxyuridine as a SPECT agent for human glioma. J Nucl Med 38. 210P, 1997.

  158. R Ahdoot, CS Marcus, Thakur ML, BA Rhodes, R Sinow, P Henneman, C Minami, L Diggles, HL Pham, S Klein and G Mason. Rapid infection/inflammation imaging with Tc – 99m – anti – SSEA – 1. J Nucl Med 38. 25p, 1997.

  159. SM Kim, DW Andrews, JJ Zhang, Thakur ML, Intenzo CM. Dynamic brain SPECT with Iododeoxyuridine in malignant glioma. Radiology 201. 401, 1996.

  160. Thakur ML, J Li, H Kolan, S Kim, C. Intenzo, J Zhang and D Andrews. Targeting tumors with radioiodinated deoxyuridine. Tissue distribution and DNA binding in experimental tumors. Radiology 201: 339P, 1996.

  161. H Kolan, Thakur ML, R Wiaderkeiwicz, J Li, R Duggaraju. Preparation and Evaluation of Tc – 99m Vapreotide (RC – 160). A somatostatin analog. Clin Nucl Med 21: 351, 1996.

  162. B. Chandy, J Li and ML Thakur. Transient Neutropenia. Neutrophil distribution and replacement. Clin Nucl Med 21: 352, 1996.

  163. J Li, DA Merton, R Duggaraju, and Thakur ML. Influence of interferon on tumor blood flow and tumor uptake of Tc – 99m labeled MEM136. Clin Nucl Med 21: 352, 1996.

  164. J Li, R Duggaraju, D Maish, and Thakur ML. Effect of Interferon – – 2b on the enhancement of tumor uptake of Tc – 99m labeled monoclonal antibody. Clin Nucl Med 21: 352, 1996.

  165. CD John, R Venugopal, J Li, WD Bowen, VM Varma and Thakur ML. Acterization and targeting of Sigma Receptor Binding sites in human prostate tumor cells. J Nucl Med 37: 205P, 1996.

  166. Thakur ML, M Donegan, J Li, H Kolan, R Duggaraju, D Maish, SC Srivastava. Tc – 99m labeled anti – CEA F(ab')2 : Augmenting tumor uptake with antibody: Interferon (MAb: IFN – – 2b) conjugate. J Nucl Med 37: 151P, 1996.

  167. Thakur ML, Wickstrom E, E John, CS John and E Chiotellis. Preparation of Tc – 99m Antisense and Distribution in Normal Mice. J Nucl Med 36: 113P, 1995.

  168. Thakur ML, E John, J Li, H Reddy, G Halmos and AV Schally. Tc – 99m – RC – 160: A somatostatin analog for imaging prostate cancer: Comparison with I – 125 – RC – 160 and In – 111 Octreotide. J Nucl Med 36: 92P, 1995.

  169. Thakur ML, J Li, B Chandy, E John. Transient Neutropenia: Neutrophil Distribution and Replacement 7th International Symposium on Radiolabeled Cellular Blood Components, New Haven, CT, 1995.

  170. S Basu, Thakur ML and HR Kolan. Solid phase synthesis of a HYNIC – D – peptide – phosphorothioate oligodeoxynucleotide conjugate from two arms of a polyethyleneglycol – polystyrene support. J Labeled Compounds & Radiopharm XXXVII: 350 – 352, 1995.

  171. HR Kolan, Thakur ML, R Wiaderkiewicz, R Duggaraju. Tc – 99m – HYNIC – RC – 160 & Tc – 99m – CPTA – RC – 160: Synthesis of chelating agents, preparation and preliminary evaluation. J Labeled Compounds & Radiopharm XXXVII: 490 – 492, 1995.

  172. Thakur ML, J Li and H Reddy. Radiolabeled Monoclonal Antibodies (MAbs): Augmenting Tumor Uptake with Biological Response Modifiers (BRMs). Radiology 197: 420, 1995.

  173. Thakur ML, H Reddy, J Li, R Duggaraju, G. Halmos and AV Schally. Imaging Breast Cancer with Tc – 99m Somatostatin Analogs RC – 160 and Sandostatin: Comparison with In – 111 Octreotide. Radiology 197: 320, 1995.

  174. CS Sutton, PM Consigny, Thakur ML. Thrombogencity of intravascular stent wires. Circulation, I – 9, 1994.

  175. E John, J Li, S Wilder and Thakur ML. Technetium – 99m labeled anti – melanoma monoclonal antibody (MAb) ME 9.2.27: Comparative evaluation of direct and preformed chelation methods. Eur J Nucl Med 21: S8, 1994.

  176. Thakur ML, G Halmos, J Jan, EK John, J Li, K Mayo, S Rifat, A Rux, J Varnum, S Wilder, AV Schally. Technetium – 99m RC – 160: A somatostatin analog. J Nucl Med 35: 359p, 1994.

  177. J Li, Thakur ML, E John, S Wilder, D Merton, B Goldberg. Augmenting tumor uptake of Tc – 99m monoclonal antibodies (MAbs) with biological response modifiers: Influence of interferon. J Nucl Med 35: 86p, 1994.

  178. JM Varnum, JH Mayo, AV Schally, and Thakur ML. Tc – 99m Labeled Somatostatin Analogue, RC – 160: 1H – NMR and Computer Modeling Confirmational Analysis. J Labeled Compounds and Radiopharm. XXXV, 549 – 551, 1994.

  179. J Li, DA Merton, J Barr, S Wilder, D Barravecchio, B Goldberg, and Thakur ML. Tc – 99m Labeled monoclonal antibodies for imaging tumors: Influence of biological response modifiers. J Labeled Compounds and Radiopharm. XXXV, 404 – 406, 1994.

  180. E John, R Baum and Thakur ML. Tc – 99m Labeled Monoclonal Antibodies: Structural variations by reduction mediated and BFCA Techniques. J Labeled Compounds and Radiopharm. XXXV, 401 – 403, 1994.

  181. E John, S Wilder, D Eshima and Thakur ML. In Vitro Evaluation and Tissue Distribution of Tc – 99m Monoclonal Antibodies Prepare by Direct and Preformed Chelate Methods. J Labeled Compounds and Radiopharm. XXXV, 306 – 309, 1994.

  182. CS John, EK John, J Barr, JG McAfee and Thakur ML. Modified Synthesis, Characterization and Evaluation of Thiolactones. J Labeled Compounds and Radiopharm XXXV, 65 – 68, 1994.

  183. J Martin – Comin, M Roca, L Mairal, AJ Petit and Thakur ML. Tc – 99m Sandostatin scanning in the evaluation of thoracic lymphomas. Eur. Journal of Nucl Med 20. 884, 1993.

  184. E John, S Wilder, Thakur ML, et al. Tc – 99m labeled monoclonal antibodies: Determination of specific and non – specific binding and its significance on Tissue distribution. J Nucl Med 34: 246, 1993.

  185. C Marcus, Thakur ML, TV Huynh, et al. Imaging Rheumatic Joint Diseases with Tc – 99m labeled OKT – 3. J Nucl Med 34: 144, 1993.

  186. Thakur ML, J Eschbach, MR McDevitt, S Wilder, E John, A Damnjanov. Tc – 99m and In – 111 labeled Somatostatin Analogue: Preparation and Preliminary Evaluation as Receptor Specific Agent. J Nucl Med 33: 851, 1992.

  187. Thakur ML, PM Consigny, S Vinitiski, DS Mitchell and FB Mohamed. Evaluation of Ferrum as a MR Contrast Agent. J Nucl Med 33: 973, 1992.

  188. E John, Thakur ML, and S Wilder. Metabolic Studies of Rhenium – 186 – IgG in Normal and Tumor Bearing Mice. J Nucl Med 33: 979, 1992.

  189. M McDevitt, Thakur ML. Preparation and Characterization of Transferrin and IgG and F(ab')2 Conjugates. J Nucl Med 33: 986, 1992.

  190. E John, Thakur ML, S Wilder, A Epstein. Rhenium – 186 Labeled TNT – 1 and TNT – 1 – F(ab')2 Monoclonal Antibodies for Radioimmunotherapy. J Nucl Med 33: 987, 1992.

  191. Thakur ML. Imaging Inflammatory Diseases: Future Directions. J Nucl Med 6: 67, 1991.

  192. Thakur ML, CS Marcus, P Hennemann, et al. Imaging Inflammatory Diseases with Neutrophil (PMN) specific Tc – 99m Monoclonal Antibody. J Nucl Med 32: p. 1836, 1991.

  193. S Vinitski, Thakur ML, PM Consigny, et al. Contrast Enhancement of Lung MR Imaging. J Nucl Med 32: 1081, 1990.

  194. Thakur ML, J DeFulvio, E John, et al. Re – 186 Labeled Monoclonal Antibodies (MAb): Preparation and Evaluation. J Nucl Med 32: 1098, 1990.

  195. Thakur ML, J DeFulvio, J Tong, et al. Imaging Tumors with Tc – 99m Labeled Tumor Necrosis Factor (TNF – a): Influence of Biological Response Modifiers (BMR). J Nucl Med 32: 1021, 1990.

  196. Thakur ML, J DeFulvio, Park CH, A Epstein, J McAfee. Tc – 99m HSA for Imaging Inflammatory Foci. Eur J Nucl Med 16: S174, 1990.

  197. Thakur ML, J DeFulvio, S Kim, Park CH. Labeling Blood Components in vivo: Evaluation of Tc – 99m Ascorbic Acid. Eur J Nucl Med 16: S48, 1990.

  198. Thakur ML, J DeFulvio, Park CH. Antibody disulfide groups: Controlled reduction, Quantification and Influence on Immunoreactivity. Am Chem Soc Div of Nucl Chem and Technology, 1990.

  199. Thakur ML, J DeFulvio, Park CH. Tc – 99m Labeled Monoclonal Antibodies: Evaluation of Agents for Direct Labeling. J Labeled Compounds. In press.

  200. J DeFulvio, Thakur ML. Quantification of Antibody (MAb) sulfhydryl following controlled reduction of disulfides. Influence on MAb properties. J Labeled Compounds. In press.

  201. Thakur ML, J DeFulvio, Park CH, D Jungkind, A Epstein, J McAfee. Evaluation of Tc – 99m Labeled Proteins for Localization of Inflammation: Comparison with I – 125 – TNT – 1 and Ga – 67 citrate. J Nucl Med 31: 810, 1990.

  202. Thakur ML, M Consigny, D Mitchell, W Morrison, M Rifkin, S Vinitski. Effect of Superparamagnetic Liposomes (Ferrosomes) in MR Imaging of Lung Parenchyma (LP), Pulmonary Emboli (PE), Liver and Heart. J Nucl Med 31: 718, 1990.

  203. Thakur ML, J DeFulvio, Park CH, A Epstein, J McAfee. Tc – 99m HSA for Imaging Inflammatory Foci. Eur J Nucl Med 16: 451, 1990.

  204. Thakur ML, J DeFulvio, Park CH. Use of Ascorbic Acid (AA) for direct labeling of monoclonal antibodies (MAbs). Eur J Nucl Med 16: 392, 1990.

  205. Thakur ML, S Vinitski, MD Rifkin, S Lin, J DeFulvio, Richard MD, DM Mitchell and D Levy. Investigations into the use of Gadolinium Labeled Microspheres (MS) and Liposomes (LP) for Magnetic Resonance Imaging (MRI) of Lung Parenchyma. J Nucl Med 30: 901, 1989.

  206. Richard MD, Thakur ML, RJ Stedman, A Damjanov, J DeFulvio. Richard MD and I Damjanov. The Preparation and Evaluation of New Agents for Immunoscintigraphy. J Nucl Med 30: 936, 1989.

  207. Thakur ML, J Lee, Richard MD, J DeFulvio, S Arnold and D Jungkind. Evaluation of Human Neutrophil (PMN) Function following interaction with a Monoclonal Antibody (MAb). J Nucl Med 30: 747, 1989.

  208. Thakur ML, Richard MD and J Leuttgen. Technetium – 99m labeled Anti – SSEA – a as a tracer specific for human neutrophils. J Nucl Med 29: 788, 1988.

  209. Thakur ML, and Richard MD. Evaluation of Radiolabeled Monoclonal Antibodies for selective cell labeling. Nucl Med 26: 42 – 43, 1987.

  210. Thakur ML, Park CH, Madsen MT, and Richard MD. Preparation and Pharmacokinetics of I – 131 Ethiodol used for the treatment of Hepatocellular Carcinoma (HCC). Nucl Med 26: 15 – 16, 1987.

  211. Madsen MT, Park CH, Thakur ML, Ayyangar K. A Dosimetric Comparison of I – 131, Y – 90 and P – 32 as Radiolabels for Ethiodol in the Treatment of Hepatoma. Medical Physics, 1987.

  212. Thakur ML, White III FA, Madsen MT. Evaluation of a new Tc – 99m agent as a tracer for leukocytes. Proceedings of the 4th World Congress in Medicine and Biology, Buenos Aires, 1986.

  213. Richard MD, Thakur ML. Evaluation of Four Bifunctional Chelating Agents used to label antibodies with In – 111 as a tracer for human neutrophils. J Nucl Med 28: 720, 1987.

  214. Madsen MT, Park CH, Thakur ML. Dosimetry of Radiolabeled Ethiodol in the treatment of Hepatoma. J Nucl Med 28: 582, 1987.

  215. Thakur ML, Richard MD, McIlvain HB. Preparation and evaluation of a new class of In – 111 compounds with potential as Bifunctional Chelating Agents. J Nucl Med 28: 657, 1987.

  216. Thakur ML. Potential of Radiolabeled Antiplatelet Antibodies in the Detection of Vascular Thrombi. J Nucl Med and Biology 13: 666, 1986.

  217. Thakur ML. Radiolabeled Leukocytes and Radiation Dosimetry: Are there better tracers than In – 111 for cell labeling? J Nucl Med 27. 1986.

  218. Thakur ML, White III FA, Trincheri G. Specific Radiolabeling of Human Neutrophils: Evaluation of In – 111 Labeled Monoclonal Antibodies B.37.2.1. J Nucl Med 27: 1986.

  219. Thakur ML, White III FA, Madsen MT. Technetium – 99m and Indium – 111 labeled leukocytes: In vitro and in vivo evaluations. 6th International Symposium on Radiopharmaceutical chemistry. Boston, June 29 – July 3, 1986.

  220. Intenzo CM, Desai AG, Thakur ML, Park CH. Comparison of In – 111 – Merc leukocytes with In – 111 – oxine leukocytes for abscess localization. J Nucl Med 26: 97, 1985.

  221. Thakur ML, Thiagarajan P, McKenney SM, Park CH, Maurer P. Evaluation of Indium – 111 labeled B79.7 monoclonal antibodies as an agent for radiolabeling of human platelets. J Nucl Med 26: 48, 1985.

  222. Thakur ML, Sedar AW, McKenney SM. Functional and ultra – structural studies on In – 111 – Merc labeled concentrated human platelets in plasma. J Nucl Med 26: 48,1985.

  223. Thakur ML. Consideration for the preparation of radiolabeled monoclonal antibodies with high specific activity. J Nucl Med 26: 439, 1985.

  224. Thakur ML, Rowley R, McKenney S, Cox S, Leeper D, Park CH. Mitochondria specific Rhodamin 123: Radioiodination and preliminary evaluation as an agent for scintigraphy and radiotherapy of certain tumors. J Labeled Compounds and Radiopharmaceuticals. 1984.

  225. Thakur ML, Patel J, Cassel D, Madsen MT, Park CH. Technical consideration of I – 123 perfusamine™ brain imaging. J Nucl Med Tech 12: 90, 1984.

  226. Thakur ML, McKenney S, Seifert C, Youngkin DLJ, Park CH. Neutrophil separation: Evaluation of different approaches, purity, viability and phagocytosis of In – 111 bacteria. J Nucl Med Tech 12: 92, 1984.

  227. Madsen MT, Patel J, Thakur ML, Park CH. Collimator selection and I – 124 contamination determination for I – 123 imaging studies. J Nucl Med: May 1984.

  228. Thakur ML, McKenney S, Seifert C, Madsen M, Suntharalingam M, Desai A, Patel J. Park CH. Leukocyte labeling in plasma made simple and efficient: Preparation and evaluation. J Nucl Med: May 1984.

  229. Thakur ML, McKenney S, Park CH, Phillip MS, Bruggman T and Werre G. Platelet labeling in plasma made simple and efficient: Preparation and evaluation. J Nucl Med 25: 65, 1984.

  230. Thakur ML. A kit prepared Technetium – 99m agent for cardiac imaging. A preliminary evaluation in dogs. Proceedings for the Third World Congress of Nuclear Medicine and Biology, Paris 1982. Vol. II: 1610 – 1623.

  231. Thakur ML, Barry MJ. Preparation and evaluation of a new In – 111 agent for efficient labeling of human platelets in plasma. 4th Inter. Symp on Radiopharm Chemistry, Julich 1982. J Labeled Compounds and Radiopharmaceuticals 19: 1410 – 1412, 1982.

  232. Thakur ML. Tc – 99m DMPE: Preparation, characterization and evaluation in normal and infracted dogs. J Nucl Med 23: 11, 1982.

  233. Zoghbi SS, Thakur ML, Gottschalk A, et al. The influence of heparin on the in vivo distribution of In – 111 platelets in experimental canine model. J Nucl Med: 22: 55, 1981.

  234. Zoghbi SS, Thakur ML, Gottschalk A, et al. Selective cell labeling: A potential radioactive agent for labeling human neutrophils. J Nucl Med 22: 32, 1981.

  235. Acharis HM, Thakur ML and Gottschalk A. Radioiodination of Archidonic acid. Preparation and Evaluation. J Labeled Compounds and Radiopharmaceuticals 18: 75,1981.

  236. Zoghbi SS, Thakur ML and Gottschalk A. Investigations into agents for improving cell labeling with positron and gamma emitting radionuclides. J Labeled Compounds and Radiopharmaceuticals 18: 280. 1981.

  237. Thakur ML, Gottschalk A. An interactive radiochemical facility between Yale Medical Center and Brookhaven National Laboratory. Nuclear Medicine Contractors Meeting, Washington, DC, 1980.

  238. Davies RA, Thakur ML, et al. In – 111 labeled autologous leukocytes (In – COBC) for imaging inflammatory response to acute myocardial infarctions (MI) in man. J Nucl Med 21: 89, 1980.

  239. Thakur ML, Walsh L, Zaret BL and Gottschalk A. Effect of membrane on active drugs on In – 111 labeled human polymorphonuclear leukocytes. J Nucl Med 21: 25,1980.

  240. Weiner R, Hoffer PB, Thakur ML. The influence of pH and other factors on Ga – 67 binding to human transferrin (TF) human polymorphonuclear leukocytes (PMNs) and bacteria (B). J Nucl Med 21: 24, 1980.

  241. Goodman MK, Thakur ML, Hoffer PB, et al. In – 111 desferrioxamine complexes: Preparations and stability studies. J Labeled Compounds & Radiopharmaceuticals 16: 1979.

  242. Ruth TJ, Lambrecht RM, Wolf AP, Thakur ML. An approach to the automated productions and simultaneous loading of multiple Rb – 81/Kr – 81m generators for shipment to regional hospitals. J Labeled Compounds and Radiopharmaceuticals 16: 1979.

  243. Berger H, Addabo M, Thakur ML, et al. Myocardial arachidenic acid uptake and distribution in acute infarction and reactive hyperemia. Relations to Thallium 201. Circulation 59/60, Suppl. II: 269, 1979.

  244. R Davies, Thakur ML, Berger H, et al. Imaging of the inflammatory response to acute myocardial infarction in man using In – 111 labeled white blood cells. Circulation 59/60, Suppl. II: 268, 1979.

  245. RR Armas, Thakur ML, Gottschalk A. A simplified method of selective spleen scanning with Tc – 99m erythrocytes: Clinical applications. J Nucl Med 20: 1979.

  246. Berger HJ, Addaba M, Thakur ML, et al. Arachidonic Acid. A potential myocardial imaging agent: Organ distribution and relation to regional myocardial perfusion. Clin Research 27: 152A, 1979.

  247. Goodman MM, Thakur ML, Hoffer PB, Riba AL, Gottschalk A. Indium – 111 labeled desferrioxamine complexes: Preparation and stability studies. J Labeled Compounds 16: 1, 1979.

  248. Riba AL, Thakur ML, Gottschalk A, Zaret BL. Cellular imaging of experimental endocarditis. Circulation 57.58, Supp l. II: 131, 1978.

  249. Riba AL, Thakur ML, Gottschalk A, Zaret BL. Imaging of acute coronary artery thrombosis with In – 111 platelets. Circulation 57/58, Suppl. II: 4, 1978.

  250. Espinola LG, Bushberg JT, Thakur ML, Caride VJ. Multilamellar lipid vesicles (liposomes) labeled with In – 111 oxine as scanning agent. 2nd International World Congress on Nuclear Medicine and Biology, Washington DC, 42, 1978.

  251. Samuel A, Hoffer PB, Bushberg J, Thakur ML. The effect of desferrioxamine on tissue localization of Ga – 67 citrate in tumored animals. 2nd International World Congress on Nuclear Medicine and Biology, Washington DC, p42, 1978.

  252. Hoffer PB, Weiner R, Miller R, Thakur ML. The role of lactoferrin and other iron binding proteins in the localization of Ga – 67. 2nd International World Congress on Nuclear Medicine and Biology, Washington DC, p48, 1978.

  253. Thakur ML, Riba A, Bushberg J, Samuel A, Hoffer P, Gottschalk A. Cardiac imaging with In – 111 labeled blood components. 2nd International Congress of Nuclear Medicine and Biology, Washington, DC, p130, 1978.

  254. Riba AL, Thakur ML, et al. Detection of Experimental infective endocarditis with In – 111 labeled platelets. Clin Research 26: 264A, 1978.

  255. Thakur ML, Gottschalk A, and Zaret B. In – 111 labeled polymorphonuclear leukocytes in acute myocardial infarction. Influence of age and regional myocardial blood flow upon imaging and tissue uptake. Clin Research 26: 274A, 1978.

  256. Thakur ML, Zaret BL, Gottschalk A. Indium – 111 labeled leukocytes for imaging acute myocardial infarction: influence of regional myocardial blood flow and age of infarct in canine models. Proceedings of the 25th Annual Meeting of the Society of Nuclear Medicine. J Nucl Med, 19:744, 1978.

  257. Thakur ML, Riba AL, Downs J, Andriole VT, Zaret BL and Gottschalk A. Indium – 111 labeled platelets for imaging bacterial endocarditis. Proceedings of the 25th Annual Meeting of the Society of Nuclear Medicine. J Nucl Med, 19:744, 1978.

  258. Weiner RE, Hoffer PB, and Thakur ML. Identification of Ga – 67 binding component in human neutrophils. Proceedings of the 25th Annual Meeting of the Society of Nuclear Medicine. J Nucl Med, 19:732, 1978.

  259. Ruth TJ, Lambrecht RM, Wolf AP and Thakur ML. An on – line, automated, multigenerator system for RB – 91/Kr – 91M production. Proceedings of the 25th Annual Meeting of the Society of Nuclear Medicine. J Nucl Med, 19:702, 1978.

  260. Thakur ML, Zakhireh B, Cohen M, Gottschalk A and Root R. In vitro evaluation of Indium – 111 labeled neutrophils: Mobility, chemotaxis and microbicidal activity. Proceedings of the 25th Annual Meeting of the Society of Nuclear Medicine. J Nucl Med, 19:672, 1978.

  261. Rannie GH, Thakur, and Ford WL. An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients. Clin Exp Immunol. 1977 Sep;29(3):509-14. PMID: 589868 PMCID: PMC1541079.

  262. Thakur ML, Rannie GH and Ford WC. In vivo distribution of In – 111 labeled lymphocytes: Comparison with 51 – Cr and 99m – Tc labels in animals and migration in man. J Nucl Med, 18:620, 1977.

  263. Thakur ML, Dees D, Harwig SSL, et al. Labeling blood components with 8 – hydroxyquinoline: Simplified procedure and mechanisms of labeling. J Labeled Compounds and Radiopharmaceuticals 13: 177, 1977.

  264. Thakur ML, Segal AW, Louis L, et al. Indium – 111 labeled cellular blood components: Mechanism of labeling with special references to studies with human neutrophils. J Nucl Med, 18:619, 1977.

  265. Thakur ML, Lavender JP, Arnot RN, et al. Indium – 111 labeled leukocytes in man. J Nucl Med, 18:619, 1977.

Books:

1. Thakur ML. Proceedings of 6th Inter. Symposium on Radiolabeled Blood Elements. Ed. J. Martin – Comin, Plenum Publishing Co., New York, 1993.

2. Ed. Sinzinger H and Thakur ML. Radiolabeled cellular blood elements. Wiley – Liss, 1990.

3. Ed. Thakur ML. Radiolabeled cellular blood elements pathophysiology, techniques and scintigraphic applications. Plenum Publishing Co., New York, 1985.

4. Ed. Thakur ML, Gottschalk A. Indium111 labeled neutrophils, platelets and lymphocytes. Trivirum Publishing Co., New York, 1980.

Book Chapters:

  1. Maina T. Thakur, ML. Radiochemistry of SPECT: Examples of 99mTc and 1111n Complexes. In Molecular Imaging: Principles and Practice. S. Gambhir & B. Ross eds Elsevier Science Publishers. Academic Press, 2022, isbn 978 0 12 816386 3

  2. Kumari M, Tripathi S, Thakur, M. Imaging Bladder Cancer, The Evolution of Radionanotargeting Toward Clinical Precision Oncology. Bentham, 2022, isbn 978 1 68108 867 9

  3. Thakur, ML. Can VPAC Targeted cu-64-TP3805 Play a Theranostic Role for Prostate Cancer?: A Quest. Springer, In Press.

  4. Truong H, Trabulsi E, Izes J, Tripathi S, Thakur, ML. VPAC1 Receptor-Targeted PET Imaging of Prostate Cancer. In Bioengineering Technology. A. Rasooly & H. Baker eds Elsevier Science Publishers. (Submitted)

  5. Thakur, ML. Can VPAC Targeted Cu-67-TP3805 Play a Theronostic Role for Prostate Cancer?: A Quest. In Beyond Becquerel and Biology to Precision Radio molecular Oncology: Festschrift in Honor of Richard P. Baum. R.P. Baum and V. Prasad eds Springer-Verlag. (Submitted)

  6. Thakur ML, Dicker AP, Kelly WK, Zaorsky NG, and Trabulsi EJ. Prostate Cancer: A multidisciplinary approach to diagnosis and treatment. Current Multidisciplinary Oncology. Demos Medical, New York. 101 – 105. 30 Dec 2014.

  7. Thakur ML, Trabulsi EJ, Kim SM, Intenzo CM, Gomella LG. PET: the future of screening, diagnosis, and staging for prostate cancer. Prostate Cancer. A. Dicker. 2014

  8. Wickstrom E, Thakur ML. Genetic and Molecular Approaches to Imaging Breast Cancer. Breast Cancer Risk Reduction and Early Detection, DOI 10.1007/978 – 0 – 387 – 87583 – 5_9, © Springer Science and Business Media, LLC 163 – 182, 2010

  9. Mukherjee A, Thakur ML. Role of Molecular Biology in Molecular Imaging. ISBN: 978 – 1 – 60692 – 447 – 1, 187 – 217, 2009

  10. Mukherjee A, Thakur ML. Role of molecular biology in molecular imaging. New cancer research developments. Ford TD (ed.). Nova Science Publishers, Inc. 187 – 217; 2009

  11. Nylla Shanthly, Zhang K, Mohan R. Aruva, Christopher Kim, Thakur ML Radiolabeled peptides: approaches to diagnosis and therapy. Chapter in Book – D.K. Hazra, 2007, in press.

  12. Nylla Shanthly, Thakur ML. Radionuclides in Medical application. in Application of Radiotracers in Chemical, Environmental and Biological Sciences. Vol I. Saha Institute of Nuclear Physics, India in cooperation with the IAEA, 2006.

  13. Imaging Oncogene Expression in Breast Cancer with Receptor Specific Peptides and Peptide Nucleic Acids. Aruva MR, Tian X, Zhang B, Shanthly N, Cardi C, Wickstrom E, and Thakur ML. Int. Symposium on Trends in Radiopharmaceuticals, ISTR – 2005, IAEA, pp. 19 – 20. 2005.

  14. Wickstrom Eric, Thakur Mathew, Sauter Edward: Receptor – Specific Targeting with Complementary Peptide Nucleic Acids Conjugated to Peptide Analogs and Radionuclides (in) Janson, Christopher (ed) and During, Matthew (ed): Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules. New York, New York. Kluwer Academic/Plenum Publishers, 2005.

  15. Wickstrom Eric, Xiaobing Tian, Amirkhanov N, Chakraborti Atis, Aruva MR, Rao PS,Qin Wenyi, Zhu Weizhu, Sauter ER, Thakur ML. Radionuclide Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer (in) Philips Ian (ed): Antisense Therapeutics. New Jersey: Humana Press, 2005.

  16. Weiner RE, Thakur ML. Radiolabeled peptides in oncology (in) Van der lely AJ (ed): Action of Somatostatin. Netherlands: Excepta Medical Publications, 2004.

  17. Wickstrom E, Thakur ML, Sauter ER. Receptor – specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides (in) Letters in Peptide Sci 10: 191 – 214 (2004). Netherlands: Kluwer Academic Publishers, 2004.

  18. Tian Xiaobing, Aruva MR, Rao PS, Qin Wenyi, Read Paul, Sauter ER, Thakur ML, Wickstrom Eric: Imaging Oncogene Expression (in) Ann NY Acad. Sci. 1002: 165 – 188(2003). New York: New York Academy of Sciences, 2003.

  19. Weiner RE, Thakur ML. Radiopharmaceuticals (in) Sandler M, Coleman RE (ed): Diagnostic Nuclear Medicine. Philadelphia. Lippincott Williams & Wilkins, 2003.

  20. Weiner RE, Thakur ML. Chemistry of Gallium and Indium Radiopharmaceuticals (in) Welch MJ, Redvanly CS (ed). Handbook of Radiopharmaceuticals. Hoboken. Wiley, 2003.

  21. Thakur ML. The use of radiolabeled monoclonal antibodies in inflammatory bowel diseases (in) Signore A, Liberatore M, Scopinaro F (ed). Nuclear Medicine in the Management of Inflammatory and Infectious Diseases. Berlin. Springer – Verlag, 2003.

  22. Rhodes BA, Thakur ML, Stewart T, Anderson T, Patel M, Smith T. Direct Tc – 99m labeling of an IgM (in) Nicolini T(ed). Proc. Of Technetium, Rhenium, and other metals in chemistry and nuclear medicine. Padova. SGE, 1999.

  23. Thakur ML, Pallela VR. Radiolabeled peptides. Experimental and clinical applications. Vera Ruiz HR, Narasimhan DVS (ed). Modern Trends in Radiopharmaceuticals and Therapy. Proc. Of the IAEA Symposium. Lisbon, Portugal, 1998.

  24. Weiner RE, Thakur ML. New developments in radiolabeled blood cells (in) Sampson C (ed). Textbook of Radiopharmacy. Gordon and Breach Science Publishers, 1998.

  25. Forsberg F, Liu LB, Kim S, Thakur ML, Rawool NM, Johnson D, and Goldberg B. Renal Perfusion Evaluated with a New Ultrasound Contrast Agent (in) Tortoli P, Masotti L. Acoustical Imaging. New York: Plenum Press, 1996.

  26. Hosain F, Thakur ML. Radiopharmaceuticals: Physics, Chemistry and Clinical Applications (in) Sood DD (ed). Frontiers in Nuclear Chemistry. Bombay, 1996.

  27. Weiner R and Thakur ML. Metallic Radionuclides: Applications in Diagnostic and Therapeutic Nuclear Medicine (in) Adloff JP, Leiser KH, Stocklin G (ed). One Hundred Years after the Discovery of Radioactivity. Munich: Roldenbourg Verlag Munchen, 1996.

  28. Thakur ML. Peptides and proteins in Radiolabeling of Blood Elements (in) Martin – Comin J, Thakur ML (ed). Proceedings of 6th Int. Symposium on Radiolabeled Blood Elements. New York: Plenum Publishing Co. 1994.

  29. Ezekowitz MD, Holley D, Thakur ML. Radionuclide imaging of thrombus (in) Ezekowitz M (ed). Systemic Cardiac Embolism. New York: M Dekker Inc., 1992.

  30. Thakur ML. Cell Labeling in Radiopharmacy: What can Radiolabeled Monoclonal Antibodies offer? (in) Schubiger P, Westera G (ed). Progress in Radiopharmacy. Kluwer Ac. Publishing Co., 1991.

  31. Thakur ML. Radiolabeled Antibodies Specific for Human Blood Elements (in) Sinzinger H, Thakur ML (ed). Proceedings of the 5th Int. Symposium on Radiolabeled Blood Elements. New York: Alan Riss Publishing Co., 1990.

  32. Thakur ML. Radiolabeled Monoclonal Antibodies for Specific Blood Cell Labeling: The State of the Art (in) Spender RP (ed). New Procedures in Nucl Med. CRC Press, 1989.

  33. Thakur ML. Potential of Radiolabeled Antiplatelet Antibodies in the detection of vascular thrombi (in) Srivastava SC (ed). Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York: Plenum Publishing Co., NATA ASI, series 152, 1988.

  34. Thakur ML, White III F, Weiner R and Park C. Indium – 111 labeled leukocytes and platelets. Mechanism of labeling and intracellular location of In – 111 (in) Billinghurst MW (ed). Current Appl in Radiopharmacology. Toronto: Pergamum Press, 1986.

  35. Thakur ML. Radiolabeled Leukocytes and Platelets (in) Fritzberg AR (ed). Radiopharmaceuticals. Progress and Clinical Perspective. Boca Raton: CRC Press, 1986.

  36. Thakur ML. Radionuclides and Chelates used for Platelet Labeling (in) Badenhorst PN, Lotter MG (ed). Platelet Kinetics and Imaging Vol.1. Boca Raton: CRC Press, Inc., 1986.

  37. Thakur ML. Radiolabeled Blood Cells: Radiation Dosimetry and Significance (in) Fourth Int. Radiopharmaceutical Dosimetry Symposium. Oak Ridge, Tennessee, Nov. 5 – 8. 1985.

  38. Thakur ML, McKenney S. Techniques of cell labeling. An overview (in) Thakur ML (ed). Radiolabeled cellular blood elements: Pathophysiology techniques and scintigraphic applications. New York: Plenum Publishing Co., 1985.

  39. Thakur ML. Radiolabeling Neutrophils Current Accomplishments and Future Possibilities (in) Feuger G (ed). Blood Cells in Nuclear Medicine, Part II: Migratory Blood Cells. Boston: Martinus Nijoff Publishing Co., 1984.

  40. Thakur ML. Approaches to Radiolabeling Blood Cells: Past, Present and Future (in) Hardeman MR, Najean Y (ed). Blood Cells in Nuclear Medicine, Part I: Cell Kinetics and Biodistribution. Boston: Martinus Nijoff Publishing Co., 1984.

  41. Thakur ML. Radiolabeled Blood Cells: Agents for Diagnostic Imaging and Kinetic Studies (in) Lambrecht RM and Marcos (ed). Applications of Nuclear and Radiochemistry. London: Pergamum Press, 1982.

  42. Thakur ML. Radioactive compounds of Gallium and Indium (in) Rayudu GVS (ed). Radiotracers for Medical Applications. CRC Press, 1982.

  43. Thakur ML. Indium Radiopharmaceutical Chemistry (in) Jones A, Welch MJ (ed). Radiopharmaceutical Chemistry. Boston: Martinus Nijoff Publishing Co., 1982.

  44. Riba AL, Thakur ML, Gottschalk A and Zaret BL. Detection of cardiovascular disorders with In – 111 labeled platelets (in) Mehta J, Mehta P (ed). Platelets and Prostaglandins in Cardiac Diseases. New York: Future Publishing Co., 1981.

  45. Thakur ML, Zoghbi S. Structure activity relationship in cell labeling (in) Spender R (ed) Radiopharmaceutical Structure Activity Relationship. Grune and Stratton, 1981.

  46. Zakhireh B, Thakur ML, Malech HL. In vitro function of 111In – labeled human polymorphonuclear leukocytes (in) Thakur ML, Gottschalk A (ed). Indium – 111 Labeled Neutrophils, Platelets and Lymphocytes. New York: Trivirum Publishing Co., 1980.

  47. Zaret BL, Davis RE, Thakur ML. Imaging of Inflammatory response to acute MI (in) Thakur ML, Gottschalk A (ed). Indium – 111 Labeled Neutrophils, Platelets and Lymphocytes. New York: Trivirum Publishing Co., 1980.

  48. Riba AL, Thakur ML, Gottschalk A, Zaret B. Indium – 111 platelet imaging of experimental intracardiac thrombosis (in) Thakur ML, Gottschalk A (ed). Indium – 111 Labeled Neutrophils, Platelets and Lymphocytes. New York: Trivirum Publishing, 1980.

  49. Thakur ML, Gottschalk A. Experiences with 111In – oxine (in) Indium – 111 labeled Neutrophils, Platelets and Lymphocytes. New York: Trivirum Publishing Co., 1980.

  50. Weiner RE, Thakur ML, Goodman M, Hoffer PB. Relative stability of In – 111 and Ga – 67 desferrioxamine and human transferrin complexes (in) Proceedings of 2nd Int. Symp. on Radiopharmaceuticals II. Bethesda: Society of Nuclear Medicine, 1979.

  51. Thakur ML, Gottschalk A. Role of radiopharmaceuticals in nuclear hematology (in) Proceedings of 2nd Int. Symposium on Radiopharmaceuticals. Radiopharmaceuticals II. Bethesda: Society of Nuclear Medicine, 1979.

  52. Coleman RE, Welch MJ, and Thakur ML. Indium – 111 labeled blood elements and their evaluation in nuclear medicine (in) Medical Radionuclide Imaging II. Vienna: I.A.E.A., 1977.

  53. Thakur ML, Merrick MV, Gunasekera SW. Some pharmacological aspects of a new radiopharmaceutical Indium – 111 bleomycin (in) Radiopharmaceuticals and Labeled Compounds 11. Vienna: I.A.E.A., 1973.

  54. Merrick MV, Gunasekera SW, Lavender PL, Nunn AD, Thakur ML and Williams ED. The use of Indium – 111 for tumor localization. A comparison of several chelates with Gallium – 67 inflammatory and neoplastic lesions, with a note on Indium labeled bleomycin (in) Medical Radioisotope Scintigraphy II. Vienna: I.A.E.A., 1973.

  55. Thakur ML, Merrick MV. Indium – 111 labeled bleomycin as a tumor localizing agent (in) Welwyn, Herts (ed): Proceedings of the International Symp. on Bleomycin.London: Lundbeck, Ltd., 1972.


Editorials:

1. Thakur ML. An interview with Society of Nuclear Medicine President Thakur ML, PhD Radiology Today 2005;10

2. Thakur ML. SNM, SNMTS and ERF: A joint venture in funding the future. J Nucl Med 2005; 46(3)

3. Thakur ML. Meeting our parents’ current, future needs for radionuclides. J Nucl Med 2005; 46(4)

4. Thakur ML. It’s time to voice why this nation needs to invest in molecular imaging/nuclear medicine. J Nucl Med 2005; 46(25N – 26N)

5. Thakur ML. SNM to Establish Center of Molecular Imaging as New Field Emerges, Grows Rapidly. J Nucl Med 2005;45(23N – 24N)

6. Thakur ML. SNM. Today and Tomorrow. J Nucl Med. 2005; 46(6)

7. Thakur ML. Leadership update from the new SNM president. J Nucl Med 2004; 45(7)

8. Thakur ML. Strategic goals generate SNM success in 2004. J Nucl Med 2004; 46(2)

Symposiums and Meetings

National and International:

1. Member, Scientific Advisory Committee, 17th ISORBE Congress, Izmir, Turkey 2015

2. Member, Advisory Committee, WFNMB, Cancun, 2014

3. Member, Advisory committee, WFNMB, Cape Town, 2010

4. Organizer, Pre – congress on “ Applications of Radiolabeled blood elements” WFNMB, Seoul, Korea, 2008

5. Organizer, Molecular Imaging, Symposium, WFNMB, Seoul, Korea, 2006

6. Organizer, SNM/Industry Summit, 2006

7. US Senate Cocus Organizer on Molecular Imaging. US Senate 2005.

8. Organizer, Post – Congress Symposium on "Imaging Infection and Vascular Thrombosis. The present and the future". Post – congress to WFNMB, Chile, October, 2002

9. Organizer, Cell labeling techniques (Pre – congress), 7th Asia and Oceania Pacific Congress of Nuclear Medicine and Biology, Istanbul, Turkey, 2000.

10. Co – organizer, Radiotracers in development. Bordeaux, France, 2000.

11. Co – organizer, Radiolabeled peptides and proteins. Rome, Italy, 2000.

12. Co – organizer, 9th Int. Symposium of Radiolabeled Cellular Blood Elements, Rio de Janeiro, Brazil, 1999.

13. Co – organizer, Scintigraphic detection of inflammation and infection. Nijmegen, The Netherlands, 1998.

14. Co – organizer, 8th Int. Symposium of Radiolabeled Cellular Blood Elements, Castel Gandolfo, Italy, 1997.

15. Co – organizer 7th Int. Symposium of Radiolabeled Cellular Blood Elements, New Haven, 1995.

16. Organized presentations by a group of selected scientists from the USA to the 25th Annual Meeting of Soc. Nucl. Med. India in New Delhi, December 1993.

17. Co – organizer 6th Int. Symposium on Radiolabeled Cellular Blood Elements, Barcelona, Spain, Nov. 1992.

18. Co – organizer of 5th Int. Symposium on Radiolabeled Cellular Blood Elements, Vienna, Austria, 1989.

19. Organized mini – symposium in the 4th World Congress in Nucl Medicine and Biology – Buenos Aires, Nov. 1986.

20. Director ASI, on Radiolabeled Cellular Blood Elements. Sponsor – NATO, Italy, 1983.

21. Director, NATO ASI, 1983. Organized several international symposia.

22. Organized state of the art symposium on Radiolabeled Cellular Blood Components. Sponsor Diagnostic Isotope, NY, 1979.

23. Scientific program committee member.

24. Chaired Scientific Sessions.

25. Invited speaker to many symposiums and international meetings in the USA and abroad.

Presentations:

Universities:

  1. Ruijin Hospital, Shanghai, China. “Diagnostic Approaches to Urologic Oncology”, August 20, 2019.

  2. KLE University, Dr. Prabhakar Kore Hospital. Belgaum, India. “Urinary Biomarkers for prostate cancer diagnosis”, March 16, 2019.

  3. KLE University, Dr. Prabhakar Kore Hospital. Belgaum, India. “Blood and serum biomarkers for diagnosis of prostate cancer”, March 16, 2019.

  4. Shah Institute of Nuclear Sciences, Kolkata, India. “Recent advance in oncologic diagnosis using Copper64”. December 21, 2018.

  5. University of Florida, Gainesville, FL, “Embracing Diversity for Excellence in Science” Invited Keynote Speaker. October 31, 2018.

  6. Abdulaziz University, Jeddah, Saudi Arabia, “Molecular imaging: From bench to bedside” Invited Presentation. February 14 – 15, 2014.

  7. Drexel University, Philadelphia, PA, “Genomic approaches to imaging concerns of the breast and prostate” Invited Presentation. June 30, 2014.

  8. Yale University School of Medicine. New Haven CT, 2012.

  9. Oklahoma University of Health Sciences, Lloyd Harris Distinguished Lecture “Exploiting Genomic Biomarkers for Oncologic imaging and Therapy” 2011.

  10. SNM/NIH, Breast Cancer Imaging Workshop. Bethesda MD, April 2011.

  11. SNM Annual Meeting, San Antonio, TX, June 2011.

  12. University of Colombia. Bogota, 2009.

  13. Juntendo University, Japan. Keynote speaker. 2006.

  14. The University of Texas, 2005.

  15. Oakwood Hospital, Detroit, Michigan, 2004.

  16. Kuwait Institute for Medical Specialization, 2002.

  17. First Hospital of Beijing University, 2001.

  18. China Atomic Energy Agency, 2001.

  19. University of Pennsylvania, 2000.

  20. University of Pennsylvania, 1999

  21. New York Methodist Hospital, 1999

  22. University of Vienna, Austria, 1998

  23. University of California, Berkeley, 1998

  24. University of Nijmegen, The Netherlands, 1998

  25. All India Institute of Nucl Med, New Delhi, India 1997

  26. Sloan – Kettering Institute, 1996

  27. National Institute of Health, 1995

  28. University of Pennsylvania, 1995

  29. Wistar Institute, Philadelphia, PA, 1994

  30. Ottawa General Hospital, Ottawa, Canada, 1994

  31. University of Mexico, Merida, 1994

  32. University of Vienna, Dept. of Radiology, 1993

  33. National Institutes of Health, Bethesda, Maryland, 1993

  34. Hospital De Bellvitge, Barcelona, Spain, 1992

  35. Cooper Medical Center, 1992

  36. Atomic Energy Commission, Chile, 1991

  37. Atomic Energy Commission, Chile, 1991

  38. Sloan Kettering Institute, New York, 1990

  39. Connecticut Health Science Center, Dept. of Nuclear Medicine, 1990

  40. University of New Mexico, Dept. of Pharmacology, 1987

  41. Thomas Jefferson University, Dept. of Pharmacology, 1987

  42. Mount Sinai Medical Research Center, New York, 1987

  43. Swiss Institute for Reactor Research, Switzerland, 1987

  44. University of Pennsylvania, Nuclear Medicine Club, 1987

  45. Temple University Medical School, 1987

  46. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia, 1986

  47. Connecticut Health Center, 1985

  48. University of Osaka, July 1984

  49. University of Chiba, July 1984

  50. Temple University Medical School, 1984

  51. University of Pennsylvania, Nuclear Medicine Club, 1983

  52. University of Amsterdam, Netherlands, 1982

  53. University of Cincinnati Medical Center, 1982

  54. Isotope Division, Bhabha Atomic Research Center, Bombay, Trombay, India, 1982

  55. The University of Kansas, 1982

  56. Jaslok Medical Center, Bombay, 1981

  57. Radiation Medicine Center, Bombay, 1981

  58. S.N. Medical College, Agra, 1981

  59. All India Institute of Medical Sciences, New Delhi, 1981

  60. Institute of Nuclear Medicine and Allied Sciences, New Delhi, 1981

  61. University of Oklahoma, Oklahoma City, 1981

  62. V.A. Medical Center, Portland, Oregon, 1981

  63. Thomas Jefferson University, 1981

  64. University of Pennsylvania, Philadelphia, Pennsylvania, 1979

  65. Radiation Medicine Center, Bombay, 1979

  66. Hammersmith Hospital, London, 1978

  67. Brookhaven National Laboratory, 1978

  68. University of Texas, Dallas, Texas, 1978

  69. Sloan Kettering Institute, New York, 1977

  70. University of Utah, Salt Lake City, Utah. 1977

  71. University of Maryland, Baltimore, Maryland, 1977

  72. Johns Hopkins Institute, Baltimore, Maryland, 1977

  73. Syracuse Medical Center, Upstate, New York, 1977

  74. William Beaumont Hospital, Detroit, Michigan, 1977

  75. Vanderbilt University, Tennessee, 1976

  76. University of California, Los Angeles, California, 1976

  77. Stanford University, Stanford, California, 1975

Training Courses:

    1. International Atomic Energy Agency, 2007

    2. “Targeting Oncogene expression for diagnosis and Therapy” Grand Rounds at MD Anderson Cancer Center. Houston, TX January 10, 2006

    3. International Atomic Energy Agency, 2006

    4. Japanese Soc. of Nucl. Med ( Plenary ) 2006

    5. Senate Caucus, Washington, DC (Invited) “ Recent Advances in Nuclear Medicine: Diagnosis and Therapy” April 26, 2005

    6. The University of Texas, San Antonio, TX (Invited) “Diagnosis of Equivocal Appendicitis” March 2 – 3, 2005

    7. American College of Nuclear Physicians, Las Vegas, NV (Invited) “Imaging Infection February 18 – 21, 2005.

    8. International Atomic Energy Agency, 2005

    9. British Soc. of Nucl. Medicine ( Plenary ), 2005

    10. Senate Caucus, Washington, DC, 2005

    11. Eastern Isotopes, Annual Gathering, Vallarta, Mexico, 2005

    12. Chinese Society of Nucl. Med. Beijing, 2005

    13. Society of Nuclear Medicine, Mid – winter Meeting, Tampa, FL, 2005

    14. Oakwood Hospital, Detroit, Michigan (Invited) “ Imaging Infection: Future Trends” November 8, 2004.

    15. University of Pennsylvania, Philadelphia, PA “Imaging oncogene expression” January 30, 2004.

    16. International Congress on Radiopharmacy and Radiochemistry, Istanbul, Turkey, 2004

    17. Pennsylvania Hospital, Philadelphia, PA “Role of nuclear medicine in molecular imagine” December 16, 2003

    18. University of Pennsylvania, PA, Radiopharmaceuticals: Pharmacokinetics” September 9, 2003.

    19. University of Pennsylvania, PA, 2003

    20. World Federation of Nuclear Medicine and Biology, Chile, 2002

    21. Mexican Society of Nuclear Medicine, Guanajuato, 2002

    22. University of Kuwait, 2002

    23. Chinese Atomic Energy Establishment, Beijing, 2001

    24. International Atomic Energy Agency, Buenos Aires, 1999.

    25. IAEA, Vienna, 1998

    26. International Atomic Energy Agency, Vienna, 1997.

    27. International Atomic Energy Agency, Lisbon, 1996.

    28. Basic sciences in the clinical practice of Nuclear Medicine, Cooper Univ. Med. Ctr. 1994.

    29. International Atomic Energy Agency, Vienna, 1992.

    30. Atomic Energy Commission, Chile, 1991.

    31. International Atomic Energy Agency, Moscow, 1990.

    32. International Atomic Energy Agency, East Berlin, 1989.

    33. Toronto Institute for Medical Technology, 1987.

    34. Temple University, 1987.

    35. Training in Nuclear Medicine, Long Island College Hospital, New York, 1983.

    36. Indian Society of Nucl. Med, 1980

    37. Radiologic and Nuclear Medicine Techniques in the Diagnosis of Obscure Infections, Yale University School of Medicine, 1980.

    38. Nuclear Cardiology, Yale University Medical School, Session Chairman, 1980.

    39. Bethesda Naval Hospital, Bethesda, Maryland, October 1980.

    40. Bethesda Naval Hospital, Bethesda, Maryland, February 1980.

    41. 27th Annual Meeting of the Society of Nuclear Medicine, June 1980.

    42. Nuclear Cardiology Course, Beth Israel Hospital, New York, 1979.

    43. Bethesda Naval Hospital, Bethesda, Maryland, October 1979.

    44. Bethesda Naval Hospital, Bethesda, Maryland, February, 1979.

    45. Nuclear Cardiology, Yale University Medical School, 1978.

    46. Bethesda Naval Hospital, Bethesda, Maryland, October 1978.

    47. Bethesda Naval Hospital, Bethesda, Maryland, February 1978.

    48. Bethesda Naval Hospital, Bethesda, Maryland, October 1977.

    49. Bethesda Naval Hospital, Bethesda, Maryland, February 1977.

    50. 25th Annual Meeting of the Society of Nuclear Medicine, June 1977.

    51. Third Training Course in Radiopharmaceuticals, Hammersmith Hospital, England, 1977.

National and International:

  1. SUO 23rd Annual Meeting, “Targeting VPAC in voided urine for detecting prostate cancer.” San Diego, CA, November 29 – December 2, 2022.

  2. 14th Annual WARMTH Conference, Nanjing, China. “WARMTH 2019, Ajit Padhy Oration” August 2019.

  3. SNMMI Annual Meeting, Philadelphia, PA. “PET imaging of urothelial bladder cancer: addressing an unmet need”, and “Comparison of N2S2 and NODAGA as chelators for 64Cu-labeled PET imaging in mice bearing prostate tumor”. Philadelphia, PA, June 2019.

  4. ISORBE & Israel Society of Nuclear Medicine, Neve Ilan Hotel, Tel Aviv, Israel. “Stem cells; A regenerative pharmaceutical”, March 8, 2019.

  5. SNMMI Annual Meeting, Philadelphia, PA. “Currently Available Radiopharmaceuticals”, “Diagnostic Approaches to Urological Oncology”, “VPAC1 biomarker for imaging triple negative breast cancer”, “A comparison of in vivo stability of Ga-68 labeled peptide conjugate for targeting VPAC receptors”. Philadelphia, PA, June 2018.

  6. 49th Annual Conference of the Society of Nuclear Medicine, “VPAC1 for Diagnosis and Treatment of Clinical Pathologies”. New Delhi, India, December 2017.

  7. 13th International Symposium on VIP, PACAP and Related Peptides, “VPAC Platform in the Theranostic Oncology”. Hong Kong, December 2017.

  8. 18th Annual Meeting of Society of Urologic Oncology Plenary, “VPAC1: A Novel Target for Imaging Prostate Cancer”. Washington, DC, November 2017.

  9. 12th WARMTH Congress ICRT, “Cu-64/Cu-67 Theranostics for Urothelial Malignancies”, Vienna, Austria. October 2017.

  10. 10th Annual World Cancer Congress, “Translating Comprehensive Molecular Approach to Oncologic Diagnosis in Humans”. Barcelona, Spain, May 2017.

  11. Thomas Jefferson University President’s Mission. Summary of Ongoing Projects on Diagnostic Imaging. Belgaum, India, November 2016.

  12. International Conference on Radiation Biology. Chennai, India, 2016

  13. 2nd World Congress on Cancer. Singapore, 2016

  14. American Chemical Society Annual Meeting, Philadelphia, PA, 2016.

  15. 47th Annual Conference of SNM India. Puducherry, November 2015.

  16. Biofluids and High – Value Diagnostics. Boston, September 2015.

  17. World Congress on Cancer and Prevention Methods. Dubai, August 2015

  18. Annual Congress of International Isotope Society. Novel emerging technologies in PET imaging of breast and prostate cancer, plenary presentation. Princeton, NJ June 2015.

  19. Seventeenth ISORBE Congress. Optical imaging of infection; Stem cells. Izmir, Turkey. March 2015.

  20. American Nuclear Society Eighth International Conference on Isotopes. Chicago, IL. August 2014.

  21. Seventy – second Annual Meeting. Vasoactive intestinal peptide and pituitary adenylate cyclase activation peptide receptor 1 (VPAC1) targeted detection of genitourinary cancer: A urinary assay. Baltimore, MD. September 2014.

  22. Eleventh Congress of World Federation of Nuclear Medicine and Biology on Infection and Inflammation Imaging. Round table, interactive session. Cancun, Mexico. Aug 2014.

  23. Eleventh Congress of World Federation of Nuclear Medicine and Biology on Exploiting Genomic Biomarkers for Diagnosis and Therapy. Invited Plenary Presentation. Cancun, Mexico. Aug 2014.

  24. Eleventh Congress of World Federation of Nuclear Medicine and Biology on New Developments in Radiolabeled Cells. Invited Plenary Presentation. Cancun, Mexico. Aug 2014.

  25. Sixty Ninth Annual Meeting of the SNMMI, St. Louis MO “Imaging bladder cancer: Correlation with histopathologic findings” June 5 – 11, 2014.

  26. NuView, Incorporated, Philadelphia, PA “Targeting VPAC1 receptors an update” Invited Presentation. April 24, 2014.

  27. International Congress on Radiation Medicine, Riyadh, Saudi Arabia “Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA” “Innovations in PET breast cancer imaging techniques” Invited Presentation. February 15 – 21, 2014.

  28. Indian Science Congress Association, Jammu, India “Targeted genomic biomolecules for diagnosis and therapy: From basic research to clinical perspective” Invited Presentation. February 8, 2014.

  29. 3rd International Conference on Applications of Radiotracers and Energetic Beams in Science, Kolkata, India “Radiolabeled biomarkers for specific imaging of the cancers of the breast, prostate and lungs” Invited Presentation. January 9 – 14, 2014.

  30. Role of Lipid soluble Complexes in Targeted Therapy. International Conference on Radiation Medicine, Riyadh, Saudi Arabia, 2014.

  31. Determining Efficacy of Breast Cancer Therapy by PET Imaging of HER2 mRNA. International Conference on Radiation Medicine, Riyadh, Saudi Arabia, 2014.

  32. Genetic Approaches to PET Imaging of Breast Cancer: Why do we need this approach? International Conference on Radiation Medicine, Riyadh, Saudi Arabia, 2014.

  33. Targeted Genomic Biomarkers for Diagnosis and Therapy from Basic Research to Clinical Perspective. Indian Science Congress Association, Jammu, India, 2014.

  34. Radiolabeled Biomolecular for the Specific Imaging of Cancers of the Breast, Prostate and Lungs. Third International Conference on Applications of Radiotracers and Energetic Beams in Science, Kolkata, India, 2014.

  35. Sixty Eighth Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, Vancouver, Canada “Remembering Henry Wagner, Jr." Invited Presentation. June 8 – 12, 2013

  36. University City Science Center, Philadelphia PA “Imaging genomic biomarkers for diagnosis and therapy" Invited Presentation. May 22, 2013

  37. 11th International Symposium on VIP, PACAP and Related Peptides, Pecs Hungary “PET imaging of KRAS2 activated lung cancer in transgenic mice using VPAC1 receptor specific for Cu – 64 – TP3805” “Personalized examination of VPAC1 biomarkers for detecting genitourinary cancer” Invited Presentation. Aug 25 – Sept 23, 2013.

  38. Annual Congress of European Association of Nuclear Medicine, Lyon, France “Detecting genitourinary Cancer ex vivo: “Correlation with histopathologic findings” October 16 – 25, 2013.

  39. 14th International Conference of International Society of Radiolabeled Blood Elements (ISORBE), Pretoria, South Africa “Stem cells; a regenerative pharmaceutical “Highlights of the 14th International Conference of International Society of Radiolabeled Blood Elements (ISORBE)" Invited Presentation. March 19 – 27, 2013

  40. Bruckner, Inc. training course at Princeton University, Princeton, NJ “Molecular imaging: from bench to bedside" Invited Presentation. March 11, 2013

  41. 2nd World Congress on Medical Applications of Ga – 68, Chandigarh, India “Can Ga – 68 contribute to the welfare of women suspected to have breast cancer?" Invited Presentation. February 27 – March 13, 2013

  42. ImaginAb, Inc., Los Angeles, CA “Targeting CD 15 receptors for imaging infection" Invited Presentation. November 8, 2012

  43. Department of Pathology, Yale University, New Haven, CT “Molecular imaging: from bench to bedside" Invited Presentation. November 1, 2012

  44. National Institute of Health, Bethesda, MD “Radiolabeled blood cells: imaging infection" Invited Presentation. September 27, 2012

  45. United Pharmacy Partners, Inc. Philadelphia, PA “Targeting genomic biomarkers for oncologic imaging" Invited Presentation. September 15, 2012

  46. NuView, Inc. Salt Lake City, UT “Targeting VPAC1 genomic biomarkers for PET/PEM imaging of breast cancer" Invited Presentation. August 27 – 29, 2012

  47. Society of Radiolabeled Blood elements, “Dual Tracer, Optical and radionuclide Imaging of Infection” Invited Presentation. 2011

  48. NIH/SNM workshop on Infection Imaging, “Targeting Apoptosis for Optical Imaging of Infection” Invited Presentation. Bethesda, 2011

  49. 42nd Annual Meeting of SNM – India. “Genetic PET imaging in translational research” Chandigarh, India. Invited Presentation. 2010

  50. Indo – US workshop on, “Targeting biomarkers for diagnosis and therapy”, “Applications of molecular imaging in health and disease and drug discovery” Hyderabad, India. Invited Presentation. November, 2010

  51. “Targeting genomic biomarkers in molecular imaging” WFNMB Cape Town, South Africa. Plenary presentation. 2010

  52. “Imaging gene expression” WFNMB, Cape Town, South Africa. Plenary presentation. 2010

  53. “Molecular imaging” WFNMB, Cape Town, South Africa. A lunchtime seminar. 2010

  54. “Role of molecular imaging in diagnosis and therapy” Johns Hopkins University, Baltimore MD. Invited Presentation. December 9, 2010

  55. Bogota Medical Center, University of Bogota, Colombia. “Targeting genomic biomarkers for imaging breast cancer” Invited Presentation. November 8, 2010

  56. 23rd Annual Meeting of the Association of Latin of Nuclear medicine. Cartagena, Colombia. “Role of high sensitivity – high resolution micro PET in molecular imaging. “Future directions in imaging infection” Invited Presentation. November 6 – 7, 2010

  57. 30th Annual Meeting of the European Association of nuclear medicine, Barcelona, Spain. “Imaging infection – challenges and prospects” Plenary presentation. October 12, 2010

  58. 18th International Symposium in Radiopharmaceutical Sciences, Edmonton, Canada. “VPAC1 gene product targeted PET imaging of breast cancer” July 14, 2010

  59. “Targeting Genomic Biomarker for Imaging Breast Cancer” 18th Annual Meeting of ALASBIMN, Cartagena, Colombia. November 3 – 7, 2009

  60. “Imaging Infection: Challenges and Prospects” 36th Annual Meeting of EANM. Barcelona, Spain. October 10 – 14, 2009

  61. Soc. Nucl. Med. 56th Annual meeting Toronto, Canada “PET imaging of spontaneous mouse mammary tumor virus (MMTV) infected breast cancer (BC) using Cu – 64 – TP3805”. June 11 – 17, 2009

  62. AAPM, Spring Symposium Philadelphia, PA “Molecular Imaging of Breast Cancer”. April 24, 2009

  63. Int. Symposium Molecular Imaging & Therapy Road Map to Modern Medicine Kuwait University “Therapeutic Radiopharmaceuticals”. March 11, 2009

  64. Int. Symposium Molecular Imaging & Therapy Road Map to Modern Medicine, Kuwait University “Genomic biomarkers for Molecular Imaging”. March 9, 2009

  65. University Of Pennsylvania “Mechanism of Radiopharmaceutical uptake”. March 4, 2009

  66. Trace Life Sciences, Dallas TX “Cu – 64 – biomolecules for diagnosis and Therapy”. Dec. 11, 2008

  67. 9th Asia, Oceania Congress of Nucl. Med. Biol. New Delhi, India “PNA based Radiopharmaceuticals for Targeted Therapy” “Imaging Infection and Inflammation” “Radionuclides in Therapy. Critical Evaluation”. Oct. 31 – Nov. 4, 2008

  68. International Symposium on Radiopharmaceutical Therapy, Goa, India “Lipid soluble radioactive agents for Intratumoral therapy” “Approaches to Stem Cell Therapy” Oct. 27 – 30, 2008

  69. “Genomic Biomarkers for Molecular Imaging: Predicting the Future” 55th Annual Meeting of the Board of Nuclear Medicine. New Orleans, Louisiana. June 15 – 18, 2008

  70. “Stem Cells: A Regenerative Pharmaceutical” Nuclear Medicine Tomorrow. Nantes, France March 30 – April 12, 2008

  71. “Radiopharmaceuticals for Targeted Therapy” 6th International Conference on Isotopes. Seoul, South Korea May 12 – 16, 2007

  72. “Future Trends in Molecular Imaging” 39th Annual Meeting of Society of Nuclear Medicine India. Lucknow, India December 6 – 9,2007

  73. “Stem Cells” 13th Symposium of International Society of Radiolabeled Blood Elements. Santa Cruz, Bolivia December 1, 2007

  74. “Trends in Radiopharmaceutical development and use” and “Molecular Imaging. Future Directions” 21st ALASBIMN Annual Meeting. Santa Cruz, Bolivia December 1 – 4, 2007

  75. "PET Imaging of Prostate Cancer: A New Approach to an Old Problem” and “PET targeting of Breast Cancer; Role of Receptor Specific Peptides” 20th Annual meeting of Eur. Association. Copenhagen, Denmark October 13 – 17, 2007

  76. “Molecular Approach to PET Imaging of Prostate Cancer” AdMeTech Foundation Washington D.C. September 17, 2007

  77. “Radiolabeling Biomolecules for Molecular Imaging: Theory and Applications” Johnson & Johnson Centocor, Pennsylvania August 15, 2007

  78. “Copper – 64 – Breast and Prostate Diagnostics” NuView Radiopharmaceuticals Inc. Park City, Utah July 27,2007

  79. “Molecular Imaging: Shaping the future” and “PET imaging of Hormone Dependent Cancers” MDs Nordion Inc. Toronto, Canada July 2, 2007

  80. International Atomic Energy Agency, Vienna, 2007

  81. International Atomic Energy Agency, Vienna, 2006

  82. WFNMB, Seoul Korea. Invited Presentation. 2006

  83. “Approach to Imaging Oncogene Expression”, “Annual Lecture” 34 Annual Meeting of the British Nuclear Medicine Society. Manchester, England. Invited Presentation. March 28, 2006

  84. “Applications of Radiotracers in Biological Sciences” International Conference in Applications of Radiotracers in Chemical, Environmental and Biological Sciences. Saha Institute of Nuclear Physics. Kolkata, India. Invited Presentation. January 26, 2006

  85. International, Atomic Energy Agency, Vienna, 2005

  86. Japanese Soc. of Nucl Med, Kagoshima. Plenary Presentation. 2005

  87. British Soc. Nucl. Med; Manchester. Plenary Presentation. 2005

  88. Senate Caucus, US Senate, 2005

  89. Society of Nuclear Medicine, 52nd Annual Meeting, Toronto, Canada “Cu – 64 labeled PNA for Imaging Pancreatic Cancer” NeutroSpec. Invited Presentation. June 16 – 23, 2005

  90. Society of Nuclear Medicine, Central Chapter, Annual Meeting Chicago, IL. ”Recent Advances in Radiopharmaceuticals” Invited Presentation. March 31 – April 1, 2005

  91. Society of Nuclear Medicine, Greater New York Chapter, Annual Meeting, “Imaging Infection: Now and the Future” Invited Presentation. April 30 – May 2, 2005

  92. American Association of Pharmacists, Annual Meeting, Orlando, FL. “Imaging Infection using NeutroSpec” Invited Presentation. April 2 – 3, 2005

  93. Eastern Isotopes Annual Gathering, Vallarta, Mexico. “Recent development of positron Radiopharmaceuticals” Invited Presentation. February 3 – 5, 2005

  94. “Society of Nuclear Medicine, Mid – winter Meeting, Tampa, FL. “Imaging Infection: NeutroSpec” Invited Presentation. January 26 – 30, 2005

  95. “Genomic approaches to Molecular Imaging” 20th Congress of Association of Latin American Societies of Biology and Nuclear Medicine. Invited Presentation. December 7, 2005.

  96. “Introduction to the Society of Radiolabeled Blood Elements” 20th Congress of Association of Latin American Societies of Biology and Nuclear Medicine. Invited Presentation. December 6, 2005.

  97. “New Trends in Radiopharmaceuticals for diagnosing infection/inflammation” 20th Congress of Association of Latin American Societies of Biology and Nuclear Medicine. Invited Presentation. December 6, 2005.

  98. “Pharmacology of radiolabeled Peptides” International Symposium in Trends in Radiopharmaceuticals. Atomic Energy Agency. Vienna, Austria. Invited Presentation. November 15, 2005

  99. “Opening Remarks” International Symposium in Trends in Radiopharmaceuticals. Atomic Energy Agency. Vienna, Austria. Invited Presentation. November 14, 2005.

  100. “Berson Yalow Award Presentation” Annual Meeting of GNY and NE Chapter of Society of Nuclear Medicine. Newport, RI. Invited Presentation. October 29, 2005.

  101. “Peptides in Oncology Imaging” Annual meeting of GNY and NE Chapter of Society of Nuclear Medicine. Newport, RI. Invited Presentation. October 28, 2005.

  102. “Role of Neutrophil Specific Antibodies in Imaging Infection” Annual Meeting of European Association of Nuclear Medicine. Istanbul, Turkey. Invited Presentation. October 18, 2005.

  103. “Imaging Oncogene mRNA” Meeting of the European Association of Nuclear Medicine. Istanbul, Turkey. Invited Presentation. October 18, 2005.

  104. “New Results” 12th meeting of the International Society of Radiolabeled Blood Elements. Villigen, Switzerland. Invited Presentation. September 2, 2005

  105. “Stem Cells. A Regenerative Pharmaceutical” Istanbul, Turkey. 12th meeting of the International Society of Radiolabeled blood Elements. Villigen, Switzerland. Invited Presentation. September 2, 2005

  106. American College of Nuclear medicine, Physicians Annual Meeting, San Diego, CA. “New Tracers for imaging infection (including FDG)” Invited Presentation. January 15 – 19, 2005.

  107. Chinese Soc. of Nucl. Med, Beijing. Invited Presentation. Plenary Presentation. 2005.

  108. Society of Nuclear Medicine, 52nd Annual Meeting, Toronto, Canada. Invited Presentation. June 2005.

  109. Society of Nuclear Medicine, Central Chapter, Annual Meeting, Chicago, IL. Invited Presentation. April 2005.

  110. Society of Nuclear Medicine, Greater New York Chapter, Annual Meeting, Tarrytown, NY. Invited Presentation. May 2005.

  111. Senate Caucus, Washington, DC. Invited Presentation. April 2005.

  112. American Association of Pharmacists, Annual Meeting, Orlando, FL. Invited Presentation. April 2005.

  113. American College of Nuclear Physicians, Las Vegas, NV. Invited Presentation. February 2005.

  114. Society of Nuclear Medicine, Mid – winter Meeting, Tampa, FL. Invited Presentation. January 2005.

  115. American College of Nuclear Medicine, Physicians Annual Meeting, San Diego, CA. Invited Presentation. January 2005.

  116. Society of Nuclear Medicine. India, 36th Annual Meeting, Mysore, India. “Novel Radiopharmaceuticals for Molecular Imaging” Invited Presentation. December 15 – 18, 2004.

  117. Society of Nuclear medicine. India, 36th Annual Meeting, Pre – congress, Bangalore India. “PET Imaging of Oncogene Expression” Invited Presentation. December 13, 2004

  118. Japanese Society of Nuclear Medicine, Annual Meeting, Kyoto, Japan. “Recent Advances in Molecular Imaging” Invited Presentation. October 31 – November 7, 2004

  119. Society of Nuclear Medicine. New England chapter, Annual Meeting. “Toward NeutroSpec” Invited Presentation. October 22 – 24, 2004.

  120. Asia Oceania Federation in Nuclear Medicine and Biology, Beijing, china. “PET Imaging of Oncogene over expression” Invited Presentation. October 9 – 13,2004

  121. International Congress on Radiopharmacy and Radiochemistry. Istanbul, Turkey. “New Trends in Radiopharmaceutical Chemistry and Molecular Imaging” Invited Presentation. September 25 – 27, 2004.

  122. Annual Meeting of the Society of Nuclear Medicine, Philadelphia, PA “PET imaging of VPAC1 oncogene overexpression with Cu – 64 – vasoactive intestinal peptide (VIP)”, “Reparation and evaluation of Tc – 99m – peptide – PNA – peptide chimeras for imaging of CCND1 mRNA expression in human breast cancer xenografts”, “Imaging experimental pulmonary embolism (PE) in swine using fibrin specific peptide Tc – 99m – TP850” June 19 – 23,2004

  123. Society of Nuclear Medicine Chapter Annual Meeting, St. Louis, MO “Novel radiopharmaceuticals in imaging infection” May 17 – 18, 2004.

  124. Society of Nuclear Medicine Chapter Annual Meeting, Pittsburg, PA “Targeting oncogene expression for imaging breast cancer” March 5, 2004.

  125. Society of Nuclear Medicine, India, 36th Annual Meeting, Mysore, India. Invited Presentation. December 2004.

  126. Society of Nuclear Medicine, India, 36th Annual Meeting, Pre – congress, Bangalore India. Invited Presentation. December 2004.

  127. Oakwood Hospital, Detroit, Michigan. Invited Presentation. November 2004.

  128. Japanese Society of Nuclear Medicine, Annual Meeting, Kyoto, Japan. Invited Presentation. November 2004.

  129. Society of Nuclear Medicine, New England Chapter, Annual Meeting. Invited Presentation. October 2004.

  130. Asia Oceania Federation in Nuclear Medicine and Biology, Beijing, China. Invited Presentation. October 2004.

  131. International Congress on Radiopharmacy and Radiochemistry. Istanbul, Turkey. Invited Presentation. September 2004.

  132. Society of Nuclear Medicine Chapter, Annual Meeting, Detroit, MI “Recent advances in imaging infection” November 7 – 8,2003.

  133. Annual Meeting of the Brazilian Society of Nuclear Medicine and AIASBNM “Imaging Infection: Now and the future”, “Nuclear medicine and molecular imaging” August 26 – 31, 2003.

  134. Annual meeting of European Association of Nuclear Medicine Amsterdam, the Netherlands “Tc – 99m – vasoactive intestinal peptide: Influence of N4 VS N2S chelation”, “Imaging r – chain fibrin to image fresh and aged venous thrombosis (VT) and pulmonary embolism (PE) in swine” August 22 – 25, 2003.

  135. Annual congress of International Society of Radiopharmaceutical Chemistry and Biology, Sydney, Australia “Preparation of Cu – 64 and Tc – 99m – N2S2 vasoactive intestinal peptide (VIP) for imaging gene expression”, “Imaging oncogene mRNA with Tc – 99m PNA – Peptide chimeras” August 7 – 16, 2003.

  136. Chair, 50th Anniversary Committee, Society of Nuclear Medicine.

  137. Annual Congress of the Latin American Society of Biology and Nuclear Medicine (ALASBIMN), Cancun, Mexico. Invited Presentation. May 2003.

  138. Annual Meeting, Turkish Society of Nuclear Medicine, Samsun, Turkey. Invited Presentation. May 2003.

  139. Round Table Coordinator, International Society of Radiolabeled Blood Elements, Coimbra, Portugal, April 2003.

  140. Session Chair, International Society of Radiolabeled Blood Elements, Coimbra, Portugal, April 2003.

  141. Member, International Science Committee, International Society of Radiolabeled Blood Elements, Coimbra, Portugal, April 2003.

  142. Annual Meeting, International Society of Radiolabeled Blood Elements, Coimbra, Portugal. Invited Presentation. April 2003.

  143. NIH/NCI Workshop, San Diego, CA. Invited Presentation. February 2003.

  144. International Society of Radiolabeled Blood Elements, WFNMB Post – Congress, Santiago, Chile. Invited Presentation. October 2002.

  145. Member, Scientific Program Committee, World Federation of Nuclear Medicine and Biology, Santiago, Chile, October 2002.

  146. 8th World Federation of Nuclear Medicine and Biology, Santiago, Chile. Invited Presentation. October 2002.

  147. Session Chair, Continuing Medical Education, World Federation of Nuclear Medicine and Biology, Santiago, Chile, October 2002.

  148. Organizer, Continuing Medical Education, World Federation of Nuclear Medicine and Biology, Santiago, Chile, October 2002.

  149. Session chair, 1st International Meeting in Nuclear Medicine and Biology, Cabo Frio, Brazil, September 2002.

  150. 1st International Meeting in Nuclear Medicine and Biology, Cabo Frio, Brazil. Invited Presentation. September 2002.

  151. European Association of Nuclear Medicine Pre – Congress Meeting, Vienna, Austria. Invited Presentation. August 2002.

  152. 49th Annual Meeting of the Society of Nuclear Medicine, Los Angeles, CA. June 2002.

  153. XXXVI Annual Congress of Nuclear Medicine, Leon, Mexico. May 2002.

  154. Kuwait Institute for Medical Specialization, Kuwait. March 2002.

  155. First Hospital of Beijing University, Beijing, China. December 2001.

  156. China Atomic Energy Agency, Beijing, China. December 2001.

  157. Imaging in 2020, Second Annual Workshop, Jackson Hole, WY. September 2001.

  158. Annual Meeting of the European Association of Nuclear Medicine Post – Congress, Capri, Italy. September 2001.

  159. 48th Annual Meeting of the Society of Nuclear Medicine, Toronto, Canada. June 2001.

  160. 10th Symposium of the International Society of Radiolabeled Blood Elements, Toronto, Canada. June 2001.

  161. 14th International Symposium on Radiopharmaceutical Chemistry, Interlaken, Switzerland. June 2001.

  162. 221st American Chemical Society Spring National Meeting, San Diego. April 2001.

  163. International Chem. Conference of Pacific Basin Societies. Hawaii. December 2000.

  164. SNM Greater New York/New England Chapter meeting, Providence, RI. November 2000.

  165. 7th Annual Meeting of the Asia and Oceania Congress of Nuclear Medicine and Biology, Istanbul, Turkey. October 2000.

  166. Pre – congress meeting of the 7th Meeting of the Asia and Oceania Congress of Nuclear Medicine and Biology, Istanbul, Turkey. October 2000.

  167. Annual Meeting of the European Society of Nuclear Medicine, Bordeaux, France. September 2000.

  168. The Rome 2000 Jubilee Symposium on Radiopharmaceuticals in Diagnosis and Therapy. May 2000.

  169. The Mid Eastern Chapter of the Society of Nuclear Medicine 30th Annual Spring Meeting. April 2000.

  170. XXXI Annual Conference of the Society of Nuclear Medicine, India, December 1999.

  171. International Atomic Energy Agency 3rd Research Coordinators Meeting of the Coordination Research Programme on “Tc – 99m Peptides for Imaging of Peripheral Receptors”, November 1999.

  172. XVI Congress of the Association of Latin American Societies of Nuclear Medicine and Biology, October 1999.

  173. 9th International Society of Radiolabeled Blood Elements, October 1999.

  174. European Association of Nuclear Medicine Congress, October 1999.

  175. 4th International Symposium on VIP, PACAP, Glucagon, and Related Peptides, September 1999.

  176. 13th International Symposium on Radiopharmaceutical Chemistry, July 1999.

  177. Sub-chairman, Scientific Program Committee, EANM Annual Meeting, 1999.

  178. 47th Annual Meeting of the Society of Nuclear Medicine, June 1999.

  179. NIH/DOE Joint Symposium on Accomplishments with medical Isotopes, March 1999.

  180. 25th Annual Meeting of ACNP, Hawaii, February 1999.

  181. International Symposium on Radiolabeled Pharmaceuticals and Radiolabeled Compounds (International Atomic Energy Agency), December 1998.

  182. Radioisotope Imaging of Infection and Inflammation: satellite meeting to the 7th World Congress in Nuclear Medicine and Biology, Strzelin, Poland, September 1998.

  183. Session chairman, 7th World Congress in Nuclear Medicine and Biology, Berlin, August/September 1998.

  184. Post – congress meeting, World Fed. Of Nucl Med and Biology, Poland, 1998.

  185. International Symposium on Recent Trends in Radiopharmaceutical Developments. Int. Atomic Energy Agency, Vienna, Lisbon, Portugal, 1998.

  186. Research Coordinator, Int. Atomic Energy Agency, Vienna, Warsaw, 1998.

  187. Chaired a session at the 29th Annual Meeting SNM – India, Chandigarh, India, 1997.

  188. Invited speaker at 29th Annual Meeting SNM – India, Chandigarh, India, 1997.

  189. Invited speaker at 8th International Symposium, ISORBE, Rome, 1997.

  190. Chaired two sessions at 8th International Symposium, ISORBE, Rome, 1997.

  191. Chaired session at 10th Int. Symposium on Radiopharmacology, Genoa, Italy, 1997.

  192. Chaired session at EANM Annual Meeting, Copenhagen, 1996.

  193. Invited speaker at EANM Annual Meeting, Copenhagen, 1996.

  194. Session chairman at 28th Annual Meeting SNM India, Gwalior, 1996.

  195. Invited speaker at 28th Annual Meeting SNM India, Gwalior, 1996.

  196. Chaired a session in Research Coordination Meeting, Portugal, 1996.

  197. Research Coordination Meeting, International Atomic Energy Agency Vienna, Portugal 1996.

  198. Chaired a session in the 7th International Symposium of Radiolabeled Cellular Blood Elements, New Haven, 1995.

  199. Invited speaker in the 7th International Symposium of Radiolabeled Cellular Blood Elements, New Haven, 1995.

  200. Chaired a session in the 27th Annual Meeting of the Society of Nuclear Medicine India, Tirupati, India, 1995.

  201. Chaired two sessions in Indian Radiological and Imaging Meeting in Bangalore, India, 1995.

  202. 27th Annual Meeting of Society of Nuclear Medicine – India, Tirupati, 1995.

  203. Indian Radiological and Imaging Association Roentgen Centenary Celebration. Bangalore, India, 1995.

  204. Rho Med meeting, July 1994.

  205. Session chair, European Society of Nuclear Medicine, Dusseldorf, Germany, 1994.

  206. Symposium organization in European Society of Nuclear Med, Dusseldorf, Germany, 1994.

  207. Invited speaker, 6th World Congress Nuclear Medicine and Biol. Sydney, Australia, 1994.

  208. Invited speaker, pre – congress meeting in Cairns, Australia (Pre – congress to 6th World Congress in Nuclear Medicine and Biol) 1994.

  209. Great Lakes Eastern Chapter, SNM, Annual Meeting, Niagara on the Lake, Canada, 1994.

  210. Annual Meeting of the Mexican Society of Nuclear Medicine, Merida, Mexico, 1994.

  211. Member, Scientific Program Committee, 6th Congress of the World Federation of Nuclear Medicine and Biology, Sydney, Australia, 1994.

  212. Member, Scientific Program Committee, 21st Inter. Symposium on Radioactive Isotopes in Clinical Medicine and Research, Bad Gastein, 1994.

  213. Session Chairman, 8th International Symposium on Radiopharmacology, Ghent, Belgium, 1993.

  214. Session Chairman, Annual Meeting of the Argentinian Association of Biology and Nuclear Medicine, Argentina, 1993.

  215. Member, Award Committee, 25th Annual Meeting of the Society of Nuclear Medicine India, New Delhi, India, 1993.

  216. Session Chairman, 25th Annual Meeting of the Society of Nuclear Medicine India, New Delhi, India, 1993.

  217. Session Chairman, 1st World Congress on Infection and Inflammation, Vienna, Austria 1993.

  218. Session Chairman, 10th Inter. Symposium on Radiopharm Chemistry, Kyoto, Japan, 1993.

  219. Session Chairman, 7th Inter. Symposium on Radiopharmaceutical Chemistry and Pharmacy, Cambridge, England, 1993.

  220. Invited speaker, Annual Meeting of Argentina Association of Biology and Nuclear Medicine, Argentina, 1993.

  221. Invited speaker, 25th Annual Meeting of the Society of Nuclear Medicine India, 1993.

  222. Invited speaker, 1st World Congress on Infection and Inflammation, Vienna, 1993.

  223. Member of Scientific Program Committee 10th International Symposium on Radiopharmaceutical Chemistry, Kyoto, 1993.

  224. Member of Scientific Program Committee 40th Annual Meeting of the Society of Nuclear Medicine, 1993.

  225. Invited speaker, 7th International European Symposium on Radiopharmaceutical Chemistry and Pharmacy, Cambridge, England, 1993.

  226. Closing Summary, 6th International Symposium ISORBE, Barcelona, 1992.

  227. Invited speaker, 6th International Symposium ISORBE, Barcelona, 1992.

  228. Session Chairman, 6th International Symposium ISORBE, Barcelona, 1992.

  229. Program Chairman, 6th International Symposium ISORBE, Barcelona, 1992.

  230. Society of Nuclear Medicine 39th Annual Meeting, 1992.

  231. Session Chairman, 9th Symposium on Radiopharmaceutical Chemistry, Paris 1992.

  232. Member Scientific Program Committee 9th International Symposium on Radiopharm Chemistry, Paris, 1992.

  233. 7th Annual Symposium of the International Research Group in Immunoscintigraphy and Immunotherapy. Nijmegen, the Netherlands, 1992.

  234. Hinduja National Hospital and Medical Research Center, Bombay, 1991.

  235. Radiation Medicine Center, Bombay, 1991.

  236. Session Chairman to the 23rd Annual Meeting of the Society of Nuclear Medicine India 1991.

  237. 23rd Annual Meeting of the Society of Nuclear Medicine India, 1991.

  238. European Nuclear Medicine Congress, Vienna, Austria, 1991.

  239. Invited speaker 4th European Symposium on Radiopharmacy and Radiopharmaceuticals, Baden, Switzerland, 1991.

  240. Chaired two sessions in the 5th World Congress in Nuclear Med and Biol, Montreal, 1990.

  241. Session Co – Chairman, 8th International Symposium on Radiopharmaceutical Chemistry, Princeton, 1990.

  242. Member Scientific Program Committee, 8th International Symposium on Radiopharmaceutical Chemistry, Princeton, 1990.

  243. Invited speaker 5th World Congress in Nuclear Medicine and Biology, Montreal, 1990.

  244. Member Scientific Program Committee 5th World Congress in Nuclear Medicine and Biology Montreal, 1990.

  245. Chairman Program Committee, 5th International Symposium on Radiolabeled Cellular Blood Elements, Vienna, 1989.

  246. Radiopharmaceutical Basis on Nuclear Medicine, Farmington, CT, 1989.

  247. DOE Workshop, Los Alamos, 1988.

  248. SNM Central Chapter Meeting, Minneapolis, 1988.

  249. International Symposium on Radiolabeled Platelets. Cologne, 1987.

  250. 4th World Congress on Nuclear Medicine & Biology, Buenos Aires, Argentina, Session Chairman; organized mini – symposium, 1986.

  251. "New Procedures in Nucl Medicine." Connecticut Heath Center, Farmington, October, 1986.

  252. NATA ASI on Monoclonal Antibodies: Applications, prospects and problems, Pascoli, India, 1986.

  253. Eastern Great Lakes Chapter of the Society of Nuclear Medicine, Ontario, Canada, 1986.

  254. International Conference on Radiopharmaceuticals, Biarritz, Sessions Chairman, France, 1986.

  255. Conference on Radiolabeled Cellular Blood Elements, Bloemfontein, S.A. 1986.

  256. International Symposium on Radiotracers Bangalore, India, 1986.

  257. 4th International Symposium on Radiopharmaceutical Dosimetry, Oak Ridge, 1985.

  258. Mid – Atlantic Radioisotopes in Medicine Meeting, 1985.

  259. Society of Nuclear Medicine Annual Meeting 1985.

  260. American Chem. Society Annual Meeting, Miami, 1985. Session Chairman.

  261. SNM 1984 Annual Meeting, Member Scientific Exhibit Award Committee.

  262. Radiopharmaceutical Science Council, Secretary – Treasurer, 1984 – 1985.

  263. SNM Annual Meeting Moderator, 1984.

  264. SNM Scientific Program Committee, 1984.

  265. Annual Meeting of the Spanish Society of Nuclear Medicine, Madrid, 1984.

  266. Eastern Great Lakes Chapter of the Society of Nuclear Medicine, New York, 1983.

  267. First Northeast Regional Scientific Meeting, Society of Nuclear Medicine, New York, 1983.

  268. Radiolabeled Cellular Blood Elements, NATA ASI, Italy, 1983. Chairman, Program Committee. Chaired several sessions.

  269. Austrian Association for Morphological and Functional Research in Atherosclerosis, 1983. Session Chairman.

  270. Labeling Migratory Blood Cells, Session Chairman, Third World Congress, Post – Congress Symposium, Graz, Australia, 1982.

  271. Symposium on Blood Cell Labeling, Univ. of Amsterdam, June 1982. Session Chairman.

  272. Thirteenth Annual Meeting of the Indian Society of Nuclear Medicine, Srinagar, Nov 1981.

  273. Twenty – seventh Annual Meeting of the Indian Society of Nuclear, 1980. Session Chairman.

  274. Structural Activity Relationship, Hartford, 1980.

  275. The Tenth Annual Meeting of Indian Society of Nuclear Medicine, November 1979.

  276. Society of Nuclear Medicine, New York Chapter, Annual Meeting, New York, 1979.

  277. The Canadian Society of Hospital Pharmacists, Toronto, February, 1978. Session Chairman.

  278. Society of Nuclear Medicine, New England Chapter Meeting, Hartford, 1978.

  279. Second International Symposium on Radiopharmaceuticals, Seattle, Washington, 1978.

  280. Twenty – fifth Annual Meeting of the Society of Nuclear Medicine, 1977.

Commercial and Radiopharmaceutical Institutions:

  1. NuView, Incorporated, Philadelphia, PA “Targeting VPAC1 receptors an update” Invited Presentation. April 24, 2014.

  2. Zevacor, International Isotopes, Forsyth, IL “Recent Advances in Molecular Imaging” Invited Presentation. October 6 – 8, 2013.

  3. Zevacor Molecular, Il, 2013

  4. 14th International Conference of International Society of Radiolabeled Blood Elements (ISORBE), Pretoria, South Africa, 2013

  5. Bruckner, Inc., Princeton, 2013

  6. ImaginAb, Inc., Los Angeles, 2012

  7. United Pharmacy Partners, Inc. Philadelphia, 2012

  8. NuView, Inc. Salt Lake City, 2012

  9. Carestream Healthcare, WFNMB, Cape Town 2010

  10. Siemens – ALASBIMN, Cartagena Colombia, 2009

  11. Johnson & Johnson – Pennsylvania, 2007

  12. NuView Radiopharmaceuticals, Utah, 2007

  13. Nordion – Canada, 2007

  14. IBA Molecular Belgium 2006

  15. IBA Molecular Belgium 2006

  16. Eastern Isotopes, 2005

  17. Amersham, 2004

  18. IBIS, France 2004

  19. Diatide, 2002

  20. G.E. Inc, 2001

  21. Diatide, Inc., 2000

  22. Palatin Technologies, Inc., 2000

  23. Bracco, Inc, 2000

  24. Diagnostic Medical Imaging, Inc., 1999

  25. Clinical Isotopes Service, 1999

  26. University of Pennsylvania, 1999

  27. New York Methodist Hospital, 1999

  28. Mallinckrodt Pharmaceuticals, 1999

  29. Nycomed, 1999

  30. Bracco, Inc. 1999

  31. Palatin Technologies, Inc., 1999

  32. DMI, Denver, 1999

  33. CIS, France, 1999

  34. Braco Pharmaceuticals, 1999

  35. Mallinckrodt Pharmaceuticals, 1999

  36. NycoMed, 1999

  37. Bracco Pharmaceuticals, 1998

  38. Palatin Technologies, Inc., 1998

  39. Palatin Technologies, Inc., 1997

  40. Palatin Technologies, Inc., 1996

  41. Lexin, Inc. 1995

  42. RhoMed, Inc. 1994.

  43. RhoMed, Inc. 1993.

  44. Sterling Drug Inc., 1992.

  45. Hausmann Laboratories, Switzerland, 1991

  46. RhoMed, Inc. 1990

  47. Zynaxis, Inc. 1989

  48. RhoMed, Inc. 1987

  49. Mallinckrodt Pharmaceuticals, Montreal, 1987

  50. Metaphysics, Osaka, 1984

  51. Metaphysics, California, 1983

  52. Sorin, Italy, 1983

  53. Diagnostic Isotopes, New Jersey, 1978

  54. MediPhysics, California, 1978

  55. New England Nuclear, Boston, Massachusetts, 1978

  56. Diagnostic Isotopes, New Jersey, 1977

  57. Mallinckrodt, St. Louis, Missouri, 1977

  58. New England Nuclear, Boston, Massachusetts, 1977

  59. Diagnostic Isotopes, New Jersey, 1976

  60. Philips Duphar, Holland, 1975

  61. Radiochemical Center Amersham, England, 1974

  62. Lundbeck, Copenhagen, 1973

Biographical References:

  1. Radiology Today, June 13, 2005

  2. Philadelphia Inquirer Health and Science Section, November 12, 2001

  3. Who's Who in Science and Engineering

  4. International Men of Achievement

  5. American Men and Women in Science

  6. Who's Who in the East

  7. Who's Who in the USA